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ABSTRACT
Acne is common and many individuals affected will seek treatment from a general 
practitioner. A wide range of anti-acne products is available over-the-counter in the 
UK and other products, including oral antibiotics, retinoids and hormonal therapy, 
can be obtained with a prescription.
Minocycline is a tetracycline antibiotic used widely to treat acne although it has been 
associated with hyperpigmentation, vestibular disturbances and hepatotoxicity. The 
anti-androgen, cyproterone acetate, in combination with ethinyloestradiol (CPA/EE), 
is licensed to treat women with antibiotic-resistant acne or moderate hirsutism. It is 
sometimes prescribed off-label for contraception. Concern has been expressed 
about an increased risk of venous thromboembolism (VTE) amongst CPA/EE users 
although this association is complicated by the possibility that women with severe 
acne or hirsutism may have an inherently higher risk of VTE. Exposure to high 
doses of cyproterone acetate has been associated with hepatotoxicity.
A review of published literature and pharmacovigilance data confirmed a duration-of- 
use effect for liver disease in people with acne using minocycline. Using data from 
the General Practice Research Database (GPRD) we found that the risk of liver 
disease associated with minocycline was small and no different from that risk 
associated with other tetracyclines. An analysis of GPRD data on COG and 
CPA/EE use demonstrated that the proportion of CPA/EE users with acne declined 
after the pill scare of 1995. Our analysis of GPRD data revealed an increased risk 
for VTE with CPA/EE compared with no use, but no different from that risk 
associated with conventional COCs. Further analysis amongst individuals with 
hirsutism, PCOS or recent diagnoses of acne confirmed that the risk of VTE 
associated with CPA/EE was no different from that associated with conventional 
COCs. We found no evidence to support an association between liver disease and 
the use of CPA/EE.
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Introduction
Intro ducto ry  statem ent
Six papers are presented in this thesis, each of which has been published in a peer- 
reviewed journal. They are presented in chronological order. The papers describe 
research carried out within the Department of Pharmacoepidemiology (formerly part 
of the European Institute of Health & Medical Sciences), Postgraduate Medical 
School at the University of Surrey, UK. The central theme of the investigations has 
been treatment for acne in the UK with particular reference to the risk of specific 
associated adverse drug reactions. The focus has been on two drugs prescribed for 
acne by UK general practitioners -  the tetracycline minocycline (Minocin®) and the 
anti-androgen cyproterone acetate in combination with ethinyloestradiol (CPA/EE 
[Dianette®]). The risk of liver disease has been explored with regard to the use of 
minocycline whilst the risk of liver disease and venous thromboembolism (VTE) has 
been investigated amongst women prescribed CPA/EE. The first paper is a review 
of the literature and spontaneous reports; the other papers describe the results of 
cohort analyses and case-control studies using data from the General Practice 
Research Database (GPRD).
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Defining  the  study  populations
Excessive androgen production in women can lead to a number of troublesome skin 
conditions, most commonly acne, hirsutism and male-pattern balding. Minocycline 
is indicated for acne whilst CPA/EE is licensed for the treatment of hirsutism and 
acne. Some women with hyperandrogenism may be affected also by irregular 
menstrual cycles, obesity and fertility problems. The following sections describe the 
androgenic conditions most commonly encountered.
Acne
Acne is a common inflammatory condition of sebaceous follicles that affects most 
individuals at some time, although most often during the teenage years. There is a 
clear association with the onset of puberty in males and females, a strong familial 
component and ethnic variation. Acne is typically characterised by the presence of 
comedones (whiteheads and blackheads), most commonly on the face, back and 
chest. Papules, pustules and macules may occur in some cases, whilst the most 
severe forms of acne are characterised by the presence of nodules and cysts.
Sometimes acne can be prompted or exacerbated by exposure to certain 
compounds (eg steroids, antiepileptics, antituberculosis drugs, some anti­
depressants and cyclosporin).
Typical acne lesions
Papules
Papules are small (< 5 mm) solid lesions that are slightly elevated above the surface 
of the skin. A group of very small papules and microcomedones may be almost 
invisible but have a "sandpaper" feel to the touch.
1.3
Introduction
Figure 1.1 Papules
Pustules
Pustules are dome-shaped, fragile lesions containing pus that typically consist of a 
mixture of white blood cells, dead skin cells, and bacteria. Minor lesions heal 
without scarring but sometimes acne pustules may progress to the cystic form.
Figure 1.2 Pustules
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Macules
Macules are the temporary red spots left by a healed acne lesion. They are usually 
flat, red or red-pink, with a well-defined border. A macule may persist for days to 
weeks before disappearing. When a number of macules are present at one time 
they can contribute to the "inflamed face" appearance of acne.
Figure 1.3 Macules
Source for Figures 1.1 to 1.3: 
http://www.derm-infonet.com/acnenet/acne.html accessed on 22/07/03
Acne severity
Acne may be graded as mild, moderate or severe and comedones and inflammatory 
lesions are usually considered separately. Many dermatologists assess the severity 
of a patient's acne more precisely by using a grading scale, such as the one 
developed by the Leeds' group.1 The inflammatory lesions are compared with a set 
of standard photographs to determine the grade between 1 (very mild) and 12 
(exceptionally severe).
The following paragraphs and pictures describe some of the many different 
manifestations of acne and indicate how extreme the condition can be.
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Acne vulgaris
Acne vulgaris is the most common type of acne amongst adolescents. Several 
types of acne lesions including comedones, papules, pustules, cysts and nodules 
can occur, often at the same time. Secondary lesions may include excoriations 
(picked or scratched spots) and scars. Acne vulgaris spans a broad range of 
severity.
Figure 1.4 Typical presentation of mild acne vulgaris
Figure 1.5 Typical presentation of moderate acne vulgaris
Source for Figures 1.4 & 1.5 
http://www.dermatologist.co.uk/ accessed on 22/7/03
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Figure 1.6 Typical presentation of severe acne vulgaris
Source: http://www.naqh.com/ accessed on 22/0703
Nodular or cystic acne
Nodules are large dome- or irregularly shaped pus-filled lesions associated with 
inflammation and pain that develop when the contents of a comedo have spilled into 
the surrounding skin and the local immune system responds, producing pus. 
Nodules are the most severe form of acne lesion and may persist for weeks or 
months. Nodules may harden into a deep cyst. Both nodules and cysts often leave 
deep scars.
Figure 1.7 Severe nodular acne
Source: http://www.aad.org/pamphlets/acnepamp.html accessed 22/07/03
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Figure 1.8 Cystic acne
Source: http://www.dermatologist.co.uk/ accessed 22/07/03 
Acne conglobata (cystic acne or nodulocystic)
Acne conglobata is a severe form of acne more common in males that affects the 
face, chest and back. It is a severe form of nodulocystic acne vulgaris characterised 
by cystic lesions, abscesses, communicating sinuses, and thickened, nodular scars.
Figure 1.9 Acne conglobata
4  . ' .
Source: http://www.emedicine.com/derm accessed 22/0703
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Acne indurata
Acne indurata is deeply seated acne with large, hard, raised and rounded papules 
and pustules that occur primarily on the back. Acne indurata can result in large 
hypertrophic scarring.
Keloid acne
Keloid acne is a rare condition that arises from secondary pyogenic infection in and 
around pilosebaceous units and results in keloidal scarring. It manifests as 
persistent folliculitis in the nape of the neck associated with occlusion of the follicular 
orifices. It is most often encountered in black or asian men and may persist for 
years.
Figure 1.10 Keloid acne in a man of African-Caribbean origin
Source: http://www.emedicine.com/derm accessed 22/0703
Acne treatments
The choice of treatment will be influenced by severity and the experience of patients 
and prescribing physicians. Some patients will not seek medical intervention or 
advice and as tolerance differs amongst individuals affected by acne, the use of 
acne treatments and consultations with a GP will not always relate to the severity of 
the condition. Some patients may simply rely upon treatment available provided by 
a beautician or upon cosmetics - such behaviour suggests mild symptoms but this 
may not always be the case.
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Several types of topical acne treatment are available over-the-counter (OTC) as 
gels, lotions, creams, cleansers and soaps and these may be suitable for individuals 
with mild to moderate symptoms. OTC products available in the UK include benzoyl 
peroxide (which helps reduce oil production) and salicylic acid (which helps to stop 
pores clogging but is now considered to be less effective). Other topical 
preparations are available with a prescription to treat mild to moderate acne and 
these include azelaic acid, antibiotics {eg tetracyclines, erythromycin and 
clindamycin), tretinoin (the acid form of vitamin A), isotretinoin (the isomer of 
tretinoin) and adapalene. Some topical preparations can bleach or stain clothing 
{eg benzoyl peroxide) whilst most are likely to irritate the skin. Benzoyl peroxide can 
cause scaling and redness but symptoms usually subside with continued use. Skin 
reactions associated with tretinoin and topical isotretinoin may be more pronounced 
with pruritus and peeling but again these reactions generally subside with time.
More serious side effects associated with tretinoin and topical isotretinoin include 
photosensitivity and changes in skin pigmentation.
Inflammatory acne may be treated with an oral antibacterial, in combination with 
topical anticomedonal treatment {eg benzoyl peroxide) if required. Antibiotics 
commonly used in the UK for acne include the tetracyclines and erythromycin. The 
use of tetracyclines has been associated with gastric and visual disturbances and 
photosensitivity. Minocycline is a tetracycline widely used in the UK for the 
treatment of acne and side effects specifically associated with minocycline use 
include dizziness, severe exfoliative rashes, changes in pigmentation, drug-induced 
lupus and liver damage.
The anti-androgen cyproterone acetate, in combination with ethinyloestradiol 
(CPA/EE), offers hormonal treatment for women with acne that has proved resistant 
to conventional antibiotic therapy. The side effects associated with CPA/EE include 
those associated with conventional combined oral contraceptives, namely nausea, 
headache, breast tenderness, intermenstrual spotting, depression, skin reactions, 
thrombosis and impairment of liver function inter alia. The use of oral contraceptives 
(OCs) can sometimes prove helpful in alleviating acne.
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The most severe forms of acne (nodulocystic, conglobate) and acne that does not 
respond to antibiotics may be treated orally with the retinoid isotretinoin. Isotretinoin 
reduces sebum secretion. It is a highly toxic drug and in the UK may be prescribed 
only under the supervision of a consultant dermatologist. It can cause several 
severe reactions including skin dryness, joint pain, photosensitivity, nose bleeds, 
alopecia, liver dysfunction and depression (although the link between isotretinoin 
and depression is complicated by the psychiatric morbidity associated with acne). 
Isotretinoin is a teratogen that can cause birth defects in babies exposed in utero. 
Pregnancy must be avoided during treatment with isotretinoin and the concomitant 
use of two contraceptive methods (including a combined oral contraceptive pill) is 
recommended.
The epidemiology of acne
Acne is likely to affect a large proportion of the general population at some time in 
their lives. Acne may persist beyond puberty into adulthood in both sexes. Post­
adolescent onset is also common, particularly amongst women.2:3 An assessment 
of acne prevalence is difficult however because of the different manifestations of the 
disease and wide range of severity. Prevalence estimates vary according to the 
population studied in terms of age, socio-economic status and ethnicity inter alia and 
there is no universally accepted grading system of acne severity. Most studies differ 
in the definition of mild, moderate or severe acne4 and use different classification 
systems. Estimates of acne prevalence are complicated further because use of 
acne therapies, OCs and other drugs (in particular steroids), pre-existing conditions, 
pregnancy, pre-menstrua! flare4 and seasonal variations5 can all influence the 
occurrence of acne. A greater availability of effective over-the-counter preparations 
for acne, a heightened awareness of available treatments, and improved primary 
care has almost certainly influenced trends in acne prevalence over time.
Amongst adolescents, estimates of acne prevalence vary between 35% and 90% 
and in some studies, the prevalence of comedones approaches 100% in both 
sexes.4 Understanding about the etiology of acne is generally poor amongst those 
affected and fewer than a third of young people with acne seek medical advice.6
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The majority of published figures demonstrate a decline in the prevalence of acne, 
particularly severe acne, over the last 20 or so years,4:7 probably because of 
improved treatments.4 Greater awareness and improved effectiveness of acne 
treatments, however, may prompt higher rates of GP consultation and confuse 
prevalence estimates.8 Data from a survey of general practices in the UK carried 
out in the early 1990s indicate an acne prevalence of about 5% amongst females 
aged 16-24 and 1.8% in women 25-44 and describe an increased consultation rate 
for acne over the previous 10 years.9 Studies that actively seek cases will 
undoubtedly report higher rates than those studies that recruit subjects who report to 
their GP unprompted.
Acne has been associated with increased psychological morbidity. Teenagers may 
be afflicted by acne at a time in their lives when they are emotionally vulnerable and 
exhibit levels of distress disproportionate to the severity of their acne. Studies have 
demonstrated that successful treatment and improvements in acne lead to 
decreased anxiety and depressive illness.10 Clinical depression has been described 
in patients attending dermatology clinics with acne. Depression caused by the 
presence of acne complicates the association that has been observed between 
suicidal ideation, suicide and isotretinoin.
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H irsutism
Hirsutism in young women is a common problem -  some 10% of young women 
having a significant degree of excess hair.11 The observation that hirsutism is 
associated with ethnicity and sometimes family history suggests that the condition 
may be genetically determined. However in some cases there may be an underlying 
endocrinological cause.12
Hirsutism develops as a result of increased androgen production and increased skin 
sensitivity to androgens. Its manifestation is excessive hair growth in areas more 
typical of males13 (Figure 1.11) and prolonged exposure to high levels of circulating 
androgens may induce androgenic alopecia.13114 Some cases of hirsutism are 
caused by medical treatment and this should be excluded eg some oral 
contraceptives, steroids, anti-epileptics, immunosuppressants, diazoxide and 
minoxidil.15 A common cause of hirsutism is polycystic ovary syndrome - other rare 
causes include congenital adrenal hyperplasia, Cushing’s disease, a pituitary 
dysfunction or, more rarely, an androgen-secreting tumour of the ovary or adrenal 
glands.
Figure 1.11 Range in severity of female hirsutism
Source: www.medscape.com accessed 22/07/2003
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Polycystic  ovary  syn d ro m e
To date, no consensus has been reached on the definition of the polycystic ovary 
syndrome (PCOS) and there is no consistent clinical marker or phenotype.16 A 
National Institute of Child Health and Human Development (National Institutes of 
Health) conference in 1990 could not reach agreement on a definition of the 
condition or on definitive diagnostic criteria. It was generally accepted, however, 
that PCOS should be defined as idiopathic hyperandrogenism and chronic 
anovulation after differential diagnoses (congenital adrenal hyperplasia, Cushing’s 
syndrome or ovarian/adrenal tumours) had been excluded. Subsequent 
clarifications of this definition have progressed through confirmation of 
hyperandrogenism by endocrinological measures to acceptance of clinical 
manifestations such as acne and hirsutism as markers for the syndrome. In the UK 
(and much of Europe) a diagnosis of PCOS generally relies upon the demonstration 
of polycystic ovaries (PCO) on ultrasound examination, associated menstrual 
disturbance (amen- or oligomenorrhoea) and signs of hyperandrogenisation (acne, 
hirsutism or alopecia). In North America, however, more emphasis is placed on the 
requirement of biochemical evidence of hyperandrogenisation and ovarian 
dysfunction. A recent publication proposed a strategy for unifying the diagnosis of 
PCOS.17 This strategy suggested a diagnosis based upon the presence of one or 
more clinical symptoms (menstrual disturbance, hirsutism, acne or anovulatory 
infertility) plus either the demonstration of PCO on ultrasound or one or more 
positive findings on biochemical examination of serum testosterone, luteinizing 
hormone, fasting glucose or free androgen level).
Given the imprecise definitions of PCOS it is not surprising that published estimates 
of PCOS prevalence amongst women of reproductive age vary between 3% (using 
endocrinological evidence only18) and 20% (based on evidence of PCO18'18). Most 
estimates for PCOS prevalence arise through investigation. The true prevalence of 
PCOS in the general population and the implications with regard to the potential 
clinical significance of covert PCOS remains unknown. Despite the uncertainty 
imposed by diagnostic difficulties, PCOS is probably the most frequently 
encountered endocrinopathy in women of reproductive age.20;21
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Symptoms of PCOS
Polycystic ovaries are characterised by multiple small cysts in the ovary and excess 
androgen production from the ovaries (and to a lesser extent from the adrenal 
glands21). PCO may not be evident in women who have all the other classic 
indicators for PCOS, and may appear in ‘normal’ worn en16:20 and women with other 
disorders.21 Subtle abnormalities (increased fasting insulin levels and low levels of 
HDL cholesterol) in young women with PCO but no other indications for PCOS 
suggest that the syndrome could become evident in later years.21
Common clinical manifestations of PCOS include hirsutism and acne - about 80% of 
patients with PCOS complain of hirsutism.14 Acne is often severe and may prove 
refractory to treatment with conventional antibiotic therapies but other factors 
involved in the formation of acne complicate an understanding of its relevance to 
PCOS diagnosis. One study of 82 women with acne demonstrated PCO on 
ultrasound in 68% but no correlation was found between acne severity or any other 
clinical manifestations of PCOS (infertility, hirsutism, menstrual irregularities, 
abnormal endocrinology).22
Amongst women with oligomenorrhoea, the prevalence of PCOS is estimated to be 
85-90%,14 and in women with concomitant hirsutism it has been estimated to be 
90%.19 About 40% of women with PCOS present with fertility problems.23 
Anovulation in PCOS is usually chronic and presents as oligomenorrhoea or 
amenorrhoea, often from around the time of menarche.21 Even though ‘normal’ 
menses may be apparent, about 21% of hyperandrogénie women may be 
anovulatory.
Between 50% and 70% of women with PCOS may be obese14:20:21 although rates 
vary according to geography and ethnicity.20 Typical of PCOS is an increased 
waist:hip ratio (ie high ratio of abdominal fat to hip fat).14
Most women with PCOS have elevated levels of serum androgens.21 Oestrogens 
are in part converted to androgens in adipose tissue thus androgen levels will be 
increased in obese patients.
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Figure 1.12 Typical presentation of a woman with PCOS
The long-term health consequences for women with PCOS
Acne, hirsutism and anovulatory infertility are clinical manifestations of PCOS that 
are distressing for the woman concerned. Morbidity is further complicated by other 
characteristics of the syndrome that predispose women with PCOS to an increased 
risk of type II diabetes and cardiovascular disease. Known risk factors for venous 
disease include obesity, diabetes and hyperoestrogenism and these conditions are 
commonly associated with PCOS. In addition, PCOS may be associated with 
hyperlipidaemia and hypertension which can predispose affected individuals to a 
higher risk of arterial disease.
An association between hyperandrogenisation and insulin resistance (IR) was first 
reported in 1921 in the account of a bearded woman with diabetes.24 The IR occurs 
mainly in peripheral tissues prompting increased pancreatic insulin secretion to 
maintain normal glucose levels. Some studies suggest that all women with PCOS 
have evidence of IR (independent of body mass18:25;26) and that IR may be more 
pronounced in women with chronic anovulation21 (insulin promotes increased 
ovarian testosterone secretion and this may halt egg maturation and interfere with 
the menstrual cycle).
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Women with PCOS cannot overcome peripheral insulin resistance and are thus at 
an increased risk of impaired glucose tolerance and type II diabetes mellitus.21:26 
The prevalence of diabetes in women with PCOS has been estimated to be 16%20 
and in women with PCOS who are obese, some 40% may have either diabetes or 
glucose intolerance.26 Legro et a F  demonstrated impaired glucose intolerance in 
31% of obese women with PCOS of reproductive age and overt diabetes in 7.5%, 
whilst 10.3% of non-obese women with PCOS had impaired glucose tolerance and 
1.5% had diabetes, a rate almost three times that of the general population.
Another risk factor for venous thrombosis is pregnancy-induced hypertension. This 
condition is generally associated with obesity, glucose intolerance and insulin 
resistance -  common features of PCOS.19
Some women with PCOS may exhibit risk factors for arterial disease. Besides 
diabetes, obesity and hyperandrogenisation, women with PCOS may demonstrate 
hyper- or dyslipidaemia (even after controlling for BMI),18:19:21 impaired fibrinolysis 
(high plasminogen activator inhibitor-1 [PAI-1]) and hypertension.19:20:28 PCOS may 
be more prevalent amongst women with coronary artery lesions as such women 
report more hirsutism and diabetes and have an increased waist:hip ratio compared 
with women with normal arteries despite similar BMIs.26 PAI-1 is an inhibitor of 
intravascular fibrinolysis and levels appear to be altered in PCOS. An increased 
PAI-1 activity in the plasma, or at the endothelial surface, may promote thrombosis 
formation by inhibiting production of the fibrinolytic enzyme plasmin. Raised PAI-1 
activity is associated with the later development of Ml in subjects with coronary 
artery disease.
The evidence for increased CVD risk
Several studies have confirmed higher rates of risk factors for cardiovascular 
disease amongst women with PCOS.29:3° The actual risk of CVD amongst women 
with PCOS aged 40-49 may be comparable to the risk in men of that age ie 4 times 
the estimated risk for the ‘normal’ female population.31 According to Carmina & 
Lobo20 women with PCOS have a 7-fold increased risk of myocardial infarction. 
There is, however, little direct epidemiological evidence to support the assumption 
that women with PCOS are at an increased risk of CVD.19 In a long-term follow-up
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study of women with PCOS, Pierpoint et aP0,32 found that although women with 
PCOS exhibited increased risk factors for CVD, they did not demonstrate an 
increased mortality from CVD.
Treatment options for women with PCOS or hirsutism
The clinical manifestations of hyperandrogenisation in PCOS (acne, hirsutism) are 
those for which many affected women will seek treatment initially. The treatment 
options for women with acne have been discussed (page 1.9). PCOS may be 
diagnosed after consultation for menstrual or fertility problems and treatments for 
these and hirsutism are discussed briefly in the next paragraphs.
Once sinister causes of hirsutism have been excluded, non-medical treatment 
options include the use of bleaching agents, depilatory creams, plucking, electrolysis 
or laser treatment.15 Weight loss may restore irregular menses although in women 
with insulin resistance and impaired adipocyte lipolysis, weight loss will be more 
difficult to achieve. Where medical intervention is indicated, suppression of ovarian 
androgens may be achieved by administering exogenous oestrogens, possibly as a 
combined oral contraceptive (COC). COCs with low androgenic progestérones (eg 
desogestrel-containing formulations) are preferred. The anti-androgen, cyproterone 
acetate, in combination with ethinyloestradiol (CPA/EE [Dianette®]) is licensed 
specifically for the treatment of hirsutism and severe acne in the UK. Both 
desogestrel-containing COCs and CPA/EE have demonstrated clinical benefit in the 
treatment of hirsutism33 although there is little evidence to support the use of 
cyproterone acetate alone.34 The use of CPA without adequate contraceptive cover 
is strongly opposed because of the risk of foetal féminisation after exposure to CPA 
in utero. Other treatment options include finasteride and flutamide,35:36 prednisolone 
and spironolactone.13137138
PCOS-associated infertility may be treated with clomiphene, gonadotrophins or 
ovarian electrodiathermy.20:39'41
Because of the cardiovascular risks associated with PCOS, the efficacy of insulin- 
sensitizing drugs (such as metformin) in PCOS is now being studied.18 
Troglitazone, an agent that directly reduces insulin resistance and
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hyperinsulinaemia has been shown to reduce circulating androgen levels in women 
with PCOS and to improve the regularity of menstrual cycles. The long-term efficacy 
of such therapy, however, has not yet been established.38
In conclusion, these brief reviews of the epidemiology of acne, hirsutism and PCOS 
allude to the complexity of the study populations defined in the papers presented in 
this thesis. In particular, there is good evidence for significant morbidity, particularly 
cardiovascular morbidity, associated with PCOS. Given the likely prevalence of the 
syndrome amongst women with acne or hirsutism, considerable significance must 
be given to potential confounding in any assessment of risk associated with 
exposure to drugs used by women with acne, hirsutism or PCOS.
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The G e n e ra l P ra c tic e  Research D atabase  (GPRD)
The General Practice Research Database (GPRD) is a large database of 
anonymised patient data from UK general practice. The current GPRD evolved from 
a computerised system developed by a practising GP, Dr Alan Dean, in the mid 
1980s. From the late 1980s Value Added Medical Products Ltd (VAMP Ltd) 
promoted the database by offering free computers and practice management 
systems to GPs on the understanding that those GPs would contribute anonymised 
patient data for research purposes to what became known as the VAMP Research 
Database. Reuters Health Information acquired the database from Vamp Ltd in 
1993 but donated it to the UK’s Department of Health in 1994 when it was renamed 
the GPRD. About 15% of the contributing practices dropped out of the scheme at 
that time. Reuters continued to have an interest in the practice management 
software and their 1995 Windows-based system, Vision, became the most widely 
used amongst GPRD contributors. After 1994 the GPRD was operated by the 
Office for National Statistics (ONS) but its management was transferred to the 
Medicines Control Agency (MCA) in 1999.
Currently the GPRD is maintained as a non-profit making, self-financed commodity 
by the GPRD Division of the UK Medicines and Healthcare products Regulatory 
Agency (MHRA). (The MHRA was created on 1st April 2003 with the merger of the 
MCA and the Medical Devices Agency.) The GPRD stored at the University of 
Surrey and used in the database studies presented here was supplied under licence 
by EPIC, Regeneration House, York Way, London N1 OUZ.
The database studies reported in this thesis used a version of the GPRD that held 
data for the period up until the end of 1999. Over eight million patients had been 
registered at some time and a small majority was female (Table 1.1).
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Table 1.1 Number of patients registered at some time 
with practices contributing to the GPRD (1999 version)
Count %
Females 4,207,850 52.2
Males 3,858,780 47.8
Persons 8,066,630 100.0
Data for nearly 23 million patient years were recorded on the GPRD between 1987 
and 1999. The database studies presented in this thesis covered the period 
between 1992 and 1998 (1992-1997 in Chapter Three) and included patients aged 
between 15 and 39. The number of data years contributed by such patients 
registered with practices contributing to the GPRD during that time was over 8.2 
million. Figure 1.13 illustrates the number of patient years for individuals aged 
between 15 and 39 that were available for study on the GPRD. The GPRD 
population declined during the study period as a number of practices ceased to 
contribute compatible data.
Figure 1.13 GPRD patient years at ages 15-39
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In 1996 6.4% of the population in England was represented on the GPRD, 
compared with 5.1% in Wales, 2.8% in Scotland and 5.8% in Northern Ireland.42 The 
GPRD population closely resembles the general population in terms of age and sex 
distribution according to a comparison with ONS data for 1994 projected from 1991 
census data,43 and represents some 5% of the UK general population based on the 
1997 population estimates published by ONS (Figure 1.14). There is a small over­
representation of women between the ages of 20 and 29.
Figure 1.14 The GPRD population as a proportion of the estimated UK general 
population (ONS) by five-year age band, 1997 
(compiled by author)
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Demographic data on age, sex and marital status is collected although a patient’s 
ethnicity is not recorded. All significant medical diagnoses are recorded with 
reference to OXMIS (Oxford Medical Information System) or Read codes and there 
is a free text field for GPs to make comments alongside diagnostic codes. Because 
the majority of prescriptions issued in general practice are computer generated, 
most prescriptions issued to patients are recorded on the GPRD. Prescriptions 
issued during home visits or by hospital physicians may be missed however. The 
database provides information on referrals and admission to hospital and also on 
smoking, height, weight, immunisation, laboratory results, clinic attendances etc.
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Doctors contributing to the GPRD are asked to record all “significant” events such as 
consultations with patients that result in referral and “events which the partner will 
require to be reminded of at a later date”.44 There is no requirement for doctors to 
record diagnoses for minor consultations or to record follow-up consultations for 
chronic conditions unless a consultation leads to new treatment or referral.
Until 1997, regular checks were made to ensure that data quality was maintained 
{personal communications: AWson Bourke, EPIC; Louise Wood, MHRA).
Contributing practices received a validation report following the six-weekly download 
of data from the practice computers to the central system. The regular checks 
included monitoring the weekly number of consultations, prescriptions and 
prevention records entered and any variations in established patterns were queried. 
The completeness of prescribing information was reviewed with reference to a 
sample of drugs to ensure that an indication for use was given. Information on 
births, deaths and pregnancies was reviewed and practices were asked to amend 
records if omissions were identified.
The GPRD thereby provides a semi-defined population, broadly representative of 
the population at large in terms of gender and age distribution.
All research studies exploring GPRD data with a view to dissemination of results 
need the approval of the GPRD's Scientific and Ethical Advisory Group (SEAG).
This panel of advisors, including epidemiologists, general practitioners, a statistician 
and member of the clergy, aims to ensure that the proposed work is scientifically 
and ethically sound.
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Id e n t ify in g  p a t ie n t s  w ith  a c n e  u s in g  t h e  GPRD
The GPRD dictionary of OXMIS/Read codes refers to about 35 different forms of 
acne although many are seldom if ever used. Table 1.2 lists the diagnostic codes 
for acne most commonly recorded on the GPRD. Most records refer simply to 
'Acne' without clarification of severity.
Table 1.2 Diagnostic codes for acne most commonly used on the GPRD
OXMIS/Read code Text Count (all GPRD) %
7061A ACNE 618,580 88.08
7061C ACNE VULGARIS 50,749 7.23
M261000 Acne vulgaris 28,081 4.00
7061CC ACNE CYSTIC 3,782 0.54
7061KL ACNE KELOID 397 0.06
7061ND ACNE NODULAR 329 0.05
7061CG ACNE CONGLOBATA 149 0.02
M261600 Cystic acne 149 0.02
7061 NR ACNE INDURATA 73 0.01
M261100 Acne conglobata 18 0.00
All above 702,307 100.00
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Acne can be a chronic condition and GPs contributing data to the GPRD are not 
required to record information about chronic conditions at follow-up consultations 
unless a new treatment or referral is initiated. In the studies on CPA/EE an ‘acne 
period’ was defined that commenced two years prior to the first evident diagnosis of 
acne and ended one year after the last apparent diagnosis (Figure 1.15). The ‘acne 
period’ was truncated where appropriate according to age and GPRD registration.
Figure 1.15 Definition of the ‘acne period’
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A bstract
Minocycline is an antibacterial drug used in the treatment of acne. Concern has 
been expressed over the possibility of severe adverse reactions to minocycline, 
including hepatitis. This study set out to identify and characterise reported cases of 
hepatotoxicity associated with the use of minocycline through a systematic review of 
the literature including a search of computerised databases and analysis of data 
from the WHO Collaborating Centre for International Drug Monitoring.
We identified 65 reported cases of hepatitis or liver damage in association with 
minocycline from either case reports or case series. 58% of cases were in women 
and 94% were aged under 40 years. For 20 case reports there was insufficient 
information to classify the type of event, but for the remaining 45, two types of 
hepatic reaction were recognised:
• autoimmune hepatitis (AIH) associated with lupus-like symptoms occurring after 
a median duration of exposure to minocycline of 365 days in women (n=20) and 
730 days in men (n=9),
• hypersensitivity reaction (HSR) associated with eosinophilia and exfoliative 
dermatitis occurring within 35 days of therapy (n=16).
Reports to the WHO of hepatic adverse drug reactions (ADRs) associated with 
minocycline accounted for 6% (493) of all minocycline-related ADRs (8,025). The 
pattern of distribution in relation to exposure demonstrated two groups, similar to 
that described by the case reports.
Severe cases of minocycline-associated hepatotoxicity appear to be an HSR and 
occur within a few weeks of commencing therapy. An autoimmune hepatitis usually 
presents after exposure to minocycline of a year or more, is more common in 
women and is sometimes associated with lupus-like symptoms.
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Introduction
The tetracyclines are a group of antibiotics that have been widely accepted for 
many years as effective systemic treatment for acne. Minocycline is a semi­
synthetic tetracycline, licensed for a broad range of indications, including urinary 
tract and ear, nose and throat infections, pneumonia and bronchitis. In the UK, 
Minocin MR® is specifically licensed for the treatment of acne.
The superior efficacy of minocycline over other anti-acne therapies, including other 
tetracyclines, has been reported.1'7 The benefits of minocycline treatment for acne 
include good oral absorption, enhanced tissue penetration, slow elimination and 
improved patient compliance through once daily dosage. The drug can be taken 
with food effectively,8 is highly lipophilic becoming rapidly concentrated in the target 
sebaceous follicles after oral administration,2,3,8 and has been demonstrated to have 
superiority over other tetracyclines in overcoming the growing problem of bacterial 
resistance.6,7,9,10 These advantages often favour the use of minocycline over other 
therapies.
The safety of minocycline in the treatment of acne has been widely reported.3,4,7,11,12 
Side effects are generally transient, though hyperpigmentation of tissues may occur 
and may persist. None of the observational studies or clinical trials has identified 
patients with liver damage.
Minocycline’s parent drug, tetracycline, was first noted to be hepatotoxic in hospital 
in-patients who received high doses of tetracycline intravenously. Serious hepatitis 
developed with a histological picture of microvesicular steatosis or ‘fatty liver’. Fatty 
liver in response to minocycline exposure is considered rare.13
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In 1983 a case of a severe leukemoid reaction in association with minocycline 
therapy was reported in the literature,14 and further cases of pneumonitis,15,16 
pancreatitis17 and myocarditis18,19 have been reported. The development of lupus­
like symptoms has also been described in patients taking minocycline. Such drug- 
induced lupus (OIL), specifically attributed to minocycline, was first described by 
Matsuura in 199216 and subsequently described in a number of other case 
reports.20'27 Sturkenboom e ta l28 demonstrated that the risk of developing a lupus­
like condition in people with acne exposed to minocycline was significantly raised 
(odds ratio 8.5 [Cl95 2.1-35.0]) compared with non-use and higher than the risk 
associated with other tetracyclines. The findings of this study indicate that 
minocycline may well be responsible for promoting OIL and also support previous 
observations that OIL is reported most frequently in young women. In this respect 
the pattern of OIL occurrence reflects the propensity of several autoimmune 
diseases to affect predominantly women (eg SLE, rheumatoid arthritis, 
scleroderma). Drug-induced lupus may involve the liver, provoking symptoms akin 
to those of autoimmune hepatitis (AIH) and a liver histology similar to that of chronic 
active hepatitis.
Case reports of AIH associated with minocycline generally describe a long period of 
exposure to the drug prior to the onset of disease.22,23,26,29 Other adverse reports 
associated with minocycline describe a hypersensitivity-type reaction typified by 
fever, rash and internal organ involvement after about 12 weeks’ exposure.18,19,23,30
It has been proposed that the risk of adverse reactions involving the liver and 
associated with minocycline is higher than that associated with other tetracyclines.31 
One explanation may be that whilst the primary route of elimination for most 
tetracyclines is the kidney, minocycline is extensively metabolised by the liver and 
renal clearance is low.32 Another important factor to consider is that unlike some 
other tetracyclines, minocycline has the potential to form reactive metabolites that 
serve as antigens and may incite an immune reaction.23
In the UK, the popularity of minocycline has waned since the mid 1990s.33 The 
paper on minocycline-associated hepatotoxicity published by Gough et al in January 
199622 had a significant effect on prescribing practice in the UK. Dispensing data
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for the first quarter of 1996, presented by Ferguson et al,33 show that the use of 
minocycline (in terms of defined daily doses) dropped to less than 70% of figures for 
the previous quarter, and then further to 62%.
Concern over the incidence of severe adverse reactions to minocycline, particularly 
acute hepatic failure, has prompted some general practitioners and dermatologists 
to advocate prescribing minocycline only as a second line treatment for acne.34 
Cautions relating to autoimmune hepatotoxicity after longer-term (> 6 months) 
exposure to minocycline have been given in the Datasheets since 1998. It is 
apparent that the 1996 article was particularly influential over UK prescribing 
patterns, although the authors do acknowledge that ‘...it was impossible to definitely 
attribute (the adverse events) to the drug’.35
This review looked at the reported association between minocycline and hepatitis in 
order to evaluate and characterise the type of liver disease that has been 
associated with oral minocycline in the treatment of acne.
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M ethods
S y s t e m a t ic  l it e r a t u r e  r e v ie w
Original studies reporting liver damage associated with minocycline therapy for acne 
vulgaris/rosacea were sought in the following databases: Medline, CINAHL, 
Cochrane, EMBASE, Current Contents and Toxline. Publications from the earliest 
years available on the databases to December 1998 were included.
The following terms for liver damage were used to identify relevant papers:
(a) liver diseases [fatty liver, liver failure, liver function tests, liver transplantation, 
hepatic dysfunction]
(b) hepatitis [hepatitis, autoimmune hepatitis, chronic hepatitis, chronic drug- 
induced hepatitis, toxic hepatitis], and
(c) jaundice.
Further searches excluding either minocycline or acne were performed and 
reviewed to ensure that no relevant material was missed. The search criteria 
sought to include papers in English as well as French, German, Swedish and 
Spanish. We did not review papers in other languages as we did not have the 
capacity to translate them.
For full evaluation of minocycline-associated hepatotoxicity, similar searches were 
performed to identify cases of hepatitis in association with all tetracyclines.
An extensive review of the papers identified from the database searches was 
carried out to find relevant secondary references, and where applicable tertiary 
references were sought. A citation search was also carried out using the Bath 
Information and Data Services database (BIDS) for those papers recognised to be 
particularly pertinent to the subject. The reference list of this study does not list all 
references identified, but notes key references to case reports and other papers 
which were considered relevant.
Grey literature was obtained from John Wyeth & Brother, UK, with regard to 
reporting data for ADRs associated with minocycline. Additional data relating to
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specific patient case histories were obtained directly from The Lancet to supplement 
one published report (Bénéton19).
The selection of published reports citing cases of minocycline-related hepatotoxicity 
was based on a critical appraisal of the medical histories presented. Those listing 
the findings of laboratory investigations indicating liver dysfunction were included, 
as were those where specific reference was made to liver dysfunction by the 
authors. Relevant case histories could then be identified from a firm indication of 
hepatic dysfunction post administration of minocycline.
Having identified case reports from the literature, patient details and medical 
histories were entered into an Access database. The interpretation and recording of 
details was further reviewed by two independent researchers (one medically 
qualified [RL]) to ensure accurate assessment of clinical symptoms and 
investigations from the given data. The possibility of reporting duplication was 
recognised, and all case reports were compared by age, gender, country of domicile 
of the patient and year of occurrence wherever possible. Cases without age and/or 
gender of the patient were excluded (accounting for three cases22), as were those 
cases where administration of minocycline was other than oral (one case36).
Decisions on the appropriateness of cases for inclusion were reached by consensus 
and cases were then classified into one of the three groups described in Table 2.1.
A diagnosis of hepatitis was made, qualified by evidence of raised liver enzyme 
levels (twice the upper limit of normal) and/or a firm indication of liver dysfunction by 
the authors of the particular case report. The classification criteria for autoimmune 
hepatitis (AIH) defined by Alvarez e ta l37 (Table 2.2) were applied to aid definition of 
the cases as were the characteristics of hypersensitivity reactions (HSR) (fever, 
rash and internal organ involvement within 12 weeks of drug initiation) described in 
the literature.18,19,23,30
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Table 2.1 Criteria used in this study for classification of hepatitis from case reports
Autoimmune hepatitis (AIH) Hypersensitivity reaction Unspecified hepatitis
(AIH) (n = 29) (HSR) (n = 16) (n = 20)
Altered liver enzyme levels Altered liver enzyme levels Altered liver enzyme levels
Positive ANA (and/or other auto-antibodies) Negative ANA No further diagnostic data
Histological evidence of CAM Eosinophilia (> 5%) Did not fit clearly criteria for
Exfoliative dermatitis AIH or HSR
ANA = antinuclear antibodies; CAH = chronic active hepatitis
Table 2.2 Diagnostic criteria for autoimmune hepatitis (from Alvarez et al, 199937)
Diagnostic criteria for autoimmune hepatitis
Liver histology CAH: piecemeal necrosis + lobular hepatitis or central-portal bridging 
necrosis.
Serum biochemistry Raised levels of serum aminotransferases. Alkaline phosphatase may 
be normal.
Serum immunoglobulins Raised total globulin, y-globulin or immunoglobulin G concentrations.
Serum auto-antibodies Seropositivity for ANA, smooth muscle antibodies or liver-kidney 
microsomal antibodies
Viral markers Negative viral serology
Other No excessive alcohol consumption.
No exposure to known hepatotoxic drugs.
ANA = antinuclear antibodies; CAH = chronic active hepatitis
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R e v ie w  o f  W H O  d a t a
The Uppsala Monitoring Centre (WHO Collaborating Centre for International Drug 
Monitoring) provided us with data on minocycline-associated adverse reactions.
The Centre collates data gathered from national centres within 53 countries 
worldwide. Notifications of adverse reactions within each country may be via 
regulatory bodies or through voluntary sources and, as such, figures obtained are of 
limited value in estimating the true incidence of specific reactions.38 This said, the 
data obtained is valuable in that it provides information on the types of reactions 
reported, the duration of treatment before the event and also changes in reporting 
frequency by year and country.
In addition to reporting the type of reaction, the WHO information usually states the 
age and gender of individuals affected and the route of drug administration. Fields 
are also available on the database to define indications for use, time of treatment 
and outcome subsequent to the reaction.
The Uppsala Monitoring Centre provided us with data on all hepatic reactions 
associated with minocycline from its inception in 1968 to October 1998 - a timespan 
which covers the first licensed therapeutic use of minocycline in the early 1970s. 
This subset of the database, along with sales figures obtained from Intercontinental 
Medical Statistics, was entered onto a local database, reviewed and analysed within 
our department.
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RESULTS
S y s t e m a t ic  l it e r a t u r e  r e v ie w
Sixty-five case reports of liver disease associated with minocycline were identified 
from the literature (Tables 2.3, 2.4 & 2.5). More adverse hepatic reactions have 
been reported in women (58%) and 94% of patients were below 40 years of age.
An autoimmune hepatitis (AIH) was attributed to 29 cases, 20 (69%) of whom were 
female (Table 2.3). The mean age of females was 22 years, and males 23 years. 
Cases of AIH were generally associated with a prolonged course of minocycline 
therapy (median = 365 days for females, 730 days for males), the presence of auto­
antibodies (a positive titre for anti-nuclear antibodies (ANA) was recorded in 26 
patients (90%)), and symptoms of arthritis and/or arthralgia in 21 (72%). The 
ethnicity of all but one patient (a 19 year-old Columbian) was unknown and no 
deaths as a consequence of this reaction were recorded. Recovery on complete 
cessation of the drug was apparent for all patients in a mean of 14 days (range 4-38 
days). Five patients had experienced a recurrence of symptoms in response to 
rechallenge with minocycline. Diagnosis was supported by liver histology in 13 
cases.
Sixteen cases of hepatic damage due to a hypersensitivity reaction (HSR) were 
identified, 10 (63%) cases were female (Table 2.4). The condition was typically 
associated with eosinophilia (69% patients) and desquamation of the skin (63%). 
The mean age of females was 25 years, and males 18 years. The duration of 
treatment with minocycline before onset of symptoms was less than 35 days in all 
cases. Six of the 16 cases of HSR were recorded in patients of African-Caribbean 
origin - data on the ethnicity of the other patients were not available. Three patients 
died from what appeared to be an HSR. An account of these three deaths is given 
below. Another young male of 16 survived his illness following liver transplantation. 
There was one patient with an HSR who demonstrated a positive response to 
rechallenge with minocycline. Liver histology was presented for only one patient 
(see summary of deaths below).
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An unspecified hepatitis was attributed to the remaining 20 cases (Table 2.5). Eight 
(40%) of these patients were female with a mean age of 28 years, while for the 
males the mean age was 25 years. Fourteen of the cases were under the age of 30 
years. The duration of treatment with minocycline before onset of symptoms 
ranged between 8-360 days for females (median 30 days) and 9-840 days for males 
(median 63 days). One female patient aged 17 years survived her illness after liver 
transplantation whilst another female of 22 years died from an illness associated 
with pancytopenia (see below). One case from this group experienced a 
resumption of symptoms on re-exposure to minocycline. Liver histology was 
reported in only one case and revealed a normal architecture.
Figure 2.1 presents the proportional distribution of hepatic reactions by duration of 
exposure to minocycline. All the cases of hypersensitivity reaction reported 
occurred within 35 days of starting minocycline, whilst the AIH occurred usually after 
one year of treatment.
Figure 2.1 Proportional distribution over time of hepatic reactions associated with 
minocycline from published case reports.
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A total of four deaths have been cited in the literature in association with 
minocycline hepatotoxicity. Three of the deaths appeared to be from a 
hypersensitivity reaction. One occurred in a 17 year-old girl who presented with 
pyrexia, myalgia, arthralgia and a pruritic erythematous rash.22,39"41 Her past 
medical history was complicated. She had been taking minocycline for 29 days 
(100mg daily to treat acne) before the onset of her illness and just prior to 
presentation had returned from a visit to Kenya for which she had taken anti- 
malarials and received various vaccinations. After two failed liver transplantations, 
she died, death being attributed to gastrointestinal and abdominal haemorrhage. At 
post-mortem, her liver and the first donor liver were found to be infected with an 
arbovirus, possibly transmitted by a biting insect whilst on holiday.
The second death from an HSR was that of a West Indian boy of 16 years who 
presented with grossly abnormal liver function after taking minocycline for acne, 
100mg daily, for 30 days.19 He was treated with corticosteroids for 6 months but 
died 15 days after stopping this therapy. Post-mortem revealed eosinophilic 
myocarditis. Another young boy of 15 presented with altered liver enzymes after 
taking minocycline, lOOmg daily, for 30 days, possibly for acne.18 Minocycline 
therapy was discontinued immediately and despite treatment with corticosteroids for 
8 weeks, he died. Post-mortem examination revealed myocardial necrosis and 
marked eosinophilia. Biochemical investigations before his death had revealed 
antibodies against parvovirus 19.
The fourth death was associated with an unspecified hepatitis and “pancytopenia” 
and was reported to the CSM in 1990. A detailed picture of this patient's illness has 
not been published, although we know from the CSM report referred to by Gough et 
a/that she had been receiving minocycline therapy, 100mg daily, for about 5 
months.22
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R e v ie w  o f  W H O  d a t a
The WHO has recorded 8,025 reactions to minocycline overall. Of these, 493 (6%) 
were reactions involving the liver, representing reporting for 393 individuals.
Information on both age and gender of individuals was available for 346 of the 393 
reports (88%) and on the route of administration for 370 reports (94%). Fields 
available to define indications for use, time of treatment and outcome subsequent to 
the reaction were seldom complete.
Twenty-two different hepatic reactions were recorded. Groupings of like reactions 
produced four principal categories - “hepatic dysfunction” (32%), “hepatitis” (26%), 
“abnormal LFTs” (24%), and “hyperbilirubinaemia/jaundice” (14%). There were a 
small number of other reactions including 11 cases of hepatic damage/necrosis, 7 
cases of fatty liver and 9 other unspecified reactions.
Gender distribution was almost even (51% females cf 49% males) and the mean 
age was 31 years for females and 30 for males. An indication for use (ICD code) 
was given for 78 of the 393 reports (20%). Of these cases, 61 (78%) cases had 
been prescribed minocycline to treat acne or rosacea, whilst a further 5 reports cited 
a different dermatological indication.
Minocycline was administered orally to 355 (96%) with information on dosage 
available for 228 (64%). The mean daily dose of minocycline for these cases was 
127mg (range 10-500mg). The duration of treatment with minocycline was 
available for 216 of the 393 reports (55%) with a mean of 269 days (Clgs 208-330). 
Reactions occurring within 35 weeks of exposure accounted for 42% of the total, 
whilst over half (53%) occurred within 10 weeks.
Of the 393 individuals experiencing a hepatic reaction to minocycline, 14 also had 
DIL-like symptoms. The precise nature of the symptoms was not specified. Twelve 
females (mean age 23) and 2 males (mean age 22) demonstrated a reaction of this 
type, and for those where the information was available (n = 5), the mean duration 
of exposure was 593 days.
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The outcome of the reactions was reported in less than half the cases. Three 
deaths were evident. One report from Japan recorded the death of a 31 year-old 
man who had taken 200mg of minocycline by mouth for only one day. The notes 
accompanying this report state that the drug “may have been contributory”. Two 
other deaths where minocycline was considered to be responsible for the patient’s 
illness were reported from the UK in 1989. Both these deaths occurred in females, 
one aged 17 and the other aged 20. The 20 year-old had been exposed to 
minocycline for 154 days.
Table 2.5 shows the reporting of minocycline-associated ADRs from each country 
identified from the WHO database. The majority of reports (63%) came from the 
USA and the UK.
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Table 2.6 Reporting to WHO by country
Country Number of reports
United Kingdom 143
USA 105
France 37
Australia 33
Japan 23
Germany 21
Canada 10
Belgium 7
New Zealand 7
Spain 3
The Netherlands 2
Eire 1
Switzerland 1
Total number of reports 393
Since 1990, more than 20 cases per year of minocycline-associated ADRs have 
been reported to WHO. In the UK, the highest annual count of ADRs was received 
in the same year that the greatest number of cases was published. At the same 
time, the number of units sold reached its lowest figure. In the USA, however, a 
peak in reporting frequency occurred earlier and the sales increased. These 
findings are presented in Figures 2.2 and 2.3.
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Figure 2.2 Sales of minocycline in the UK versus worldwide reports of adverse 
hepatic reactions sent to the WHO
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D iscussion
This review of the literature has indicated that minocycline therapy has been 
implicated in several instances of severe hepatic dysfunction,14’17‘19’22'23,25'27,29,30’39,42' 
54 including four deaths.18,19,22,39'41
Our investigation into the cases cited in the medical literature supported the 
previous division of the most severe adverse reactions into two groups. Firstly, 
those that appear to be due to a hypersensitivity reaction (with rapid onset usually 
within one month of treatment) and then those that can be classed as an 
autoimmune hepatitis or “late-onset hepatitis” (generally after a year or more of 
therapy). A characterisation of the 20 cases of ‘unspecified hepatitis’ was not 
attempted because of the sparsity of evidence from the medical histories. The 
onset of illness in 9 of those patients with an unspecified hepatitis, however, was 
within 35 days of commencing therapy whilst for the remaining 11 cases, data on 
duration of exposure to minocycline was available for 8 patients, giving a mean of 
376 days.
The classification of 29 case reports as an autoimmune hepatitis in association with 
minocycline, using the criteria set out in Tables 2.1 and 2.2, demonstrated that this 
type of reaction generally occurs after exposure of at least a year. The medical 
summaries of 20 cases (69%) revealed a history of exposure of a year or more. Of 
the remaining 9 cases, the duration of exposure ranged between 10 and 240 days 
(median 60 days). The most notable outlier in this pattern of distribution is the case 
of a 43 year-old woman presented by Knowles et al (case 13).23 The authors of this 
report describe a DIL-like reaction with hepatic involvement after only 10 days’ 
exposure to minocycline. Over the previous 10 years, however, the woman had 
been exposed to minocycline intermittently. This would be a significant factor in her 
illness and may explain the development of AIM after the unusually short exposure 
period quoted in the case-report.
In a review of this nature, an appraisal of causation in reported deaths is important. 
As mentioned previously, four deaths have been cited in the literature in association 
with minocycline hepatotoxicity. The case of the 17 year-old girl who died after
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taking minocycline22 is complicated by her recent exposure to multiple drugs and the 
presence of an arbovirus. Post-mortem findings from her liver and the first donor 
liver indicated both intra- and extra-hepatic infection with the arbovirus and the role 
of minocycline exposure in her death is unclear.39'41
Postmortem examination of the 16 year-old boy who died from an apparent HSR 
revealed eosinophilic myocarditis.19 Generally, in cases of hypersensitivity 
myocarditis, the condition regresses upon discontinuance of the drug, so any 
association with minocycline exposure, which in this instance was withdrawn 
immediately at the onset of illness, is unsubstantiated.
Evidence of antibodies to parvovirus 19 and post-mortem findings of myocardial 
necrosis and marked eosinophilia on the 15 year-old boy who died from a HSR18 
also raises some doubt over the causative role of minocycline. Antibodies against 
parvovirus 19 have previously been implicated in deaths from myocarditis with 
associated mono-nuclear infiltrates.18 The opinion of the authors of this case report 
was that minocycline was implicated in the boy’s death but, in the light of evidence 
they themselves present of parvovirus infection and also because of evidence for 
myocarditis at post-mortem, the association with minocycline is arguable.
Good evidence to support the role of minocycline exposure in the death of a 22 
year-old woman from an unspecified hepatitis and “pancytopenia” is not available. 
The case was notified to the CSM22 but the published case history does not provide 
enough clinical evidence to substantiate the role of minocycline in her illness. 
Therefore, minocycline-related hepatotoxicity cannot be established firmly as the 
cause of death.12
In an investigation of causality such as addressed in this paper, evidence from re­
challenge is particularly important. From our series, seven cases demonstrated a 
positive re-challenge to minocycline, all of whom recovered from the illness. Given 
the potential seriousness of reactions, however, and the reported cross-sensitivity 
between the tetracyclines32 physicians should not prescribe tetracyclines to patients 
in whom an adverse reaction has been suspected previously.
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There were three deaths associated with minocycline recorded on the WHO 
database. One was reported by Japan but apparently was not published as a case 
report in the specialist journals. The two other deaths, however, present similarities 
to those CSM reports cited in the literature (see Table 2.4, Gough et aF2, *case 22 
and Table 2.5, Gough e taF2, *case 26), and are thus likely to be duplications.
It is apparent from the cases identified from the literature that 6 of the 16 cases of 
HSR were recorded in people of African-Caribbean origin. A genetic predisposition 
to HSR has previously been suggested55'57 and this may be important to consider 
when prescribing minocycline.
The population which experienced an hepatic ADR to minocycline as identified from 
the WHO database has shown an almost equal male:female distribution with a 
mean age of 30 years, whilst 58% of cases of hepatic injury drawn from the 
literature are female, and the mean age of the population is younger at 24 years.
Around 22% of the WHO data for hepatic reactions was recorded for cases aged 
40+ years, compared with only 6% for this age group in the literature case reports. 
Part of the explanation for the discrepancy in the age profile of the two populations 
may be associated with different utilisation of minocycline in reporting countries. 
From Japan, for example, of the 23 reported ADRs, 16 (70%) were in patients over 
the age of 40 years and in 11 cases minocycline was administered intravenously.
An indication for use was given for only two cases, neither of which specified acne. 
No case reports in the literature originating from Japan would have been relevant to 
this study as none was found where hepatic dysfunction was associated with 
minocycline administered orally.
The literature search sought to identify all patients experiencing an ADR with liver 
involvement after ingestion of minocycline. We know from our preliminary analysis 
of utilisation data from the General Practice Research Database (GPRD) that 
around 90% of minocycline prescribed in the UK is used to treat acne, and evidence 
from the case reports on indication for use supports this finding. Because acne 
occurs mainly in people under 40, this would account for the high proportion of 
younger patients in case reports. Seventy eight per cent of cases recorded from
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the literature review had a record of acne. A specific reason for treatment was 
available for only 20% of individuals on the WHO database, of whom 65% had 
received minocycline for acne.
An interesting aspect of the present material is the relationship between reporting 
frequency, published cases in the literature and the sales of minocycline.
Worldwide reporting of ADRs to the WHO have shown a gradual increase since 
1978.38 Figures 2.2 and 2.3 show the relationship between the two countries most 
frequently reporting ADRs, the UK and the USA, in terms of the reporting frequency 
per number of units sold and the number of published hepatic cases in the 
literature. In the UK, the reporting frequency of hepatic reactions reached its peak 
in the same year that the highest number of cases was published. At the same 
time, the number of units sold reached its lowest figure. In the USA, however, a 
peak in reporting frequency occurred earlier and the sales increased. The 1996 
paper published in the BMJ by Gough et a l22 alerted doctors internationally to the 
possibility of serious ADRs associated with minocycline but apparently only 
influenced subsequent prescribing practice in the UK.
The characteristics of patients reported to have an autoimmune liver disease 
associated with minocycline use include an excess incidence in women (69%).26,27 
Over three-quarters of cases are under the age of 40. Utilisation data from the 
GPRD would suggest that much of the excess in young people is because they are 
the age group most affected by acne and who thus consume most of the 
minocycline prescribed. This raises the question as to whether this excess 
occurrence in younger patients is because they are predominantly the users or 
whether they truly have an increased risk. The apparently higher risk of AIH in 
women may reflect gender-specific differences in drug metabolism. Without long­
term observational studies, it is difficult to predict the attributable risk of AIH, 
especially for young women in whom autoimmune hepatitis is already more 
common.37
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C o nclusio ns
To determine if minocycline is likely to be causally related to the occurrence of 
hepatitis, we need to establish whether there is a strong association when 
compared with the general population or more importantly when compared with the 
population that have acne. The temporal relationship is well-documented, evidence 
of positive re-challenge and the fact that cases get better after the removal of the 
minocycline adds weight to there being a causal relationship. However, transient 
hepatitis can occur in some patients and it is possible that some of these patients 
would have recovered without stopping the medication. From our preliminary 
unvalidated analysis of incidence rates for non-viral hepatitis in the general GPRD 
population compared with the acne population, people with acne appear more likely 
to suffer an hepatic illness. There is no obvious explanation for this finding, and 
whilst various ideas could be discussed regarding the role of exposures, lifestyle or 
predisposing factors, more research is required to elucidate exactly why this should 
be so.
Despite the reported cases, we do not have any clear information about the 
absolute and relative risks of hepatitis, whether HSR or AIH, in patients receiving 
minocycline therapy for varying lengths of time. The WHO data show that whilst in 
the UK the utilisation has fallen, the reporting of adverse events has increased. The 
converse is true in the United States. This suggests that there are considerable 
biases in using spontaneous reports to assess risk. There does however seem to 
be an association between hepatitis and the use of minocycline. A review of this 
nature cannot quantify the absolute or attributable risk of liver dysfunction 
associated with minocycline exposure and we think it inappropriate to make 
comment on whether monitoring of patients is worthwhile. A study of the 
comparative rates of hepatitis in people exposed to minocycline compared with 
those not exposed is required.
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A bstract
Using the General Practice Research Database, we performed:
(a) A cohort analysis comparing the incidence of liver dysfunction in new users of 
minocycline, compared with new users of oxytetracycline/tetracycline
(b) A case-control study assessing antibiotic exposure in new cases of liver 
dysfunction and controls without liver dysfunction.
Results: (a) In new users, the incidence of liver dysfunction in those exposed to 
minocycline was 1.04 cases/10,000 exposed person-months (EPM) and 0.69 
cases/10,000 EPM in those exposed to oxytetracycline/tetracycline (relative risk
1.51 [ C I 9 5  0.63,3.65]). The risk in both groups was greatest in the first month of 
use.
(b) The adjusted odds ratio ( O R a d j) of liver dysfunction associated with exposure to 
minocycline compared with non-use was 2.10 ( C I 9 5 1.30,3.40), for 
oxytetracycline/tetracycline ORadj 1.46 (Cl95 0.81,2.64) and for exposure to 
erythromycin, ORadj 1.64 (Cl95 0.71,3.80).
We thus support a weak association between the use of oral antibiotics and liver 
dysfunction in patients with acne. The risk associated with exposure to minocycline 
appears to be very small. Our cohort analysis demonstrated that any risk 
associated with minocycline was not significantly greater than that associated with 
oxytetracycline/tetracycline exposure.
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B a c kg ro und
Minocycline is an antibacterial drug of the tetracycline group prescribed for the 
treatment of a wide range of infections and specifically licensed in the UK for the 
treatment of acne (Minocin MR®). It has been implicated in a number of case 
reports of hepatitis.1'20 These have been characterised as acute hypersensitivity 
reactions,3,7’9,13,16"18 and a less severe autoimmune hepatitis which typically occurs 
after long-term use, sometimes with lupus-like symptoms and predominantly in 
young women.1’2’4’8’10'13’15’17,19'21 In this respect, those apparently most susceptible 
to such a drug-induced lupus are similar to those observed to be at increased risk of 
systemic lupus erythematosus. Since 1996 utilisation of minocycline in the UK has 
fallen 22 presumably because of concerns raised about its safety, particularly in 
relation to hepatitis.1’3"9,11*19’23"27
In the treatment of acne, minocycline demonstrates superior efficacy to first 
generation tetracyclines (tetracycline and oxytetracycline) 28'33 being more efficiently 
absorbed 29,32,34 and particularly useful in overcoming the growing problem of 
bacterial resistance.30,35,36 It is the most commonly used tetracycline for long term 
therapy37 and treatment may last several months and sometimes years. Whilst 
minocycline has been associated with the transient and usually mild side effects 
typical of tetracyclines (vestibular and gastrointestinal disturbances, 
hyperpigmentation of tissue), it has been proposed that the potential to form a 
reactive metabolite may associate minocycline with a higher incidence of side 
effects compared with other tetracyclines.17 Evidence from clinical trials in acne 
patients comparing minocycline therapy with other acne treatments, however, does 
not appear to substantiate fears of an increased risk of serious side effects to 
minocycline.29,38 Large cohort studies together accounting for over 10,000 months of 
minocycline use, record some minor ADRs to minocycline but none report drug- 
induced liver damage.32,33,39
To our knowledge, the incidence of hepatitis in users of minocycline has not been 
studied. Neither has the relative risk of hepatitis following exposure to minocycline 
compared with the risk of hepatitis in non-users or users of other antibiotics. 
Autoimmune hepatitis is a rare event that occurs most often in young women.
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If there is a substantial number of young people taking oral minocycline for long 
periods to treat acne, then by chance a number of these patients will develop an 
autoimmune hepatitis whilst taking the medication. In some cases the patient’s 
symptoms and biochemical tests return to normal after withdrawal of minocycline, 
and are exacerbated by a re-challenge. Nonetheless, not all cases of autoimmune 
hepatitis can be attributed to the therapy being taken at the time. It was therefore 
thought useful to undertake an observational study to ascertain the relative, 
absolute and attributable risks of liver dysfunction associated with using 
minocycline, compared with other systemic anti-acne therapies commonly used in 
the UK.
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M etho ds
The study was carried out using the General Practice Research Database (GPRD). 
The GPRD contains the anonymised patient records of approximately 8 million 
patients from 750 practices throughout the UK. The validity and utility of this 
database for studies of drug safety have been published elsewhere.40-43
Because minocycline is used almost exclusively in patients with acne, the study 
population comprised all patients with acne aged between 15 and 39 years of age 
and registered with practices contributing to the GPRD at any time between 1992 
and 1997 (418 practices).
Patients with liver dysfunction were identified from the study population by 
searching the database for specific codes relating to liver dysfunction. Records of 
liver dysfunction had to occur within the study period and potential cases included 
patients with raised liver enzymes, jaundice or a record of liver failure or hepatitis. 
Cases were excluded if there was a known cause for their liver dysfunction ie 
evidence of malignancy, viral infection (Hepatitis A, B, C, Non A-Non B or glandular 
fever), alcohol abuse, drug misuse or Wilson’s disease.
An attempt was made to validate the medical histories of all cases of liver 
dysfunction where there was evidence of referral or admission to hospital. To 
ensure anonymity of the patients, retrieval of information from general practitioners 
was performed through a third party*.
Three reviewers independently assessed true “caseness” from the patients’ medical 
notes, blinded to antibiotic exposure. When discrepancies arose over case 
assignment, agreement was reached by consensus.
The study was performed in two parts:
(a) a cohort analysis comparing the incidence of liver dysfunction in people who 
have had a diagnosis of acne and who were new users of minocycline or 
oxytetracycline/tetracycline (hereafter referred to as (oxy)tetracycline*).
* Comasco Computer Services Ltd, Regeneration House, York Way, Kings Cross, London.
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(b) a case-control study looking at exposure to systemic anti-acne treatments in 
patients with liver dysfunction (cases) and matched controls.
An independent Scientific Advisory Board that included a dermatologist, physician, 
general practitioner, epidemiologist and a statistician was consulted about study 
design.
C o h o r t  s t u d y
Within the study population “new users” were identified as those patients with 
prescriptions for oral tablets of minocycline or (oxy)tetracycline without evidence of 
prior exposure to minocycline or (oxy)tetracycline.
The number of tablets prescribed and dosage were used to calculate the duration of 
therapy. Where further prescriptions were issued before, or up to 30 days after, the 
end of the previous script, then the days of exposure to the specific antibiotic 
prescribed were joined to give a total uninterrupted patient exposure. If more than 
30 days had elapsed after the end of cover, then the exposure period was 
considered to be at an end.
We identified patients with liver dysfunction who were newly exposed to either 
minocycline or (oxy)tetracycline. Rates of liver dysfunction in patients exposed to 
minocycline or (oxy)tetracycline for the first time were calculated and stratified by 
gender and duration of exposure. Relative risks with 95% confidence intervals were 
calculated using a computerized statistical package (Epilnfo44).
The rate of liver dysfunction in patients with acne not exposed to 
minocycline/(oxy)tetracycline was determined and the attributable risk of liver 
dysfunction associated with exposure thereby calculated.
*  Oxytetracycline and tetracycline were grouped together on the recommendation of the 
Scientific Advisory Board who considered that the pharmacokinetics and prescribing patterns 
of the two preparations were very similar.
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C ase-control  stu d y
The event date for each case identified was established as the date on which the 
hepatic illness was first evident from the medical notes. Episodes of liver 
dysfunction more than a year apart qualified as separate events and only the first 
event was included.
Exposure to oral acne therapies prior to the event date was assessed. Cases were 
considered to be exposed if there was a prior prescription that if taken as directed 
would have meant that the medication was being taken on the day of the event. 
However, it is possible that the first note of liver dysfunction in the cases may have 
been several days after the patient had ceased taking prescribed antibiotics.
Events occurring up to three weeks after the patient would have ceased treatment 
were identified and a sensitivity analysis carried out with exposed cases defined by 
exposure within 0,7,  14 or 21 days of the event. The duration of any exposure to 
antibiotics was calculated and patient characteristics including alcohol consumption, 
smoking status and BMI category recorded. Exposure to other potentially 
hepatotoxic drugs was noted.
For each case identified, four controls of the same gender and from the same 
practice were selected. Wherever possible, controls were also matched to cases by 
exact year of birth. Where this could not be achieved, the search was widened to 
identify controls born within a year of the case, within two years and so on, using a 
best-fit algorithm. Controls had to be registered on the event date of the matched 
case. Patient characteristics and drug exposures were recorded as for cases using 
the case’s event date as index date for the control.
Unadjusted and adjusted conditional logistic regression analyses were performed 
and odds ratios with 95% confidence intervals calculated using a computerized 
statistical package (Stata45). A subgroup analysis was also carried out using only 
verified cases where case status was confirmed by a case’s own general 
practitioner.
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R e s u lts  
C o hort Study
The study population included 153,530 people aged between 15 and 39 years with 
a diagnosis of acne. Of these, 29,322 (19.10%) were patients exposed to 
minocycline who had not been exposed previously (new users) and 40,748 
(26.54%) were new users on (oxy)tetracycline. Total exposed person months 
(EPM) for new users of minocycline was 125,347 compared with 116,581 for new 
users of (oxy)tetracycline. The mean duration of uninterrupted exposure to 
minocycline was thus 4.27 months compared with a mean exposure of 2.86 months 
in those exposed to (oxy)tetracycline. The numbers of new users with liver 
dysfunction are presented in Table 3.1.
Table 3.1 Number of new cases of liver dysfunction in patients newly exposed to 
minocycline or (oxy)tetracycline
Males Females Total
Number of newly exposed cases
Minocycline 7 6 13
(Oxy)tetracycline 6 2 8
Number of newly exposed cases exposed < 30 days
Minocycline 2 3 5
(Oxy)tetracycline 2 1 3
Number of newly exposed cases exposed > 30 days
Minocycline 5 3 8
(Oxy)tetracycline 4 1 5
Rates of liver dysfunction in new users on minocycline and (oxy)tetracycline are 
presented in Table 3.2. There were 13 cases of liver dysfunction in new users on 
minocycline giving a rate of liver dysfunction of 1.04 cases/10,000 EPM. Eight 
cases of liver dysfunction were identified in new users of (oxy)tetracycline (0.69 
cases/10,000 EPM). Thus, the overall relative risk (RR) of liver dysfunction in those 
exposed to minocycline compared with those exposed to (oxy)tetracycline in terms 
of EPM was 1.51 (Cl95 0.63,3.65). The RR of liver dysfunction in patients exposed
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to minocycline for 30 days or less was 1.98 (Cl95 0.47,8.27) compared with patients 
exposed to (oxy)tetracycline for the same period. Similarly, the RR in patients 
exposed to minocycline for more than 30 days was 1.37 (Cl95 0.45,4.18). None of 
the apparently raised risks associated with minocycline were statistically significant.
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Table 3.2 Rates of liver dysfunction and relative risks (with 95% CIs) in patients 
with acne exposed to minocycline or (oxy)tetracycline
Persons Males (M) Females (F) Relative Risk 
M vs F
Rate in exposed new users/10,000 EPM1
Minocycline 1.04 1.04 1.04 1.00 (0.34,2.97)
(Oxy)tetracycline 0.69 0.87 0.42 2.08 (0.42,10.33)
Relative Risk2 1.51 (0.63,3.65) 1.19(0.40,3.53) 2.48 (0.50,12.30)
Rate in exposed new users exposed < 30 days/10,000 EPMi
Minocycline 1.75 1.42 2.07 0.68 (0.11,4.09)
(Oxy)tetracycline 0.88 1.08 0.65 1.67 (0.15,18.44)
Relative Risk2 1.98 (0.47,8.27) 1.31 (0.18,9.29) 3.20 (0.33,30.76)
Rate in exposed new users exposed>30 days/10,000 EPMi
Minocycline 0.83 0.94 0.69 1.35 (0.32,5.65)
(Oxy)tetracycline 0.60 0.80 0.31 2.57 (0.29,23.01)
Relative Risk2 1.37 (0.45,4.18) 1.18(0.32,4.38) 2.24 (0.23,21.55)
Rate ratio (exposure ;< 30 days: exposure > 30 days)
Minocycline 2.11 (0.69,6.45) 1.51 (0.29,7.80) 2.98 (0.60,14.79)
(Oxy)tetracycline 1.46 (0.35,6.11) 1.36 (0.25,7.42) 2.09 (0.13,33.43)
Rate in exposed new users/10,000 exposed new users
Minocycline 4.43 4.85 
(Oxy)tetracycline 1.96 2.84 
Relative Risk2 2.26 (0.94,5.45) 1.71 (0.57,5.08)
4.03
1.02
3.95 (0.80,19.59)
1.21 (0.41,3.59) 
2.79 (0.56,13.83)
1EPM = exposed person months
^Relative risk calculated for minocycline versus (oxy)tetracycline
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The rate of liver dysfunction in cases never exposed to minocycline was 0.46 
cases/10,000 observable person months (OPM) and in those never exposed to 
(oxy)tetracycline 0.45 cases/10,000 OPM. The attributable risk of liver dysfunction 
in patients newly exposed to minocycline compared with non-exposure was 
potentially 5.74 cases/100,000 EPM (Cl95 1.80,9.67) and for patients newly exposed 
to (oxy)tetracycline compared with non-exposure, 2.39 cases/100,000 EPM ( C I 9 5  -  
1.56,6.34) (Table 3.3).
Table 3.3 Attributable risk of liver dysfunction: exposed versus not exposed 
(95% confidence intervals in parentheses)
AR/100,000 EPM Persons Males Females
Minocycline 5.74(1.80,9.67)* 4.71 (-1.21,10.64) 6.52 (1.23,11.81)*
(Oxy)tetracycline 2.39 (-1.56,6.34) 3.12 (-2.70,8.95) 0.51 (-5.00,6.03)
AR = attributable risk; EPM = exposed person months; * statistically significant at p<0.05
The results suggest that the incidence of hepatic dysfunction in the first 30 days of 
taking minocycline was higher in females compared with males and the rate of liver 
dysfunction in patients exposed to minocycline for more than 30 days was slightly 
higher in males. The respective relative risks of liver dysfunction by gender and 
duration of exposure were not, however, statistically significant. Rates of liver 
dysfunction in people taking (oxy)tetracycline were higher in males at both time 
intervals, though not significantly so. Rate ratio calculations indicate an overall 
higher risk of liver dysfunction in the first 30 days of exposure to minocycline or 
(oxy)tetracycline, but this was not statistically significant.
A calculation of the risk of liver dysfunction in terms of the number of new users 
gave a risk of 4.43 cases of liver dysfunction/10,000 new users on minocycline and 
in new users on (oxy)tetracycline, a risk of 1.96 cases/10,000 new users (RR 2.26 
[ C I 9 5  0.94,5.45]).
None of the new users on minocycline identified as cases with liver dysfunction had 
a record of hospital admission. In two cases drug-induced liver dysfunction
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associated with minocycline was suggested by the GP (one case had been exposed 
to minocycline for more than 4 years and the other for about 11 months). Another 
case exposed to minocycline had an autoimmune hepatitis after only 4 days’ 
exposure, although the drug was not implicated by the GP. One new user on 
(oxy)tetracycline was admitted to hospital for five days with vomiting and altered 
liver function of unknown aetiology after 5 weeks’ exposure to oxytetracycline.
C ase-c o n tr o l  stu d y
The number of cases of liver/hepatic dysfunction identified from the study 
population was 250. Each case was matched by year of birth, gender and practice 
to 4 controls. 37% of the cases were matched to a control by exact year of birth and 
83% of the controls were born in the same year as the case or the same year ± 1 
year.
Of the 250 cases, 113 (45%) were female and 59% aged below 25 years. There 
were 52 cases with a diagnosis of hepatitis and 70 with a record of jaundice. A 
further 139 cases were identified with abnormal liver function test results only.
There were 136 cases referred to hospital (55%) of which 15 had a record of 
admission. Three cases underwent a liver transplant, one of whom had a record of 
Gilbert’s disease prior to transplant but no drug exposure of significance recorded in 
the notes. This patient died 2% years after transplant from Burkitt’s lymphoma. 
Neither of the other two patients who underwent transplant had significant drug 
exposure within 6 months of the event.
Odds ratios calculated as part of the sensitivity analysis on valid intervals between 
exposure to an antibiotic and hepatic event were similar at 0,7, 14 and 21 day 
intervals. Only those results for exposure within 14 days of the event are 
presented.
The results of unadjusted conditional logistic regression analyses are presented in 
Table 3.4. These indicate statistically significant predictors of the outcome variable 
as exposure to minocycline (OR 1.65 [ C I 9 5 1.07,2.54]) and also exposure to 
(oxy)tetracycline for 30 days or less (OR 2.30 [Cl95 1.00,5.26]).
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Table 3.4 Results of unadjusted conditional logistic regression analyses 
(reference = no exposure unless otherwise indicated)
Patient characteristics Controls 
N %
Cases
N % Odds Ratio3
Previous exposure (> month)
Minocycline 321 32.1 77 30.8 0.77 (0.55,1.07)
(Oxy)tetracycline 337 33.7 85 34.0 0.90 (0.65,1.23)
Erythromycin 130 13.0 38 15.2 1.26 (0.84,1.90)
Other antibiotics 104 10.4 26 10.4 1.00 (0.61,1.64)
Exposure within 14 days of event date
Minocycline 93 9.3 35 14.0 1.65 (1.07,2.54)*
(Oxy)tetracycline 54 5.4 17 6.8 1.38 (0.77,2.46)
Erythromycin 25 2.5 9 3.6 1.64 (0.71,3.75)
Other antibiotic 20 2.0 2 0.8 0.43 (0.10,1.89)
Duration of exposure lasting < 30 days
Minocycline 29 29.6 15 41.7 1.72 (0.82,3.59)
(Oxy)tetracycline 17 28.3 9 50.0 2.30 (1.00,5.26)*
Erythromycin 14 53.8 4 44.4 1.25 (0.41,3.82)
Other antibiotics 6 28.6 1 50.0 0.67 (0.07,6.17)
Duration of exposure lasting > 30 days
Minocycline 69 70.4 21 58.3 1.58 (0.96,2.61)
(Oxy)tetracycline 43 71.7 9 50.0 0.91 (0.43,1.93)
Erythromycin 12 46.2 5 55.6 2.02 (0.61,6.70)
Other antibiotics 15 71.4 1 50.0 0.29 (0.04,2.24)
Alcohol status: Unknown 363 36.3 86 34.4 0.78 (0.49,1.24)
Teetotal 137 21.5 41 25.0 Reference
Lightb 477 74.9 111 67.7 0.77 (0.51,1.17)
Moderate0 23 3.6 12 7.3 1.83 (0.80,4.20)
Exposure to antidepressant
within a month of event 16 1.6 11 4.4 2.91 (1.31,6.45)*
Exposure to oral contraceptives (females)
within a month of event 148 32.7 29 25.7 0.68 (0.42,1.11)
Prior exposure to isotretinoin
(within a year of event) 1 0.1 5 2.0 20.00 (2.34,171.19)*
a Prediction of outcome (‘caseness’) expressed as an odds ratio with 95% confidence intervals 
b Light alcohol intake: Females <15 units/week; males <21 units/week 
0 Moderate alcohol intake: Females >15<40 units/week; males >21 < 50 units/week 
* Statistically significant at p<0.05
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We did not find any association between smoking status or raised BMI and liver 
dysfunction. Exposure to an antidepressant within a month of the event date 
proved a significant predictor of the outcome variable (OR 2.91 [Cl951.31,6.45]). 
There was no difference in the use of selective serotonin re-uptake inhibitors 
(SSRIs) and tricyclic antidepressants (TCAs) between cases (SSRIs 55%; TCAs 
45%) and controls (SSRIs 56%; TCAs 44%).
Prior use of isotretinoin produced an odds ratio of 20.00 ( C I 9 5  2.34,171.19), 
although this was based on very small numbers (5 cases and 1 control). Two cases 
with prior exposure to isotretinoin were exposed to minocycline on the event date.
A conditional logistic regression analysis was performed adjusted for past exposure 
of a month or more to minocycline and/or (oxy)tetracycline, exposure to an 
antidepressant within a month of the event date and exposure within 14 days of the 
event to minocycline, (oxy)tetracycline, erythromycin or other antibiotics (Table 3.5). 
Significant predictors of outcome were found to be exposure to minocycline ( O R adj 
2.10 [ C I 9 5 1.30,3.40]) and exposure to an antidepressant within a month of the event 
( O R  adj 2.84 [Cl9 5 1.25,6.44]). Previous exposure of a month or more to minocycline 
appeared to confer a protective effect ( O R  adj 0.54 [Cl95 0.35,0.83]).
3.15
Minocycline & liver damage: risk assessment
Table 3.5 Results of adjusted conditional logistic regression adjusted for 
exposure to an antibiotic within 14 days of the event 
(reference = no exposure; number observations = 1250)
Adjustment factor Odds Ratio3
Previous exposure (> month) Minocycline 0.54 (0.35,0.83)*
(Oxy)tetracycline 0.77 (0.52,1.13)
Minocycline & (oxy)tetracycline 0.63 (0.36,1.10)
Exposed to antibiotic within 14 days of event date Minocycline 2.10(1.30,3.40)*
(Oxy)tetracycline 1.46 (0.81,2.64)
Erythromycin 1.64 (0.71,3.80)
Other antibiotics 0.42 (0.09,1.84)
Exposure to an antidepressant within a month of event date 2.84 (1.25,6.44)*
a Prediction of outcome (‘caseness’) expressed as an odds ratio with 95% confidence intervals 
* Statistically significant at p<0.05
The validation exercise identified 57 confirmed cases of idiopathic or drug-induced 
liver dysfunction referred or admitted to hospital. In the aetiology of four cases 
current or prior minocycline exposure was implicated by the general practitioner. 
One case experienced an autoimmune hepatitis after a period of exposure to 
minocycline of three weeks. Two cases of chronic active hepatitis were confirmed 
though neither was exposed to an oral anti-acne therapy. Three cases of liver 
dysfunction were temporally associated with (oxy)tetracycline although this 
exposure was not causally implicated by the GP.
A sub-group analysis of cases confirmed by validation using conditional regression 
analysis adjusted for the same factors as before gave an O R  adj of 1.56 for 
minocycline exposure and an O R adj of 2.67 for (oxy)tetracycline exposure within 14 
days of the event with wide confidence intervals (Table 3.6).
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Table 3.6 Results of adjusted conditional logistic regression using 
the 57 cases confirmed by validation 
(reference = no exposure; number of observations = 285)
Adjustment factor Odds Ratio3
Previous exposure (> month) Minocycline 0.89 (0.37,2.17)
(Oxy)tetracycline 0.77 (0.33,1.80)
Minocycline & (oxy)tetracycline 1.04 (0.37,2.94)
Exposed to antibiotic within 14 days of event date Minocycline 1.56 (0.58,4.25)
(Oxy)tetracycline 2.67 (0.83,8.60)
Erythromycin 2.74 (0.28,27.12)
Other antibiotics 0.54 (0.06,4.58)
Exposure to an antidepressant within a month of event date 2.49 (0.46,13.43)
a Prediction of outcome (‘caseness’) expressed as an odds ratio with 95% confidence intervals
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D iscussio n
Of the 29,322 new users on minocycline, 13 developed liver dysfunction, though 
none had a record of hospital admission. One patient was described as having an 
autoimmune hepatitis temporally associated with exposure to minocycline that 
resolved on withdrawal of the drug. Two others had a drug-induced hepatitis 
associated with minocycline exposure. The remaining cases experienced only 
transient jaundice and/or mildly abnormal LFTs. The relative risk of liver 
dysfunction in those exposed to minocycline versus (oxy)tetracycline was raised at
1.51 but this was not statistically significant. There was a non-significant increase in 
the risk of liver dysfunction in the first 30 days of exposure to minocycline or 
(oxy)tetracycline. There was no difference in risk of liver dysfunction between 
males and females taking minocycline or (oxy)tetracycline. The attributable risk of 
liver dysfunction in patients with acne exposed to minocycline was calculated as 
5.74 cases per 100,000 EPM.
From the case-control study, a calculation of the risk that those patients developing 
liver dysfunction were exposed to an antibiotic showed an elevated risk for users of 
minocycline, (oxy)tetracycline and erythromycin, although this finding was only 
statistically significant for minocycline ( O R adj 2.10 [Cl9 5 1.30,3.40]). This is 
consistent with an increased risk compared with non-use.
We found no association between smoking or raised BMI and liver dysfunction. 
Because of missing data, a BMI status could be ascertained for fewer controls than 
cases. The lack of association observed between BMI and liver dysfunction may 
therefore be an artefact. There was no difference between cases and controls in 
the availability of smoking information.
In the case-control study we included all cases of liver dysfunction -  thus there were 
more cases exposed at the time of the event to minocycline than we found in the 
cohort study where we restricted the study to new users. The majority of cases of 
liver dysfunction that occurred that were associated with minocycline use (n=35) 
were in patients who had previously taken minocycline (n=22), had stopped for a 
period or switched to another antibiotic and then started minocycline again.
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Five cases of hepatitis/liver dysfunction had a record of prior isotretinoin use by the 
patient, whilst this medication was only mentioned once in the 1,000 controls. 
Isotretinoin has been associated with jaundice and hepatitis and so these cases 
may be causally associated. However because in the UK only hospital specialists 
prescribe isotretinoin and scripts will not appear on the GPRD, the mention of its 
use in these cases may reflect reporting bias. Two of the cases with a history of 
isotretinoin exposure were exposed to minocycline on the event date. If isotretinoin 
treatment is taken as a proxy for severity of acne, the susceptibility to hepatitis may 
be a factor of the cases’ acne status or indeed related to minocycline.
The case-control study also revealed a significant association between the use of 
antidepressants and hepatitis. These may be a true association or may indicate a 
missed diagnosis during the prodromal phase of an hepatic illness when patients 
feel lethargic and depressed. We did not find any evidence to suggest an 
association between hepatitis and type of antidepressant used. We believe further 
work would need to be undertaken in people with depression to ascertain if 
antidepressants are causally associated with hepatitis.
When considering cases in young women, we found only 20% were taking an oral 
contraceptive at the time of the event, a lower percentage than expected. There is 
no evidence, therefore, that in young women with acne, oral contraceptive use is 
associated with hepatitis. Oestrogens have been associated with an increased risk 
of liver dysfunction and progestogens are known to exacerbate acne. It may be that 
prescribing bias affects young women with acne requiring contraception. Further 
work would be required to explore this observation.
To our knowledge, a relationship between acne and hepatitis, irrespective of drug 
exposure, has not been established. An initial examination of the database, 
however, suggested that the acne population had an almost 2-fold excess risk of 
liver dysfunction compared with an age-matched general population. No evidence 
could be found in the literature to explain why people with acne should be more 
susceptible to hepatitis although it may be that people with acne are more likely to 
succumb to inflammatory diseases in general. In our study population, eight cases 
of liver dysfunction occurred in patients with a diagnosis of arthritis, three cases had
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psoriasis, and one case had Crohn’s disease. The possible co-morbidity of acne 
and liver dysfunction may warrant further study.
The absolute risk of liver dysfunction in patients exposed to minocycline appears to 
be in the order of one event per every 10,000 EPM and the risk appears to be 
greatest in the first month of use. The majority of these cases are mild changes in 
liver function that resolve without further sequelae. This is also true for the cases 
that were identified in the non-exposed population and those exposed to other 
antibiotics.
In summary, liver dysfunction in this age group is a rare event and most cases were 
excluded because of an association with alcohol abuse or viral infection. Idiopathic 
liver dysfunction is rarely severe. Of 153,530 patients with up to 5 years of 
recorded data we found 52 cases with a clear diagnosis of hepatitis, and 15 cases 
with a record of hospital admission as a consequence of liver dysfunction. Our 
findings suggest that there could be a small increase in risk associated with the use 
of minocycline (although residual confounding cannot be ruled out).
Given the published case reports, very few of the events we identified from the 
GPRD were similar to the reactions described in the literature.21 Whilst it is 
important to remember that from the evidence of case reports hepatitis can be a 
rare adverse event associated with minocycline use, this study has allowed us to 
quantify that risk and shows that the excess risk is extremely small. This allows a 
judgment to be made on the value of screening for liver dysfunction for new users. 
We also believe that our study shows that the use of oral minocycline should not be 
precluded when clinically indicated.
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A b str a c t
Background: Cyproterone acetate combined with ethinyloestradiol (CPA/EE) 
provides a treatment option for women with acne, hirsutism or polycystic ovary 
syndrome. CPA/EE may be prescribed as an oral contraceptive but is not licensed 
as such in the UK. The use of CPA/EE steadily increased after its introduction to 
the UK market in 1987 but there was a marked increase in its share of the oral 
contraceptive (OC) market after 1995.
Methods: We compared utilisation patterns of CPA/EE and conventional OCs in 
women aged 15-39 with or without acne or PCOS using the General Practice 
Research Database.
Results: Between 1994 and 1998, CPA/EE accounted for an increasing proportion 
of all OC use. The proportion of CPA/EE prescribed to women with acne declined 
between 1994 and 1998 but the proportion prescribed to women with PCOS 
remained constant. The age-specific use of CPA/EE by women with acne or PCOS 
almost doubled. After 1995, there was a marked increase in the use of products 
containing levonorgestrel by women with acne or PCOS.
Conclusions: A large proportion of CPA/EE is prescribed to women with acne 
and/or PCOS although this proportion decreased between 1992 and 1998. This has 
important implications in CPA/EE risk assessment studies.
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Introductio n
Acne is generally associated with the onset of puberty and increased sebum 
production from the hair follicles on the face, chest and back. Propionibacterium 
acnes may proliferate within blocked pilosebaceous units and cause comedones 
and inflamed pustules. The severity of acne varies as does the tolerance to the 
condition demonstrated by affected individuals. Many women rely on over-the- 
counter preparations and/or cosmetics and not all women with acne will consult a 
general practitioner (GP). The pattern of consultation with a GP is therefore not a 
reliable measure of acne severity.
Conventional medical treatments for acne act by reducing sebum production, 
unblocking pores, delivering antibiotics or suppressing the effects of androgens. 
Some combined oral contraceptives (COCs) may be helpful in alleviating acne. 
Whilst none of the progestogens in conventional COCs is anti-androgenic, 
desogestrel has low androgenic activity, as does gestodene.1 Consequently, in 
women with acne COC formulations containing desogestrel or gestodene are likely 
to be prescribed in preference to COCs containing the more androgenic 
progestogen levonorgestrel.
In the UK, the anti-androgen cyproterone acetate (CPA 2mg) combined with 
ethinyloestradiol (EE 35ug) is licensed for the treatment of women with acne that is 
refractory to prolonged antibiotic therapy and women with moderately severe 
hirsutism; it also provides contraception. Acne and hirsutism are commonly 
associated with polycystic ovary syndrome (PCOS).2:3 Other common features of 
PCOS include obesity, secondary infertility, dyslipidaemia and insulin resistance, 
independent of obesity.4'7 Some women with acne will exhibit other PCOS co­
morbidities and thus present an intrinsically adverse cardiovascular risk profile.
In October 1995, the UK Committee on Safety of Medicines (CSM) informed doctors 
and pharmacists that the risk of venous thromboembolism (VTE) amongst women 
using combined oral contraceptives (COCs) containing desogestrel or gestodene 
was twice that amongst women using COCs containing other progestogens.8 The 
use of COCs containing desogestrel and gestodene consequentially declined 
(Figure 4.1). Figure 4.2 illustrates a coincident increase in the COC market share
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occupied by CPA/EE (as a proportion of all COC cycle packs sold) from 1995. 
Trend lines for the periods 1987-1995 and 1995-mid year 2000 indicate a marked 
increase in CPA/EE market share after 1995.
Figure 4.1: Trends in oral contraceptive market share in the UK by progestogen 
(Source: company sales data, Sobering AG, personal communication)
80 n
70 -
60 -
— 50 - —  Desogestrel
—  Gestodene
—  Levonorgestrel
—  CPA/EE
20  -
0 4—
1981 1983 1985 1987 1989 1991 1993 1995 1997 1999
Figure 4.2: Trends in UK CPA/EE sales
(Source: company sales data, Sobering AG, personal communication)
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This paper uses data from the General Practice Research Database (GPRD) to 
compare patterns of use of conventional COCs and CPA/EE in young women by the 
presence or absence of acne and/or PCOS. We describe the characteristics of 
CPA/EE users and COC prescribing practice in women with or without acne or 
PCOS during the years 1992 to 1998.
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M ethods
The GPRD contains the anonymised patient records for about 4% of the UK 
population at any one time. Data have been collected from 1987 and since the 
beginning of 1992 most contributing practices have provided good quality data. The 
validity and utility of this database for studies of drug safety have been published 
elsewhere.9'12 The number of practices contributing data to the GPRD has changed 
in recent years: over the last 5 years about 300 of the initial 750 practices have 
ceased to contribute either because of concerns about the quality of their data or 
because they have changed to another computer system. This report is restricted to 
practices that have contributed data deemed to be of research standard by the 
owners of the database (the UK Medicines Control Agency). In addition to 
demographic information the GPRD contains three types of coded data. Medical 
diagnoses are coded to an OXMIS (Oxford Medical Indexing System) or Read code. 
Prescribed drugs are recorded with reference to Prescription Pricing Authority (PPA) 
drug codes, dosage and quantity. Prescribing information is around 95% complete.11 
Other information related to smoking habits, alcohol consumption, height and weight 
are recorded with some incompleteness that varies by practice.
The study population comprised women aged between 15 and 39 registered with a 
general practitioner who provided data of research quality to the GPRD at any time 
during the study period (01/01/1992 to 31/12/1998). Patients could join the study 
cohort (by registering with one of the contributing practices) or leave (by changing 
their doctor, as a result of death or by the doctor ceasing to contribute to the GPRD) 
at any time during the study period.
For each woman her age (calculated as observation year minus year of birth) and 
the number of days on which was she was registered with the practice during each 
calendar year was calculated. The age-specific number of woman-years of 
observation (observed women years [OWY]) was aggregated in 5-year age bands 
(by summing the number of days on which each woman was registered during each 
calendar year of observation within each year of age and dividing by 365). COC 
and CPA/EE prescriptions for all women with at least 6 months’ prior data were 
identified and used to map drug use to each day in the study period.13 Where there 
were prescriptions for the same product and the periods covered by the two
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prescriptions overlapped, the duration of overlap was added to the logical end date 
of the last overlapping script. Overlapping prescriptions were defined as two 
prescriptions where the start date of the second was within 14 days of the logical 
end-date of the first (represented by the start date plus duration of exposure). The 
14-day period was used because any new prescription could ordinarily be started 
any time between one and 28 days after the day of issue. Non-overlapping scripts 
with a gap between them of more than 14 days were represented in the file as 
discontinuous periods of exposure whether or not there was a change in product. In 
cases where there were overlapping prescriptions for different products, the 
exposure to the first product was truncated to the day of the switch and a new period 
of exposure to the switched product assumed from the subsequent day. Thus, all 
logically unused packs of OC were discounted in the calculation of exposed women 
years (EWY).
Women with a diagnosis of acne, polycystic ovaries or PCOS were identified using 
appropriate OXMIS and Read codes. Because of its chronic nature, women were 
deemed to have acne in the year of an acne diagnosis, in the subsequent year, and 
in the two years prior to diagnosis. For women with more than one diagnosis of 
acne the acne period extended from two years prior to the first diagnosis until one 
year after the last. All women with a diagnosis of polycystic ovaries or PCOS at any 
time were included in the PCOS cohort. We also included those women who at any 
time had three or more markers for PCOS (acne, hirsutism/alopecia, anovulation/ 
infertility, amenorrhoea/oligomenorrhoea, obesity or endocrinological abnormalities).
A cohort of CPA/EE users was described by age and by presence of acne and/or 
PCOS as well as the proportionate use of CPA/EE amongst all COC use. Amongst all 
women with or without acne or PCOS, age-specific use of the different COCs was 
calculated.
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R e s u l t s
Table 4.1 shows the patterns of CPA/EE use for the years 1992 to 1998. In all age 
groups the use of CPA/EE increased throughout the period covered, with the 
highest overall use amongst women aged 20-24 years. CPA/EE use as a 
percentage of all COG preparations increased in all age groups between 1992 and 
1998 -  for all ages combined, CPA/EE use almost tripled from 2.4% to 7.0% during 
the 7-year period. At the same time, the proportion of all CPA/EE that was 
prescribed to women with acne halved. The proportion of CPA/EE prescribed to 
women with PCOS increased with age and remained relatively constant between 
1992 and 1998, except in older women for whom there was a 45% increase in the 
proportion of CPA/EE prescribed to women with PCOS.
Table 4.1 Patterns of CPA/EE use, 1992-1998 (Source: GPRD)
Age-specific use of CPA/EE 
(years of use/100 OWYa)
CPA/EE as % of all COC use
Ages 1992 1994 1996 1998 1992 1994 1996 1998
15-19 0.6 0.8 1.1 1.5 3.1 4.6 7.0 9.5
20-24 0.8 1.2 1.7 2.2 2.5 3.6 5.9 8.1
25-29 0.7 0.9 1.2 1.6 2.2 3.0 4.5 6.3
30-34 0.4 0.5 0.7 0.9 1.9 2.4 3.5 4.8
35-39 0.1 0.3 0.3 0.4 1.6 2.3 2.9 3.7
All ages 0.5 0.7 1.0 1.3 2.4 3.3 5.1 7.0
Percentage of CPA/EE prescribed to Percentage of CPA/EE prescribed to
women with acne women with PCOS
Ages 1992 1994 1996 1998 1992 1994 1996 1998
15-19 69.6 66.2 62.6 51.2 3.3 3.6 3.0 2.5
20-24 56.5 48.2 41.7 30.8 5.0 4.9 4.7 4.4
25-29 51.9 42.7 37.9 26.9 5.2 7.4 7.8 7.1
30-34 51.2 40.1 35.0 24.9 5.5 8.7 8.4 8.5
35-39 44.6 38.7 37.0 22.3 5.8 7.4 9.8 10.3
All ages 56.0 47.8 43.0 32.3 4.9 6.1 6.1 5.8
a OWY = observed women years
4.8
Use of COCs in acne
Table 4.2 shows the estimated prevalence of acne and PCOS by year. Our study 
period was truncated at the end of 1998 so women with a first diagnosis of acne 
after that time would not have contributed to the acne cohort. Only women with 
acne diagnoses after 1991 and before the end of 1997 might have contributed the 
full complement of acne time to the numerator according to our definition of the 
‘acne period' although that period would have been truncated at 1998 for any 
woman with a further diagnosis of acne in 1998. An additional complication arises 
from the decline in the number of practices contributing data to the GPRD during the 
study period and the consequent right-truncation of data for almost half of the study 
population. Consequently in Table 4.2 we present acne prevalence data for the 
years 1992 and 1994 only. Prevalence estimates for PCOS would be unaffected by 
these right-censoring issues as the numerator was derived from the total time 
registered with the contributing practice. Thus PCOS prevalence data for 1992 to 
1998 are presented in Table 4.2.
The prevalence of acne decreased with increasing age whilst the prevalence of 
PCOS was highest amongst women aged between 25 and 34 years - increased 
case ascertainment would result when women with menstrual or fertility problems 
present to the general practitioner during childbearing years. The overall prevalence 
of acne and PCOS appeared to have remained fairly stable during the study period 
although the prevalence of PCOS declined in younger women (ages 15-24) and 
increased in older women (ages 25-39).
We identified 32,889 women who had been prescribed CPA/EE between the ages of 
15 and 39 years. The medical record at the time of first prescription implied oral 
contraception as the indication in almost 44% of women; in about 35% the implied 
indication at the time of first prescription for CPA/EE was acne or disorders 
suggestive of PCOS. However, 66% of CPA/EE users had a diagnosis of acne on 
or at some time before the date of their first script for CPA/EE. 23% of women 
prescribed CPA/EE had no recorded indication for CPA/EE (an acne diagnosis, 
prescription for an acne treatment, PCOS-like condition) before or on the date of 
their first prescription for CPA/EE and 21% had no recorded indication for CPA/EE 
treatment anywhere in the records. These data are limited by the data censoring 
imposed by registration periods on the GPRD and be limited also by the quality of
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recording. To explore the possibility that these observations might be affected by the 
data censoring issue, we identified women prescribed CPA/EE for whom there was 
at least two years' data prior to the first prescription for CPA/EE and at least one 
year’s data after the first prescription for CPA/EE (n=11,994). Of these women 
10,190 (85%) had a diagnosis of acne, PCOS or hirsutism at some time.
21% of women with a diagnosis of acne had been prescribed CPA/EE at some time 
(19,782/94,717). Of those, 90% had a diagnosis of acne on or before the date of 
the first CPA/EE script and the rest had been prescribed an acne-specific treatment 
prior to the first CPA/EE script. 9,629 women had PCOS; 2,082 of these (22%) had 
been prescribed CPA/EE at some time between 1992 and 1998.
Table 4.2 Estimated prevalence3 of acne and PCOS, 1992-1998 (Source: GPRD)
Acne PCOS
1992 1994 1992 1994 1996 1998
15-19 133.4 135.1 7.6 5.9 4.3 2.7
20-24 71.8 70.1 10.1 10.2 10.0 8.6
25-29 56.8 52.3 10.5 12.3 12.9 13.2
30-34 47.9 44.6 7.7 10.1 12.5 13.8
35-39 35.9 34.9 3.6 5.4 7.9 9.9
All ages 66.2 63.7 8.1 9.1 9.9 10.1
3 Prevalence = acne (or PCOS) observed women years /1000 observed women years
Table 4.3 shows the changes in the patterns of use of the major COC formulations 
and CPA/EE amongst women with and without acne. In 1994 the use of products 
containing levonorgestrel declined, particularly in younger women. Amongst women 
with and without acne there were similar patterns of use of products containing 
desogestrel and gestodene in all age groups. The use of CPA/EE amongst women 
with acne reached levels comparable with desogestrel and gestodene although in 
women without acne the use of CPA/EE was much less. By 1996 there had been a 
sharp fall in the use of both gestodene- and desogestrel-based COCs by both 
women with and without acne of all ages. In women with acne there was a rise in 
the use of levonorgestrel and CPA/EE but the proportionate increase in the use of 
levonorgestrel was greater than that for CPA/EE. For example, there was a 3.6-fold
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increase in levonorgestrel use in the 15-19 year olds with acne between 1994 and 
1998 compared with a 2.2 fold increase in the use of CPA/EE during the same 
period (p<0.001). The proportionate increase in the use of levonorgestrel-based 
products was less amongst the women aged over 20 with a history of acne, but in 
each age group the proportionate increase in levonorgestrel use was greater than 
that for CPA/EE (p<0.01). Between 1996 and 1998 the pattern changed: the use of 
levonorgestrel products altered little amongst women with acne whereas the use of 
CPA/EE increased. Amongst women without acne, similar increases in the use of 
products containing levonorgestrel by all age-groups were sustained through to 
1998. The use of CPA/EE by women without acne increased only fractionally.
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Table 4.3 Use of different formulations of COC amongst women with and without 
acne by progestogen^ 1992-1998 (Source: GPRD)
Age Progestogen Age-specific use of COCs (years of use per 100 women years)
(years) Women with acne_____________ Women without acne
1992 1994 1996 1998 1992 1994 1996 1998
Levonorgestrel 3.2 2.0 7.2 7.2 4.6 2.7 9.6 10.2
Desogestrel 4.9 4.7 0.5 0.6 6.8 6.7 0.9 0.5
15-19 Gestodene 3.8 4.1 0.3 0.2 5.6 6.2 0.8 0.3
CPA 3.0 4.0 5.4 8.9 0.2 0.3 0.5 0.8
Others* 1.3 1.6 3.3 3.2 1.5 1.8 3.9 3.9
Levonorgestrel 11.0 6.5 14.0 11.3 12.6 7.9 15.6 14.7
Desogestrel 9.0 9.6 1.8 1.4 10.0 11.0 2.6 1.9
20-24 Gestodene 7.0 8.4 1.5 1.3 7.2 9.4 2.2 1.7
CPA 6.6 8.1 10.9 15.2 0.4 0.7 1.0 1.6
Others* 3.6 3.7 6.4 5.8 3.8 3.5 6.5 6.9
Levonorgestrel 11.8 8.8 13.6 11.3 13.5 10.4 15.3 13.7
Desogestrel 7.1 8.3 2.0 1.9 6.6 7.9 2.2 2.1
25-29 Gestodene 4.6 5.9 1.5 1.3 4.8 6.4 1.7 1.7
CPA 5.9 7.2 9.2 13.1 0.3 0.5 0.8 1.2
Others* 3.4 3.8 6.0 5.1 3.7 3.8 5.8 5.9
Levonorgestrel 7.9 6.7 9.6 8.5 9.5 8.4 11.8 11.3
Desogestrel 4.5 5.5 1.2 1.0 4.2 5.2 1.4 1.3
30-34 Gestodene 3.2 4.2 0.8 0.5 3.1 4.2 1.0 1.0
CPA 3.9 4.5 5.9 8.5 0.2 0.3 0.5 0.7
Others* 2.0 2.7 4.0 3.5 2.2 2.5 4.0 4.2
Levonorgestrel 3.5 3.5 5.7 5.7 4.2 4.2 6.4 6.7
Desogestrel 2.3 3.0 0.8 1.0 2.2 3.0 1.0 0.9
35-39 Gestodene 1.7 2.3 0.4 0.4 1.4 2.0 0.6 0.6
CPA 1.8 2.8 3.6 4.3 0.1 0.2 0.2 0.3
Others* 0.8 1.2 1.9 2.3 1.0 1.2 2.2 2.3
Levonorgestrel 7.5 5.2 10.1 8.8 9.4 7.1 11.9 11.3
Desogestrel 6.0 6.4 1.2 1.1 6.0 6.8 1.7 1.4
All ages Gestodene 4.4 5.3 0.9 0.7 4.4 5.6 1.3 1.1
CPA 4.4 5.5 7.2 10.3 0.2 0.4 0.6 0.9
Others* 2.3 2.6 4.4 4.0 2.6 2.7 4.5 4.6
* Other progestogens include ethynodiol, lynoestrenol, mestranol, 
norethisterone, norgestimate and norgestrel.
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Table 4.4 Use of different formulations of COC amongst women with and without 
PCOS by progestogen* 1992-1998 (Source: GPRD)
Age Progestogen Age-specific use of COCs (years of use per 100 women years)
(years) Women with PCOS____________ Women without PCOS
1992 1994 1996 1998 1992 1994 1996 1998
Levonorgestrel 3.9 1.8 8.4 5.7 4.5 2.6 9.3 10.0
Desogestrel 6.4 7.8 0.5 0.2 6.6 6.4 0.9 0.5
15-19 Gestodene 5.5 6.3 0.3 1.0 5.3 5.9 0.7 0.3
CPA 2.5 4.9 7.9 14.4 0.6 0.8 1.1 1.5
Others* 1.3 1.8 4.8 3.9 1.5 1.8 3.8 3.9
Levonorgestrel 7.1 3.4 8.7 8.3 12.5 7.9 15.6 14.6
Desogestrel 8.0 8.2 1.3 0.8 10.0 11.0 2.6 1.9
20-24 Gestodene 5.3 6.3 0.6 0.7 7.2 9.4 2.1 1.7
CPA 4.1 5.7 7.8 11.3 0.8 1.1 1.6 2.1
Others* 2.3 2.2 5.1 3.9 3.8 3.5 6.5 6.9
Levonorgestrel 6.0 4.3 8.3 6.5 13.4 10.4 15.3 13.7
Desogestrel 5.6 6.3 1.2 0.9 6.7 7.9 2.2 2.2
25-29 Gestodene 4.5 4.6 0.9 0.6 4.8 6.4 1.7 1.7
CPA 3.2 5.3 7.0 8.4 0.6 0.8 1.1 1.5
Others* 1.9 1.7 3.4 4.5 3.7 3.8 5.9 5.9
Levonorgestrel 3.2 2.2 6.0 5.8 9.5 8.4 11.8 11.3
Desogestrel 3.4 4.2 0.7 0.8 4.2 5.3 1.4 1.3
30-34 Gestodene 2.0 3.1 0.6 0.7 3.1 4.2 1.0 0.9
. CPA 2.6 4.3 4.4 5.4 0.3 0.5 0.6 0.8
Others* 0.8 1.4 2.4 2.1 2.2 2.5 4.1 4.2
Levonorgestrel 1.2 1.3 2.2 2.5 4.2 4.2 6.4 6.8
Desogestrel 1.2 2.7 0.8 0.7 2.2 3.0 0.9 0.9
35-39 Gestodene 1.2 0.9 0.2 0.3 1.4 2.1 0.6 0.6
CPA 2.3 3.4 3.8 4.2 0.1 0.2 0.3 0.4
Others* 0.5 0.5 0.8 1.0 1.0 1.3 2.2 2.4
Levonorgestrel 5.0 3.0 6.8 5.7 9.3 7.0 11.9 11.3
Desogestrel 5.6 5.9 1.0 0.8 6.0 6.8 1.6 1.4
All ages Gestodene 4.1 4.3 0.6 0.6 4.4 5.6 1.3 1.0
CPA 3.2 4.9 6.0 7.3 0.5 0.7 0.9 1.2
Others* 1.6 1.6 3.1 2.9 2.6 2.7 4.5 4.6
* Other progestogens include ethynodiol, lynoestrenol, mestranol, 
norethisterone, norgestimate and norgestrel.
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Table 4.4 shows the changes in the patterns of use of the major COC formulations 
and CPA/EE amongst women with and without PCOS. The use of CPA/EE and of 
products containing levonorgestrel increased over time in both women with PCOS 
and without PCOS, whilst the use of products containing desogestrel or gestodene 
decreased considerably. There was greater use of CPA/EE by women with PCOS 
than by those without PCOS.
Overall the use of COCs (including CPA/EE) by women without acne fell following 
the “pill scare” (Figure 4.3); amongst women with acne it remained unchanged 
(Figure 4.4). A similar pattern of all COC use was observed in women with and 
without PCOS (data not shown).
Figure 4.3 Use of all combined oral contraceptives (including CPA/EE) by women 
without acne (Source: GPRD)
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Figure 4.4 Use of all combined oral contraceptives (including CPA/EE) by women 
with acne (Source: GPRD)
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S e n s it iv it y  a n a l y s is
The definition of an ‘acne period’ as two years prior to first acne diagnosis until one 
year after last diagnosis arose through a considered though arguably arbitrary 
process. To assess the impact of an alternative definition the data were re-analysed 
based on an ‘acne period’ commencing one year prior to the first acne diagnosis 
and ending two years after the last acne diagnosis. Acne prevalence was 
comparatively lower in the younger women and higher in the older women. A 
decline in the percentage of CPA/EE prescribed to women with acne similar to that 
based on the original ‘acne period’ was observed. Age-specific rates of use 
amongst women without acne were unchanged for all products. In 1992, amongst 
younger women (15-24 years) with acne, the age-specific use of most products was 
decreased slightly by the change in acne period definition although the use of 
CPA/EE increased slightly. In 1994 and 1996 a slight increase in the age-specific 
use of all products by the youngest women was apparent with the change in 
definition but in women aged 20-24, age-specific utilisation rates decreased a little 
or remained constant for all products except CPA/EE. By 1998, the use of all 
products was increased slightly or unaffected by the changed definition although the 
use of CPA/EE declined. The patterns of change in CPA/EE use according to the 
definition of the ‘acne period’ must be due in part to the prescription of CPA/EE to 
treat diagnosed acne.
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D iscussion
CPA/EE is not licensed for use as an oral contraceptive in the UK although our 
analysis shows that for some women prescribed CPA/EE, no legitimate indication 
for CPA/EE treatment was recorded. CPA/EE accounts for a relatively small market 
share of oral contraceptives. Since the introduction of CPA/EE in the UK in 1987, 
sales have steadily increased and after the “pill scare” in 1995, the market share of 
COCs occupied by CPA/EE more than doubled (from 4% in 1995 to nearly 9% by 
June 2000). Using data extracted from the GPRD, we have described an increase 
in use of CPA/EE both in terms of use as a proportion of all COCs and in age- 
specific use between 1992 and 1998.
Several studies have found an apparent increased risk of VTE associated with 
exposure to CPA/EE13'17 although efforts to adjust those risk estimates for 
confounding have been mostly inadequate. The only study that adjusted for the 
presence of acne, hirsutism and PCOS was that carried out by Vasilakis- 
Scaramozza & Jick. Because the investigators considered all CPA/EE users and a 
sample of levonorgestrel users, however, the population will have been a mixture of 
CPA/EE users more likely to have acne, hirsutism and PCOS than women prescribed 
COCs containing the more androgenic progestogen levonorgestrel. It is difficult to tell 
whether the adjusted analysis in their study would have adequately controlled for all 
potential confounding by acne, hirsutism and PCOS.
Our observations on changes in the pattern of CPA/EE sales and the issue of VTE 
risk raise important questions. First, is CPA/EE associated with an increased risk of 
VTE? If this is the case, then increased use of CPA/EE as a result of the ‘pill scare’ 
would have been counterproductive. Second, is CPA/EE selectively prescribed to 
women with a higher intrinsic risk of VTE, associated with underlying co-morbidity 
and if so, will the results of the study by Vasilakis-Scaramozza & Jick have been 
adequately adjusted?
Our analysis of secular trends in CPA/EE prescribing indicates that the proportion of 
CPA/EE prescribed to women with acne declined between 1992 and 1998. At the 
same time, the age-specific use of CPA/EE by the youngest women with a diagnosis 
of acne almost tripled. The proportion of CPA/EE prescribed to women with PCOS
4.16
Use of COCs in acne
has remained fairly constant (except in older women), although the age-specific use 
of CPA/EE has increased considerably in younger women with PCOS.
Particularly interesting are the secular trends in use of COCs containing different 
progestogens in women with acne or PCOS. In younger women with acne in 1994, 
the age-specific use of CPA/EE and COCs containing desogestrel and gestodene 
was greater than the use of COCs containing levonorgestrel. In 1996, however, 
subsequent to the “pill scare”, the use of products containing levonorgestrel 
amongst those women with acne increased to levels comparable with CPA/EE. A 
similar trend was observed for women with PCOS.
The observation that in later years more CPA/EE was being prescribed to women 
without acne could be because the recording of acne was declining or it could also 
be an effect of the ‘pill scare’ -  women with troublesome skin that had not been 
recorded as acne who, prior to October 1995 had been using the less androgenic 
COC formulations containing gestodene and desogestrel, switched to CPA/EE as a 
consequence of the “pill scare”.
It appears, therefore, that as a result of the “pill scare” women may have stopped 
using COCs containing desogestrel and gestodene in favour of COCs containing the 
more androgenic progestogen, levonorgestrel, or CPA/EE. CPA/EE use has been 
associated with an increased risk of VTE compared with levonorgestrel,17 but it 
remains unclear whether this is a drug effect or because the women prescribed 
CPA/EE in this study have an inherently adverse VTE risk profile. The study 
presented here clearly demonstrates that a large proportion of CPA/EE is prescribed 
to women with acne and/or PCOS, although this proportion appears to decrease 
with calendar time. This has implications for the evaluation of VTE risk associated 
with CPA/EE use: analyses should be stratified by use before versus after the pill 
scare, and the results should be adjusted for presence of acne and/or PCOS. 
Investigators should be aware of the potential for residual confounding given that 
acne is probably under-recorded. In conclusion, the morbidity of CPA/EE users 
needs to be more fully explored in order to understand the underlying risk profile of 
women prescribed CPA/EE and anticipate any future risk assessment of CPA/EE.
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A bstract
Background: Cyproterone acetate combined with ethinyloestradiol (CPA/EE) is 
licensed in the UK for the treatment of women with acne and hirsutism and is also a 
treatment option for polycystic ovary syndrome (PCOS). Previous studies have 
demonstrated an increased risk of venous thromboembolism (VTE) associated with 
CPA/EE compared with conventional combined oral contraceptives (COCs). We 
believe the results of those studies may have been affected by residual 
confounding. Methods: Using the General Practice Research Database we 
conducted a cohort analysis and case-control study nested within a population of 
women aged between 15 and 39 with acne, hirsutism or PCOS to estimate the risk 
of VTE associated with CPA/EE. Results: The age-adjusted incidence rate ratio for 
CPA/EE versus conventional COCs was 2.20 ( C I 9 5 1.35,3.58). Using as the 
reference group women who were not using oral contraception, had no recent 
pregnancy or menopausal symptoms, the case-control analysis gave an adjusted 
odds ratio (O R adj) of 7.44 (Clgs 3.67,15.08) for CPA/EE use compared with an O R adj 
of 2.58 (Clgs 1.60,4.18) for use of conventional COCs. Conclusions: We have 
demonstrated an increased risk of VTE associated with the use of CPA/EE in 
women with acne, hirsutism or PCOS although residual confounding by indication 
cannot be excluded.
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In t r o d u c t io n
Acne is generally associated with the onset of puberty and increased sebum 
production from the hair follicles on the face, chest and back. Propionibacterium 
acnes may proliferate within blocked pilosebaceous units and cause comedones 
and inflamed pustules. Sometimes acne is provoked by prolonged exposure to oral 
steroids. Conventional treatments for acne act by reducing sebum production, 
unblocking pores, delivering antibiotics or suppressing the effects of androgens.
The anti-androgen cyproterone acetate (2mg) combined with ethinyloestradiol 
(35pg) (CPA/EE) is licensed in the UK for the treatment of women with severe acne 
that is refractory to prolonged oral antibiotic therapy and for moderately severe 
hirsutism. Although it is not licensed as an oral contraceptive (OC) in the UK, 
CPA/EE is sometimes prescribed for contraception. Acne and hirsutism are 
associated with polycystic ovary syndrome (PCOS) as are obesity, dyslipidaemia 
and insulin resistance, independent of obesity.1"4 Thus women with PCOS have an 
intrinsically adverse cardiovascular risk profile, as demonstrated by a higher 
prevalence of cerebrovascular and cardiovascular morbidity5 and a positive family 
history of thrombotic disease in women with PCOS.4
Recent observational studies have suggested that CPA/EE may be associated with 
an increased risk of venous thromboembolism (VTE) compared with conventional 
combined oral contraceptives (COCs).6"9 The use of CPA/EE in the UK more than 
doubled following the “pill scare” of 1995 possibly because women with androgenic 
skin conditions were switched to CPA/EE from COCs containing less androgenic 
progestogens (desogestrel and gestodene).
Because the VTE risk profile of women who have androgenic skin conditions (or 
PCOS) differs from that of other women of the same age, we conducted a cohort 
analysis and a case-control study to estimate the risk of VTE associated with 
CPA/EE in such women.
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M e t h o d s
Our study used data from the General Practice Research Database (GPRD). The 
GPRD contains the anonymised patient records for about 4% of the UK general 
population. Routine demographic information is recorded. Medical diagnoses are 
coded to an OXMIS (Oxford Medical Indexing System) or Read code. Prescribing 
information is around 95% complete.10 Other information relating to smoking habits, 
alcohol consumption, height and weight are incompletely recorded. The validity and 
utility of this database for studies of drug safety have been published elsewhere.10'13
The study population was drawn from a cohort of women who had ever had a 
diagnosis of acne, hirsutism or PCOS. Women with PCOS were identified as those 
with an unequivocal diagnosis of PCOS or the identification of polycystic ovaries by 
ultrasound examination and also any women with three or more markers for PCOS 
(acne, hirsutism/alopecia, obesity, anovulation/infertility, amenorrhoea/ 
oligomenorrhoea or endocrinological measures). From that population we selected 
women who at any time between 1st January 1992 and 31st December 1998 were 
aged from 15 to 39. Women who had a VTE (pulmonary embolism or deep vein 
thrombosis) confirmed by evidence of anticoagulant therapy were identified and the 
‘event date' taken as the date on which the first symptoms were recorded. These 
symptoms included haemoptysis, shortness of breath, chest pain and swelling or 
redness of a limb. Prescriptions for conventional OCs and CPA/EE were identified 
and used to map drug use to each day in the study period.6 We were thus able to 
ascertain for each case her OC exposure status on the VTE event date. Total 
exposure to CPA/EE and conventional OC products in terms of exposed women 
years was used to calculate rates of VTE stratified by age.
For the case-control study, up to seven controls were randomly selected from the 
study population matched to the case by event (index) date, general practice and 
year of birth. The GPRD records for cases and controls were reviewed and relevant 
medical and drug exposure information recorded. Women with chronic illness, which 
included diabetes, asthma, systemic lupus erythematosus, Crohn’s 
disease/ulcerative colitis, thyroid and renal disease, were identified. The use of 
conventional OCs and CPA/EE amongst controls was described with reference to 
the index date as before. The period of uninterrupted exposure prior to the
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event/index date for each case and control exposed to a conventional COC or 
CPA/EE was calculated. Also, because it appeared that the use of CPA/EE in the 
UK increased considerably following the “pill scare” of 1995 ,14 we partitioned the 
study population according to whether the event/index date was prior to or after 
1995.
Differences in the length of time cases and controls were registered with practices 
contributing to the GPRD could have biased our observations with regard to 
assignation of acne status. In order to address this potential confounding we 
performed a sub-group analysis including only those cases and controls with at least 
two years' (730 days) registration after the index date and at least one year’s (365 
days) registration prior to the index date.
Conditional logistic regression models were built to provide risk estimates for VTE 
associated with CPA/EE adjusted for potential confounding.
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R esults
179 women had a VTE during the study period; none were fatal. Of these, 23 (13%) 
were exposed to CPA/EE on the index date giving a crude VTE incidence rate of 
8.05 cases/104 exposed women years. The rate of VTE increased with increasing 
age. The age-adjusted incidence rate ratio for CPA/EE versus conventional COCs 
was 2.20 (Clgs 1.35,3.58) (Table 5.1).
Table 5.1 Crude rates and incidence rate ratio (IRR) for VTE (1992-1998)
VTE (n) OWY/EWY Rate per 104
OWY/EWY (95% CIs)
Baseline rate
Age < 30 years 96 458587 2.09
Age > 30 years 83 211485 3.92
All ages 179 670072 2.67 (2.28,3.06)
Women exposed to CPA/EE
Age < 30 years 8 22698 3.52
Age > 30 years 15 5863 25.58
All Ages 23 28562 8.05 (4.76,11.34)
IRR (Clgs):
Women exposed to conventional COCs CPA/EE vs COCs
Age < 30 years 36 109315 3.29 1.07 (0.43,2.34)
Age > 30 years 16 30888 5.18 4.94 (2.27,10.67)
All ages 52 140203 3.71 (2.70,4.72) 2.17(1.27,3.61)
Age-adjusted IRR 2.20 (1.35,3.58)
The 179 cases were matched to 1076 controls. Characteristics of cases and 
controls are shown in Table 5.2. Cases were more likely to have a history of VTE 
and to have visited the general practitioner more frequently in the six months prior to 
the index date. Pregnancy, especially the intra/postnatal period or post termination, 
chronic illness, recent surgery or trauma and use of oral steroids were all 
significantly associated with VTE. Using as the reference group women who were 
not using oral contraception and who had no recent pregnancy or menopausal 
symptoms, exposure to conventional COCs gave a crude OR of 2.57 (Clgs 
1.69,3.91) compared with 6.86 (Clgs 3.71,12.69) for CPA/EE use. Cases and
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controls were similar in terms of BMI and smoking status. Amongst women in our 
study population who had been using conventional COCs on the index date, 90% 
had been using a conventional COC containing the same or a smaller dose of 
ethinyloestradiol as contained in CPA/EE (35pg). The remaining 10% had been 
using triphasic products.
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Table 5.2 Characteristics of cases and controls
Variable Cases (n = 179) Controls (n = 1076) Crude OR
n % n % (95% CIs)
VTE prior to 1992 8 4.47 12 1.12 4.04 (1.57,10.40)
Body Mass Index 
<20 18 10.06 88 8.18 1.40 (0.79,2.46)
20-24 70 39.11 472 43.87 Reference
25-29 34 18.99 196 18.22 1.19 (0.77,1.85)
30-34 13 7.26 65 6.04 1.37 (0.71,2.63)
35+ 10 5.59 42 3.90 1.60 (0.77,3.33)
Unknown 34 18.99 213 19.80 1.07 (0.67,1.72)
Smoking status (closest to index date) 
Non smoker 103 57.54 667 61.99 Reference
Smoker 45 25.14 252 23.42 1.19 (0.81,1.74)
Unknown 31 17.32 157 14.59 1.29 (0.80,2.08)
Number of consultations with the general practitioner in the 6 months before index date
None 13 7.26 274 25.46 Reference
1-2 30 16.76 327 30.39 1.92 (0.98,3.78)
3-9 83 46.37 389 36.15 5.29 (2.83,9.91)
10+ 53 29.61 86 7.99 20.43 (9.89,42.19)
Reproductive status on index date 
Reference group3 56 31.28 675 62.73 Reference
Antenatal period 21 11.73 53 4.93 5.72 (3.07,10.67)
Intra/postnatal period or post TOPb 18 10.06 9 0.84 25.46 (10.56,61.40)
Exposed to conventional COC 52 29.05 259 24.07 2.57 (1.69,3.91)
Exposed to POP0 1 0.56 17 1.58 0.78 (0.10,6.01)
Exposed to CPA/EE 23 12.85 41 3.81 6.86 (3.71,12.69)
Menopause 8 4.47 22 2.04 3.86 (1.59,9.38)
Chronic illness 49 27.37 169 15.71 2.10 (1.44,3.05)
Recent surgery or traumad 21 11.73 8 0.74 18.72 (7.49,46.76)
Recent use of oral steroidsd 10 5.59 9 0.84 7.53 (3.06,18.54)
a Women for whom no current or recent pregnancy and no current use of systemic oral contraception 
was apparent, and who were not menopausal/post menopausal 
b Termination of pregnancy 
c Progestogen-only pill 
d Within the 6 week period before index date
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Information on duration of exposure in those women exposed to a conventional 
COC or CPA/EE is presented in Table 5.3. In women exposed to a conventional 
COC, cases were significantly more likely than controls to be exposed for < 6 cycles 
prior to the index date. That relationship was not demonstrated in women exposed 
to CPA/EE. A sub-group analysis of CPA/EE-exposed cases and controls who, 
according to the information available, had not been exposed to a conventional COC 
at any time prior to the index date included 13 cases (6 exposed for < 6 cycles and 7 
exposed for > 6 cycles) and 16 controls (6 exposed for < 6 cycles and 10 exposed 
for > 6 cycles). With reference to a exposure of > 6 cycles, the age-adjusted OR for 
VTE was 1.36 (Clgs 0.26,7.17).
Table 5.3 Duration of exposure in women exposed to a conventional COC or 
CPA/EE
Exposed to conventional COC on index date Cases (n = 52)
n %
Controls (n = 259) 
n %
Age-adjusted 
OR (95% CIs)
Duration of exposure <= 6 cycles prior to index 
Duration of exposure > 6 cycles prior to index
32 61.54 
20 38.46
108 41.70 
151 58.30
2.17(1.16,4.05)
Reference
Exposed to CPA/EE on index date Cases (n = 23)
n %
Controls (n = 41)
n %
Age-adjusted 
OR (95% CIs)
Duration of exposure <= 6 cycles prior to index 
Duration of exposure > 6 cycles prior to index
12 52.17 
11 47.83
18 43.90 
23 56.10
1.05 (0.34,3.21) 
Reference
Stepwise conditional logistic regression was used to identify variables for the final 
conditional logistic model (Table 5.4). The strongest predictors of VTE were recent 
surgery or trauma and the intra/postnatal period or post termination of pregnancy. 
Using as the reference group women who were not using oral contraception and 
who had no recent pregnancy or menopausal symptoms, use of CPA/EE gave an 
adjusted odds ratio (ORadj) of 7.44 (Cl95 3.67,15.08) compared with an ORadj of 2.58 
(CI951.60,4.18) for users of conventional COCs.
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Table 5.4 Conditional multivariate logistic regression (number of observations = 1255)
Variable ORadj (95% CIs)
No recent surgery or trauma3 Reference
Recent surgery or trauma 28.62 (8.95,91.58)
No prior VTE Reference
VTE prior to 1992 10.52 (2.58,42.85)
No recent pregnancy, OC use or menopausal symptoms Reference
Antenatal period 3.76 (1.83,7.72)
Intra/postnatal period or post TOPb 14.45 (5.41,38.62)
Exposed to conventional COC 2.58 (1.60,4.18)
Exposed to POP0 0.30 (0.03,3.30)
Exposed to CPA/EE 7.44 (3.67,15.08)
Menopause 1.64 (0.56,4.79)
No consultations with the general practitioner^ Reference
1 -2 consultations with the general practitioner 1.66 (0.82,3.36)
3-9 consultations with the general practitioner 3.24 (1.66,6.32)
10+ consultations with the general practitioner 11.18 (4.99,25.07)
No recent use of oral steroids3 Reference
Recent use of oral steroids 9.36 (3.21,27.27)
a Within the six weeks before the index date 
b Termination of pregnancy; 
c Progestogen-only pill
d Within the six-month period before index date
Our sub-group analysis identified 82 cases and 457 matched controls with at least 
365 days’ registration time prior to the index date and 730 days’ registration time 
after the index date. 77 cases (94%) had at least four matched controls. Stepwise 
logistic regression was used to identify variables for sub-group conditional logistic 
regression analysis (Table 5.5). Recent surgery or trauma, a prior VTE, the 
antenatal and postnatal period of pregnancy and increasing numbers of consultation 
with the general practitioner remained significantly associated with VTE. Exposure 
to conventional COCs gave a significantly raised OR of 2.26 (Clgs 1.13,4.56) and the 
OR for exposure to CPA/EE was significantly raised to 3.87 (1.13,13.30). Using 
exposure to conventional COCs as the reference category, further analysis revealed 
that the point estimates for CPA/EE and conventional COCs were not significantly 
different (OR 1.71 [Clgs 0.49,5.96]; p=0.401).
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There were 86 cases of VTE prior to 1995 and 62 cases after 1995. Conditional 
logistic regression analysis revealed no difference in the risk estimates for VTE 
associated with CPA/EE prior to or after the 1995 “pill scare” (OR 7.22 [Clgs 
2.10,24.82] versus 7.27 [Clgs 2.53,20.87]).
Table 5.5 Conditional multivariate logistic regression restricted to cases and
controls with at least two years’ GPRD registration after the index date 
and at least one year prior to the index (number of observations = 539)
Variable ORadj (95% CIs)
No recent surgery or trauma3 Reference
Recent surgery or trauma 45.89 (4.85,434.28)
No prior VTE Reference
VTE prior to 1992 44.09 (2.63,737.71)
No recent pregnancy, OC use or menopausal symptoms Reference
Antenatal period 2.40 (0.76,7.55)
Intra/postnatal period or post TOPb 11.79 (1.92,72.48)
Exposed to conventional COC 2.26 (1.13,4.56)
Exposed to POP0 0.54 (0.01,39.09)
Exposed to CPA/EE 3.87 (1.13,13.30)
Menopause 1.40 (0.12,16.31)
No consultations with the general practitioner^ Reference
1-2 consultations with the general practitioner 1.67 (0.62,4.50)
3-9 consultations with the general practitioner 2.70 (1.00,7.27)
10+ consultations with the general practitioner 10.41 (3.29,32.89)
Teetotal Reference
1-9 units of alcohol per week 0.15 (0.07,0.31)
10+ units of alcohol per week 0.16 (0.04,0.62)
Unknown alcohol intake 0.90 (0.38,2.14)
a Within the six weeks before the index date 
b Termination of pregnancy 
0 Progestogen-only pill
d Within the six-month period before index date
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D iscussio n
Our study population comprised a group of women who were likely to have an 
increased risk of VTE. That risk appeared to be amplified by exposure to CPA/EE. 
Previous work on CPA/EE and VTE risk has compared the risk in users of CPA/EE 
with that of conventional COC users6*9 although in only one paper was the risk 
estimate adjusted for acne or PCOS.8 In most countries, CPA/EE is not licensed as 
an oral contraceptive. Thus, we believe it is appropriate to consider the adverse 
event risk profile associated with CPA/EE alongside that associated with other acne 
therapies. The adverse reactions associated with topical acne treatments include 
local inflammation and occasionally photosensitivity. The tetracyclines have been 
associated with vestibular disturbances, hyperpigmentation and photosensitivity 
and, more seriously, lupus-like reactions and hepatitis. The treatment options for 
women whose acne proves non-responsive to topical or oral antibiotic treatment 
include CPA/EE and oral retinoids although in the UK the use of oral isotretinoin 
requires specialist dermatological supervision.15 Isotretinoin is teratogenic and in 
women of childbearing age concomitant use of a combined oestrogen-progesterone 
oral contraceptive is recommended. The potential side effects of isotretinoin use 
include hypervitaminosis A-like symptoms, benign intracranial hypertension, 
alopecia, liver disease, elevated serum cholesterol levels, photosensitivity and 
pancreatitis.15 More recently spontaneous reports linking the use of isotretinoin with 
severe depression and suicide attempts have been cited16 although there is 
currently no epidemiological evidence to support a causal association.17
We have demonstrated an increased risk of VTE associated with the use of CPA/EE 
in women with acne, hirsutism or PCOS. The oestrogen component of the CPA/EE 
formulation in current use and used by women in our study barely exceeds that of 
the majority of conventional COCs. To our knowledge no published research has 
associated CPA with VTE and as far as we are aware there is no biological 
plausibility for any such relationship. The ‘depletion of susceptibles’ principle 
maintains that patients who remain on a drug are those who can tolerate it whilst 
those who can’t are selected out of the population at risk.18 Thus risk per unit of time 
depends both on history of prior exposure and on duration of exposure. Whilst 
mindful of the limitations imposed by censoring of data held on the database (a 
patient’s medical and drug exposure experience prior to or after periods of
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registration with a contributing practice are unknown) and the small numbers of 
exposed cases, we found that, compared with long-term use (>6 cycles), there 
seemed to be an increased risk for VTE in short term users (< 6 cycles) of 
conventional COCs but not users of CPA/EE. Thus we did not find evidence to 
support the possibility that the increased VTE risk in women using CPA/EE was 
associated with depletion of susceptibles, even when we restricted the analysis to 
CPA/EE-exposed cases and controls who had no evidence of prior oral 
contraceptive use. The growth of the GPRD in longitudinal data will allow us to 
further explore the duration of exposure issue in future work.
The observation that the use of CPA/EE in the UK increased considerably following 
the “pill scare” of 1995 should be considered in an assessment of VTE risk in 
women prescribed CPA/EE. As part of the analysis, therefore, the data were 
partitioned according to whether the VTE occurred prior to or after 1995 - conditional 
logistic regression analysis revealed no difference in the risk estimates for VTE 
associated with CPA/EE before or after the “pill scare”.
Women with an acne diagnosis at any time in the medical records contributed to our 
study population. Thus it was possible that if the time registered with practices 
contributing to the GPRD differed for cases and controls a bias could be introduced 
into the analysis with regard to acne status. Previously we have described an ‘acne 
period' for patients with acne diagnoses on the GPRD.14 That theoretical period 
began two years prior to a patient's first acne diagnosis and ended one year after 
the last acne diagnosis. Based on that reasoning, to reliably assign acne status to 
cases and controls we performed a sub-group analysis including only those cases 
and controls with at least two years’ (730 days) registration after the index date and 
at least one year’s (365 days) registration prior to the index date. The results of the 
sub-group conditional logistic regression indicated a statistically significant 
association between VTE and exposure to CPA/EE (OR 3.87) and exposure to 
conventional COCs (OR 2.26). Thus it appears that at least part of the significantly 
elevated risk estimate for VTE in women prescribed CPA/EE may be accounted for 
by residual confounding with regard to acne status. The difference in risk between 
CPA/EE and conventional COCs was not significant, unlikely to be associated with 
ethinyloestradiol dose and could be a chance finding. The age-adjusted IRR for
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V IE  associated with CPA/EE use versus use of conventional COCs was 2.2 and 
after adjustment in the sub-group case-control analysis this ratio was reduced to 1.7. 
Thus if complete adjustment for confounding could be achieved it is possible that no 
difference in risk between conventional COCs and CPA/EE would remain.
Our study population comprised women with acne, hirsutism or PCOS. It is possible 
that the morbidity associated with more severe symptoms in such women may 
include an elevated VTE risk. We cannot determine disease severity using routinely 
collected data such as that available on the GPRD and further work is planned to 
explore the underlying risk profiles of CPA/EE users.
In conclusion, it is likely that confounding by disease severity is an important 
component of the elevated VTE risk associated with CPA/EE exposure in women 
with acne, hirsutism or PCOS. Our findings suggest that CPA/EE remains a viable 
treatment option for women with hirsutism or acne that has proved unresponsive to 
other drugs. In addition the findings of this study suggest that, compared with other 
oestrogen-containing products of a similar dose, CPA/EE does not increase a 
woman’s baseline VTE risk. Careful consideration should be given to the risks 
associated with CPA/EE versus other treatment options.
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S ummary
Purpose: To explore the risk of liver disorders associated with cyproterone acetate 
combined with ethinyloestradiol (CPA/EE). CPA/EE is licensed in the UK for the 
treatment of women with acne and hirsutism and is a treatment option for polycystic 
ovary syndrome (PCOS). It acts also as a contraceptive.
Methods: Using the General Practice Research Database we conducted a cohort 
analysis and case-control study in women aged 15-39 with acne, hirsutism or PCOS 
to estimate the risk of liver disorders associated with CPA/EE.
Results: Compared with cases exposed to conventional COCs, the age-adjusted 
incidence rate ratio for liver disorders in women using CPA/EE was 1.7 (Cl9 5  0.9,3.4) 
and compared with no use it was 1.5 (Cl9 5 0.8,2.8). In the case-control study the 
adjusted odds ratio for liver disorders in women exposed to CPA/EE was 1.6 (CI9 5  
0.7,3.5) and 0.8 (ClggO.SJ.S) for exposure to conventional COCs, compared with no 
use. The risk of liver disorders in women prescribed CPA/EE was not significantly 
greater than that risk in women prescribed conventional COCs (OR 2 . 1  [CI9 5  
0.9,4.8]).
Conclusion: Our results do not indicate an increased risk for liver disorders 
associated with CPA/EE use in women with acne, hirsutism or PCOS after adjusting 
for potential confounding. This may be due to lack of statistical power.
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K ey  points
• There is some evidence from case reports and animal studies to suggest that 
patients prescribed cyproterone acetate may be at an increased risk of liver 
disorders, including carcinoma.
• It is unclear whether low-dose cyproterone acetate prescribed in combination with 
ethinyloestradiol (CPA/EE) is associated with hepatotoxicity.
• CPA/EE is licensed in the UK to treat acne and hirsutism and is a treatment 
option for polycystic ovary syndrome (PCOS). It acts also as a contraceptive.
• The use of CPA/EE has been increasing, particularly since the 1995 “pill scare” 
and after 1995 there was an increase in the annual number of hepatic adverse 
events associated with CPA/EE recorded on the manufacturers’ spontaneous 
reports database.
• This analysis of data from the General Practice Research Database does not 
indicate an increased risk of liver disorders associated with CPA/EE use by 
women with acne, hirsutism or PCOS.
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Intro ductio n
Cyproterone acetate (CPA) is an anti-androgen with progestogenic properties that 
reduces the production of sebum and thereby helps to clear acne. CPA (2mg) 
combined with ethinyloestradiol (EE 35pg) is licensed for the treatment of women 
with severe acne refractory to prolonged oral antibiotic therapy. It is also licensed 
for the treatment of moderately severe hirsutism and thus provides a treatment 
option for women with polycystic ovary syndrome (PCOS, also known as Stein- 
Leventhal syndrome), a common condition amongst women with acne or hirsutism. 
CPA/EE acts as a contraceptive but is not licensed as such in the UK. The use of 
CPA/EE has been increasing since its introduction to the market in 1987; in 1995 
there was a further marked increase in its use, possibly associated with the “pill 
scare”.1
CPA is metabolised in the liver and is a non-specific inducer of hepatic enzymes. 
Oral absorption of CPA is almost complete; it is very lipophilic and the half-life is 
prolonged in obese patients.213 CPA in high doses has been demonstrated to have a 
mitogenic and carcinogenic effect in adult rat liver, with a higher incidence in 
females4 and several case reports have been published linking exposure to CPA 
with the development of hepatic tumours.5'7 Hepatotoxicity associated with the use 
of CPA in high doses has been reported8"19 mainly amongst men treated for 
prostatic cancer,5:8-18 women treated for breast cancer19 or children with disorders of 
growth.6:7 CPA toxicity appears to be dose-related. Prescribing physicians are 
advised to assess liver function before commencing therapy with CPA alone and to 
monitor liver function during CPA use.20 The relevance of CPA hepatotoxicity for 
women prescribed low-dose CPA as in CPA/EE remains unclear. Case reports have 
suggested an association between the development of hepatic tumours and ‘1st’ and 
‘2nd generation’ combined oral contraceptives (COCs)21 but we could not find any 
published reports of hepatocellular carcinoma associated with ‘3rd generation’
COCs. In the Multicentre International Liver Tumor Study (MILTS),22 exposure to 
CPA/EE and conventional COCs was assessed in 317 women aged less than 65 
years (mean age 50 years) with primary hepatocellular carcinoma and compared 
with age-matched controls. Whilst there was some evidence to support an 
association with duration of use of conventional COCs in a subgroup of women with 
negative viral serology and no cirrhosis, the authors found no evidence to suggest
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that CPA/EE exposure for any length of time was associated with hepatocellular 
carcinoma.
We explored the spontaneous reports database maintained by the manufacturers of 
CPA/EE and identified 33 cases of liver disorder worldwide. In three cases the 
episode of liver disorder was fatal. One death was attributed to hepatocellular 
carcinoma and was also reported in the literature by Rudiger et al in 1995.23 This 
case report describes a 45 year-old woman with an apparently unremarkable 
medical history whose hepatocellular carcinoma was identified by chance upon 
routine pre-operative consultation. Long-term exposure to oral contraceptives was 
noted including CPA/EE (50jig) for seven years, followed by CPA/EE (35pg) for 
another seven years. The woman had stopped taking CPA/EE (35pg) 18 months 
prior to diagnosis. Another fatal event occurred in a 25 year-old woman with PCOS 
who had been treated with Androcur® (CPA 50mg tablets [Sobering Healthcare]) and 
Progynova® (oestradiol valerate 1 mg [Sobering Healthcare]) for approximately six 
months. The daily dose of Androcur administered was not recorded. Treatment of 
the PCOS continued with CPA/EE but three days after commencing therapy, the 
woman was admitted to hospital with a subicterus of cholestatic origin. Laboratory 
investigations revealed hepatocellular insufficiency. The third fatal episode occurred 
in a 17 year-old girl with acne who had been treated with CPA/EE at its normal dose 
for about three months prior to a diagnosis of haemolytic-uraemic syndrome. She 
died five months later.
Other than the report from Rudiger et al,23 there were few published case reports 
where CPA/EE was implicated in adverse hepatic events. We found two where the 
association between CPA/EE exposure and a lupus-like reaction with altered liver 
function was complicated by concomitant exposure to minocycline.24 In 1994 in 
response to evidence suggesting that CPA induces DMA synthesis in rat 
hepatocytes, the German Federal Institute for Drugs and Medicinal Products 
requested an investigation into the human risk associated with CPA, both in 
combination with EE and in the 50mg CPA preparation Androcur.25:26 Rabe21 
reported later in 1994 that after nearly 19 million exposed woman years to CPA/EE 
(both 50pg and 35pg EE preparations), no reports of liver cell tumours had then 
been described, an observation supported subsequently.27 Nevertheless, the
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Datasheet indicates that CPA/EE might be associated with an increased risk of liver 
tumours, including carcinoma.
Our review of the literature yielded no epidemiological evidence for an association 
between CPA/EE and non-neoplastic liver disorders. Furthermore, although case 
reports have associated hepatitis or altered liver function with high doses of CPA, 
observational studies have found no evidence to support an association between 
CPA/EE use and changes in liver function.28 27:29:30
We have used the General Practice Research Database (GPRD) to estimate the 
risk of liver disorders (including carcinoma) in association with exposure to CPA/EE. 
Previous work has described an increased rate of liver disorders amongst women 
with acne.31 Therefore, because the risk of liver disorders amongst women 
prescribed CPA/EE might be different from that amongst the general female 
population, we restricted our study population to women with acne, hirsutism or 
PCOS.
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M ethodology
The UK General Practice Research Database (GPRD) is a database that contains 
the anonymised general practice records for approximately 4% of the UK population. 
The validity and utility of this database for studies of drug safety have been 
published elsewhere32'35 and the database is quality-controlled to ensure that only 
practices contributing data of research standard are included.34136
For each patient registered with a general practice contributing data to the GPRD, 
routine demographic information is recorded. Medical diagnoses and symptoms are 
coded to an OXMIS (Oxford Medical Indexing System) or Read code and 
prescribing information is linked to PPA (Prescription Pricing Authority) codes.
Other information related to smoking habits, alcohol consumption, height and weight 
is recorded with some incompleteness that varies by practice -  contributing 
practices are not specifically required to record such information.
The study population comprised women with a diagnosis of acne, hirsutism or 
PCOS. We selected women aged between 15 and 39 registered with a general 
practitioner (GP) who provided data to the GPRD at any time between 1st January 
1992 and 31st December 1998. For each woman in the study population a minimum 
of 6 months’ data of research quality (‘up-to-standard’ data) were required for entry 
into the study. Patients could leave or join the study cohort at any time during the 
study period.
Appropriate OXMI S/Read codes were used to select women who had one or more 
diagnosis of acne or hirsutism. Over 88% of GPRD acne diagnoses referred to 
OXMIS code 7061 A’ (simply ‘Acne’). Other OXM I S/Read codes for acne exist but 
were used rarely. Women with PCOS were identified as those with a record of 
PCOS (ie a code for Stein-Leventhal syndrome [codes for PCOS perse  do not exist 
in the GPRD coding dictionary]) or the identification of polycystic ovaries by 
ultrasound examination and also any women with three or more markers for PCOS 
(acne, hirsutism/alopecia, obesity, anovulation/infertility, amenorrhoea/ 
oligomenorrhoea or endocrinological measures) at any time.
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OXMIS/Read codes were used to identify potential cases with liver disorders. The 
codes included those for altered liver enzymes, jaundice, hepatomegaly, hepatitis, 
liver biopsy, liver malignancy and transplantation. Records indicating jaundice, 
hepatomegaly and liver biopsy were used as supporting evidence for liver disorder 
but alone were insufficient to assign case status. Potential cases were excluded if 
there was a recognised possible alternative cause for the liver disorder, eg liver 
métastasés, viral infection, alcohol abuse (> 40 units/week), drug abuse, congenital 
metabolic anomaly or pregnancy. It is stressed that we refer to all hepatic events 
as episodes of ‘liver disorder’. Women with mild or transient symptoms of hepatic 
dysfunction were included.
Patients with records indicating liver morbidity prior to January 1992 were excluded 
from the study population as were women with other conditions meeting our criteria 
for exclusion as above.
Once potential cases with liver disorders had been selected from the database the 
complete patient records for each woman were scrutinised to confirm case status 
and establish an event date. At this stage the investigator was unaware of the 
exposure status of the case. The event date was taken as the date on which the 
first symptoms were recorded. These symptoms included jaundice, referral for liver 
function test etc.
For each woman in the study population, the number of days on which she was 
registered with the practice during each calendar year was calculated.
A file was compiled from the GPRD therapy records representing the hormonal 
contraception and CPA/EE prescriptions for each woman registered on the GPRD. 
In this file, hormonal contraception and CPA/EE use was mapped to each day in the 
study period. The mapped utilisation was then adjusted to take account of 
overlapping prescriptions. In cases where there were overlapping prescriptions for 
different products, the exposure to the first product was truncated to the day of the 
switch and a new period of exposure to the switched product assumed from the 
subsequent day. Non-overlapping scripts were represented in the file as 
discontinuous periods of exposure whether or not there was a change in product. It
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was thereby possible to identify which product (if any) would have been used on any 
particular day, assuming prescribed products were taken.37
For each case identified, up to seven controls were randomly selected from the 
study population matched by year of birth and general practice. The same exclusion 
criteria were applied to controls as cases. Controls had to be registered on the 
database on the date established as the case's event date (index date) and have at 
least six months data prior to that date.
With reference to potentially relevant medical conditions and other drug exposures, 
all GPRD records for each case and control were reviewed and coded. Wherever 
possible, relevant conditions and exposures were identified by automatic coding and 
verified by appraisal of printed patient records.
Rates of liver disorder and age-adjusted incidence rate ratios with 95% confidence 
intervals were calculated. Stepwise conditional logistic regression analysis was 
used to identify variables for multivariate models. Finally risk estimates for liver 
disorder were derived using standard conditional (fixed effects) regression, adjusted 
for potential confounders and effect modifiers. (Appropriate computerized statistical 
packages were used: Stata 7 (Stata Corporation, Texas, USA) and Epilnfo 2000 
(Centres for Disease Control and Prevention, USA)).
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R esults
We identified 172 women who had a hepatic event during the study period (mean 
age 27.3 years [sd 7.2]). Eleven of the 172 cases were exposed to CPA/EE on the 
event date (3.8 cases/10,000 EWY) and 31 were exposed to conventional COCs 
(2.2 cases /10,000 EWY). The crude rates of liver disorder and age-adjusted 
incidence rate ratios (IRRs) by exposure status are given in Tables 6.1 and 6.2. The 
age-adjusted IRR for the rate of liver disorders in women exposed to CPA/EE 
versus that in conventional COCs was 1.7 [ C I 9 5  0.9,3.4]; p=0.16. The age-adjusted 
IRR for the rate of liver disorders in women exposed to CPA/EE versus that in 
women not using hormonal contraception or CPA/EE was 1.5 [Cl950.8,2.8]; p=0.23).
Table 6.1 Crude rates of liver disorders in women aged 15-39 with acne, 
hirsutism or PCOS
Cases (n) OWY° Rate6 (95% Cl)
All women 172 655807 2.6 (2.2,3.0)
Women not exposed to hormonal contraception or CPA/EE 126 468923 2.7 (2.2,3.2)
Cases (n) EWYC Rateb (95% Cl)
Women exposed to CPA/EE 11 29086 3.8 (1.5,6.0)
Women exposed to conventional COCs 31 141314 2.2 (1.4,3.0)
Women exposed to other hormonal contraception 4 16484 2.4 (0.0,4.8)
a Observed women years
b Rates per 10,000 women years (exposed/observed women years as appropriate) 
c Exposed women years
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Table 6.2 Rate ratios for liver disorders by exposure status
Rate ratio
P-value
(95% Cl)
CPA/EE exposed vs conventional COCs exposed Crude IRRa 1.7 (0.8,3.5)
Age-adjusted IRR 1.7 (0.9,34) p=0.16
CPA/EE exposed vs no useb Crude IRR 1.4 (0.7,2.6)
Age-adjusted IRR 1.5 (0.8,2.8) p=0.23
Conventional COC exposed vs no useb Crude IRR 0.8 (0.5,1.2)
Age-adjusted IRR 0.9 (0.6,1.3) p=0.53
incidence rate ratio
bNo use of hormonal contraception or CPA/EE
Amongst the case population (n=172), 14 of 98 cases referred to hospital were 
admitted as a consequence of the episode of liver disorder. There were 25 cases of 
hepatitis (16 of whom were referred or admitted to hospital), including 6 cases of 
autoimmune hepatitis or chronic active hepatitis. One woman aged 37 with hepatitis 
died after liver transplantation - she had been exposed to CPA/EE at the time of 
onset of hepatic symptoms. Amongst cases not exposed to CPA/EE or 
conventional COCs, one woman of 17 years survived liver transplantation and a 29- 
year old woman with a hepatoma died.
One hundred and forty six of the 172 cases (85%) were matched to at least four 
controls. 84% of controls were matched to the case by exact year of birth, 13% 
were matched + 1 year and 3% were matched + 2 years. There were no cases for 
whom no controls could be found. The population characteristics of cases and 
controls are given in Table 6.3. The unadjusted odds ratios for liver disorder 
associated with each variable are also provided. We found significantly raised crude 
ORs for liver disorder associated with a BMI of 35+, higher rates of consultation with 
the GP in the six months prior to index date (which we used as a proxy for general 
health), autoimmune disease, exposure to antibiotics, exposure to other known 
hepatotoxic drugs and antidepressant use. To describe cases' and controls’ alcohol 
consumption, we used information recorded within a year prior to the index date until 
7 days after the index date. This information was more available for cases than 
controls (33% cf 13%) and our analysis indicated a significant association between
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liver disorder and unknown alcohol consumption. The crude OR associated with 
CPA/EE exposure on the index date was 1.6 (Cl950.8,3.3); p=0.23, 0.9 (Cl95 
0.6,1.3); p=0.50 for exposure to conventional COCs and 1.7 (Cl950.5,5.4); p=0.39 
for use of other hormonal contraceptives.
The hormonal contraception or CPA/EE exposure status of cases and controls was 
reassessed according to exposure within a 14-day or 21-day period prior to the 
index date. The crude ORs associated with exposure within 14-days and 21-days 
were the same -  for CPA/EE exposure the OR was 1.4 (Cl950.6,2.9); p=0.42, 0.8 
(Cl950.5,1.3); p=0.40 for exposure to conventional COCs and 1.6 (Cl950.5,5.3); 
p=0.41 for use of other hormonal contraceptives.
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Table 6.3 Characteristics of cases and controls
Variable Categories Cases 
(n = 172) 
n(%)
Controls 
(n = 899)
n (%)
OR (95% Cl) P-value
Mean age (sd) 27.3 (7.2) 26.8 (7.3)
BMI <20 24 (14.0) 108 (12.0) 1.1 (0.6,1.8) p=0.85
20-24 73 (42.4) 335 (37.3) Reference
25-29 23 (13.4) 147 (16.4) 0.7 (0.4,1.2) p=0.23
30-34 8 (4.7) 39 (4.3) 0.9 (0.4,1.9) p=0.71
35+ 12 (7.0) 27 (3.0) 2.1 (1.0,4.5)* p=0.05*
Unknown 32 (18.6) 243 (27.0) 0.6 (0.4,1.0)* p=0.04*
Alcohol intake1
(units/week) None 19 (11.1) 31 (3.4) 1.2 (0.5,2.4) p=0.71
1-9 35 (20.4) 76 (8.5) Reference
10-39 3 (1.7) 7 (0.8) 1.0 (0.2,4.3) p=0.98
Unknown 115 (66.9) 785 (87.3) 0.3 (0.2,0.4)* p<0.01*
Smoking2 No 95 (55.2) 514 (57.2) Reference
Yes 43 (25.0) 188 (20.9) 1.2 (0.8,1.7) p=0.48
Unknown 34 (19.8) 197 (21.9) 0.9 (0.6,1.6) p=0.81
Prescriptions issued3 0 23 (13.4) 282 (31-4) 0.3 (0.2,0.5)* p<0.01*
1-2 49 (28.5) 287 (31.9) 0.7 (0.5,1.0) p=0.06
3-9 67 (39.0) 267 (29.7) Reference
>10 33 (19.2) 63 (7.0) 2.2 (1.3,3.6)* p<0.01*
Consultations with GP3 0 15 (8.7) 228 (25.4) 0.3 (0.1,0.5)* p<0.01*
1-2 38 (22.1) 294 (32.7) 0.5 (0.3,0.7)* p<0.01*
3-9 79 (45.9) 308 (34.3) Reference
>10 40 (23.3) 69 (7.7) 2.7 (1.6,4.4)* p<0.01*
Autoimmune disease4 26 (15.1) 47 (5.2) 3.1 (1.8,5.2)* p<0.01*
Hormonal
contraceptive use5 None 126 (73.3) 660 (73.4) Reference
COCs 31 (18.0) 185 (20.6) 0.9 (0.6,1.3) p=0.50
Other 4 (2.3) 13 (1.4) 1.7 (0.5,5.4) p=0.39
CPA/EE 11 (6.4) 41 (4.6) 1.6 (0.8,3.3) p=0.23
Antibiotic exposure6 Any antibiotic 41 (23.8) 102 (11.4) 2.4 (1.6,3.6)* oQ.
Minocycline 9 (5.2) 24 (2.7) 2.4 (1.1,5.5)* p=0.03*
Other tetracycline 9 (5.2) 30 (3.3) 1.8 o>COCOd p=0.16
Macrolide 5 (2.9) 14 (1.6) 2.0 (0.7,5.8) p=0.18
Penicillin 9 (5.2) 18 (2.0) 3.0 (1.3,7.2)* p=0.01*
Cephalosporin 4 (2.3) 8 (0.9) 2.5 (0.7,8.7) p=0.16
Other antibiotic 5 (2.9) 8 (0.9) 4.1 (1.3,12.5)* p=0.02*
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Table 6.3 Continued
Variable Cases 
(n = 172)
n (%)
Controls 
(n = 899)
n (%)
OR (95% Cl) P-value
(Iso)tretinoin exposure6 
Use of other drugs
3 (1.7) 1 (0.1) -
known to be hepatotoxic7 9 (5.2) 5 (0.6) 11.1 (3.7,33.2)*
01
Antidepressant exposure6 11 (6.4) 20 (2.2) 2.8 (1.3,6.0)* p=0.01*
Gilbert’s syndrome 4 (2.3) 1 (0.1) -
History of glandular fever8 4 (2.3) 17 (1.9) 1.3 (0.4,3.8) p=0.67
History of drug abuse8 7 (4.1) 21 (2.3) 1.9 (0.8,4.7) p=0.16
Asthma 42 (24.4) 168 (18.7) 1.4 (0.9,2.1) p=0.09
Renal disease 7 (4.1) 21 (2.3) 1.7 (0.7,4.0) p=0.25
Cancer before event/index date 1 (0.6) 4 (0.4) 1.2 (0.1,11.2) p=0.85
1 Observation window: one year before to 7 days after the event/index date
2 Using information closest to event/index date
3 Count within the 6 months preceding event/index date
4 Multiple sclerosis, rheumatoid arthritis, psoriasis, Type 1 diabetes, thyroid disease, lupus, coeliac
disease, Crohn’s disease, fibromyalgia, myasthenia gravis, vitiligo
5 On the event/index date
6 Within 14 days before event/index date
7 Exposure on the event/index date to methotrexate, anti-tuberculosis drugs, anti-epileptics or 
general anaesthesia within prior 30 days
8 More than 6 months before event/index date
* Statistically significant at p<0.05
Reference categories = ‘no exposure’/ ’no disease’ unless otherwise indicated
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Forward and backward stepwise regression analysis was carried out with inclusion 
criteria for variables set at p<0.05. The variables thereby indicated for the final 
conditional logistic regression analysis were autoimmune disease, use of known 
hepatotoxic drugs, BMI and the number of consultations with the GP in the six 
months preceding the event/index date. We also selected the variable for exposure 
to CPA/EE, conventional COCs or other hormonal contraceptives for inclusion in the 
final analysis. To confirm that no other variable would significantly contribute to the 
model, each was systematically included to assess any effects on the odds ratio.
We also checked the model for stability. The results presented in Table 6.4 were 
derived from the optimum most stable model. The adjusted OR for liver disorder 
associated with CPA/EE was 1.6 (Cl950.7,3.5; p=0.22) compared with no use of 
hormonal contraceptives or CPA/EE. The risk of liver disorder in women prescribed 
CPA/EE was not significantly greater than that risk in women prescribed 
conventional COCs (adjusted OR 2.1 [Cl950.9,4.8]; p=0.09).
Table 6.4 Conditional logistic regression analysis (number of observations^ 071 )
Variable ORadj (95% Cl) P-value
No consultations with the GP in prior 6 months 0.3 (0.2,0.5)* p<0.01*
1-2 GP consultations 0.5 (0.3,0.8)* p<0.01*
3-9 GP consultations Reference
>10 GP consultations 2.3 (1.4,4.0)* p<0.01*
Autoimmune disease 2.2 (1.2,3.9)* p=0.01*
Exposure to known hepatotoxic drugs 5.1 (1.7,19.5)* p=O.O1*
BMI < 20 1.0 (0.6,1.7) p=O.9O
BMI 20-24 Reference
BMI 25-29 0.6 (0.4,1.1) p=0.11
BMI 30-34 0.8 (0.3,1.9) p=0.56
BMI 35+ 2.0 (0.9,4.5) p=0.10
Unknown BMI 0.6 (0.3,1.0) p=0.06
No use of hormonal contraception or CPA/EE Reference
Use of conventional COCs 0.8 (0.5,1.3) p=0.31
Use of other hormonal contraception 1.7 (0.5,5.7) p=0.40
Use of CPA/EE 1.6 (0.7,3.5) p=0.22
* Statistically significant at p<0.05
Reference categories = ‘no exposure’/’no disease’ unless otherwise indicated
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The characteristics of the 11 cases exposed to CPA/EE on the event date are 
presented in Table 6.5. A sub-group analysis was proposed using only those cases 
referred or admitted to hospital at the time of the hepatic event (98 cases and 488 
matched controls). Six of the 98 cases were exposed to CPA/EE on the index date 
(Table 6.5: cases 3, 5, 7-10) and the data were insufficient for further meaningful 
analysis.
107 women were included in the study population because of a record of altered 
liver function and only 7 of these women (6.5%) had other diagnoses supporting 
case status. Of the 11 CPA/EE-exposed women, eight were included in the case 
population because of a record of altered liver function only (see Table 6.5). Three 
women with altered liver function only were prescribed further courses of CPA/EE - 
one of these women (case 3) experienced a further transient episode of altered liver 
function and another (case 8) was diagnosed with intrahepatic cholestasis induced 
by use of oral contraceptives 7 months after the event date (observations limited by 
censoring). Three CPA/EE-exposed women had diagnoses of hepatitis. The 
medical records of one of these women (case 2) suggested that there may have 
been a history of liver problems. Hepatitis was diagnosed in another who had 
recently returned from a holiday in Kenya with diarrhoea and vomiting (case 5), and 
the third woman died from hepatic failure (case 10). For case 10 there was no 
significant prescribing or medical history evident in the records.
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Table 6.5 Characteristics of cases ‘exposed’ to CPA/EE
Case Age
CPA/EE
Event
exposure 
(days, ‘ ype
Referred/ Further use of
Further
admitted to CPA/EE & days to
event
hospital that use
Observation
period
(days)8
1 32 471 LFT only No Yes 20 No 108
2 23 136 CAHb No Yes 56 No 169
3 23 246 LFT only Yes Yes 20 Yes 1448
4 35 28 LFT only No No - No 1411
5 33 113 Hepatitis Yes No - No 98
6 21 572 LFT only No No - No 94
7 36 333 LFT only Yes No - No 37
8 19 204 LFT only Yes Yes0 - Yes 999
9 28 167 LFT only Yes Yes 209 No 407
10 38 308 Hepatitis Yes No - No 24d
11 37 91 LFT only No No - No 1439
a Interval between event date (or date of first CPA/EE script after the event date for those cases re­
exposed) to date when data were right censored 
b CAM = Chronic active hepatitis
0 CPA/EE prescribed on the event date (venesection recorded) - unclear whether CPA/EE was taken 
[exposed status confirmed by prior prescription] 
d Patient died
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D is c u s s io n
The results of our case-control study do not support an association between the use 
of CPA/EE and liver disorder after adjustment for potential confounders. The risk of 
liver disorder in women prescribed CPA/EE was not significantly greater than that 
risk in women prescribed conventional COCs (adjusted OR 2.1 [Cl950.9,4.8]; 
p=0.09). The results confirm an association between liver disorders and increasing 
rates of consultation with the GP, autoimmune disease and exposure to known 
hepatotoxic drugs including methotrexate, drugs to treat tuberculosis and epilepsy 
and general anaesthesia. In previous work we have demonstrated an association 
between the use of antidepressants and liver disorders in people with acne31 and the 
crude ORs described here support that observation, although antidepressant use 
did not contribute to the final model.
We have previously demonstrated higher rates of liver disorder in people with acne 
compared with the general population.31 This could influence rates of liver disorder 
in women with PCOS although we could not find any evidence in the literature to 
support such an association. Studies in animals have indicated dose-related CPA 
hepatotoxicity but, apart from those case studies mentioned and spontaneous 
adverse event reports, to our knowledge there is no epidemiological evidence to 
suggest an association between hepatotoxicity and low-dose CPA such as 
contained in CPA/EE. The results of this study support findings from observational 
studies in women prescribed oral contraceptives or CPA/EE that did not 
demonstrate an increased risk for liver tumours, hepatitis or altered liver function 
associated with CPA/EE use.21:22:27"29
The GPRD provides a rich source of diagnostic and prescribing data for some 4% of 
the general population in England and Wales and thus facilitates a nested study 
design. Data are quality-controlled and free from recall bias. A number of 
limitations affect all studies conducted using GPRD data however. Firstly, although 
drug prescribing is recorded, a patient's compliance with treatment cannot be firmly 
established. Next, practices contributing to the GPRD are not specifically required 
to record data relating to bodyweight, smoking, alcohol intake etc and thus 
potentially important information may be missed. Another problem with database
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studies arises from data censoring -  a patient’s medical and prescribing history prior 
to GPRD registration and after registration ceases is largely unknown. Thus, the 
results of our study are potentially limited by misclassification of disease, 
misclassification of exposure and possibly some residual confounding, including 
confounding by disease severity.
The justification for including cases with records of altered liver function in our 
analysis is based on the knowledge that drug-induced liver dysfunction is often mild 
and/or transient, generally resolves on withdrawal of the drug and progression to 
more serious disease thus may be halted. The inclusion of such cases in this 
analysis raises several issues however, particularly if there were no other supporting 
evidence for liver disorder. Firstly, there is the possibility of misclassification of 
disease status. GPs have different rules when describing the results of liver function 
tests and it is not possible to classify patients on the basis of values for liver 
enzymes as they are not always available (44% of women with codes for abnormal 
liver function had some indication of the test results in the GPRD records). 
Additionally, our results could be affected by differential misclassification of disease 
by exposure status. Physicians prescribing CPA/EE are not required to monitor liver 
function but it is possible that transient and/or mild alterations in liver function might 
be recorded more readily when a GP suspects an association with a drug being 
used.
It is also possible that some cases apparently exposed did not comply with the 
prescribed medication and thus were misclassified in terms of exposure status. This 
misclassification could be non-differential and bias the results towards the null. 
Alternatively the misclassification could be differential amongst women with varying 
degrees of symptoms or co-morbidity. For example, women may be less inclined to 
comply with medication if they are already taking a number of other drugs or if their 
acne is less severe. Such differential misclassification could lead to a bias in either 
direction.
We identified a small number of CPA/EE-exposed cases in our study population -  
only 11 cases were apparently exposed to CPA/EE on the index date. Any
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misclassification of those cases in terms of disease or exposure status would add 
instability to the model and render the point estimate less reliable. Confirmation of 
disease status and determination of disease severity is difficult using routinely 
collected data such as that available on the GPRD and we did not attempt to clarify 
the disease status of the cases by contacting the GP. If the use of CPA/EE were 
truly associated with an increased risk of severe liver disorders only, by including in 
the case population women with transient and/or mild alterations in liver function the 
strength of any association between serious liver disorders and CPA/EE would be 
diluted. This does not appear to be the case in our study: of the 172 cases with liver 
disorders, 25 had diagnoses of hepatitis (three were exposed to CPA/EE) of whom 
seven were admitted to hospital (one had been using CPA/EE at the time of onset of 
her symptoms and she later died). It is also possible that our case population was 
under-representative - transient episodes of liver dysfunction may escape the 
attention of the GP or be considered clinically insignificant and thus not recorded by 
the GP. The importance of possibly missing mild and transient abnormalities is 
moderated by the likelihood of such episodes representing clinically significant 
disease.
It is possible that CPA/EE may be prescribed without reference to the condition 
actually requiring treatment ie acne or hirsutism and if so, we might have excluded a 
number of exposed individuals from our study population. In previous work we have 
found that amongst women with at least two years’ data prior to and at least one 
year’s data after a prescription for CPA/EE, 85% had a diagnosis consistent with the 
licensed indications for CPA/EE.1
The results presented in this paper are those for exposure defined as use of a 
hormonal contraceptive or CPA/EE on the index date according to the mapped 
prescribing information. To address the effect of possible misclassification of 
exposure status, we performed a sensitivity analysis after redefining exposure as 
drug use within 14 days or 21 days prior to the index date. The point estimates for 
liver disorder associated with use of a hormonal contraceptive or CPA/EE changed 
very little.
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Women prescribed CPA/EE may be more likely to have a diagnosis of acne or 
hirsutism recorded and women who have such a diagnosis recorded who are not 
prescribed CPA/EE could be different from those who are prescribed CPA/EE. For 
example, in the UK the potentially hepatotoxic drug isotretinoin may only be 
prescribed for oral administration under the supervision of a consultant 
dermatologist and therefore GPRD records of isotretinoin use will not be complete in 
the GPRD. This would have an impact on the estimation of risk amongst women 
with acne apparently unexposed to CPA/EE, effectively reducing the risk associated 
with CPA/EE.
Residual confounding by disease severity cannot be ruled out. The association 
between acne and liver disorders previously mentioned could be related to acne 
severity. The severity of acne varies, as does the tolerance to the condition 
demonstrated by affected individuals. Many women with acne rely on, inter alia, 
over-the-counter preparations or cosmetics and don't always consult a GP.
Although it is not possible to establish acne severity using data from the GPRD, in 
an effort to identify women with current acne we performed a sub-group analysis in 
women with at least two years' data after the index and one year’s data prior to the 
index date (91 cases [4 CPA/EE-exposed] and 425 matched controls). We found 
the point estimates to be largely unchanged with wide confidence intervals.
In conclusion, the association between the use of CPA/EE and liver disorders in 
women with acne, hirsutism or PCOS was not raised significantly after adjusting for 
potential confounding although this could be due to lack of statistical power.
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A bstract
Purpose: To derive risk estimates for venous thromboembolism in women 
prescribed cyproterone acetate combined with ethinyloestradiol (CPA/EE), a drug 
licensed in the UK for the treatment of women with acne or hirsutism. CPA/EE 
provides a treatment option for women with polycystic ovary syndrome (PCOS). 
CPA/EE has been associated with an increased risk of VTE.
Methods: Using the General Practice Research Database, we conducted cohort 
and case-control analyses in all women aged 15-39 and then nested in a population 
of women of the same age with acne, hirsutism or PCOS.
Results: The incidence rate ratio (IRR) for VTE in women exposed to CPA/EE 
versus conventional combined oral contraceptives (COCs) was significantly raised 
(all women: 1.92 [C W  .22,2.88]; nested: 2.51 [CI951.07,5.75]). Using exposure to 
conventional COCs as the reference, the adjusted odds ratio (ORadj) for VTE 
associated with CPA/EE was 1.45 (CI95 0.80,2.64) in all women and 1.71 (Cl95 
0.31,9.49) in women with acne, hirsutism or PCOS.
Conclusions: The risk of VTE associated with CPA/EE use does not differ 
significantly from that risk associated with use of conventional COCs. These data 
are reassuring and together with knowledge of the risks associated with other 
treatments for acne, in particular, should influence prescribing practice.
Key words: acne, cyproterone acetate, ethinyloestradiol, General Practice 
Research Database, polycystic ovary syndrome, venous thromboembolism.
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K ey points
• The use of CPA/EE has been associated with an increased risk of VTE.
• Although CPA/EE provides contraception, it is licensed in the UK to treat women 
with acne and/or hirsutism, common complaints amongst women with polycystic 
ovary syndrome (PCOS).
• PCOS is associated with an adverse cardiovascular risk profile.
• The issue of confounding was addressed rigorously and subsequent risk 
estimates indicated that the risk of VTE with CPA/EE use was not significantly 
greater than that risk in women prescribed conventional COCs.
• This study highlights the complexity of association with VTE in women prescribed 
CPA/EE and emphasizes the need to adequately adjust for confounding in risk 
assessment analyses.
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Introductio n
Cyproterone acetate (CPA) is an anti-androgen with progestogenic properties which, 
combined with ethinyloestradiol (EE) (CPA 2mg/EE 35pg), is licensed for the 
treatment of women with severe acne and moderately severe hirsutism. Although it 
is not licensed as an oral contraceptive (OC) in the UK, CPA/EE is sometimes 
prescribed for contraception.
Acne is generally associated with the onset of puberty and increased sebum 
production from the hair follicles on the face, chest and back. Propionibacterium 
acnes may proliferate within blocked pilosebaceous units and cause comedones 
and inflamed pustules. Sometimes acne is provoked by prolonged exposure to oral 
steroids. Conventional treatments for acne act by reducing sebum production, 
unblocking pores, delivering antibiotics or suppressing the effects of androgens. In 
the UK, acne treatments purchased over-the-counter, cosmetics or the services of a 
beautician may offer acceptable remedies for some individuals, whilst others may 
seek advice from a general practitioner (GP). Some combined oral contraceptives 
(COCs) (especially those with less androgenic progestogens such as desogestrel or 
gestodene) may help alleviate symptoms and long-term use of a tetracycline, 
particularly minocycline in the UK, is common. For women with acne that has 
proved refractory to prolonged oral antibiotic therapy, CPA/EE is indicated. The 
severity of hirsutism and tolerance levels also vary and, like in acne, affected 
women may rely on remedies available without recourse to GP services. Simple 
weight-loss may prove advantageous in obese women with hirsutism. In some 
cases, once sinister causes of hirsutism have been excluded (virilizing tumours of 
the ovary or adrenal and congenital adrenal hyperplasia), women may benefit from 
systemic drug treatment. As with acne, the use of certain COCs may prove helpful. 
The efficacy of several agents including the anti-androgen flutamide, the steroidal 
derivative spironolactone and the insulin-sensitizing agent metformin in treating 
hirsutism is being explored. Currently the only licensed systemic treatment for 
hirsutism in the UK is CPA/EE.
Importantly the severity of acne and hirsutism varies, as does the tolerance to the 
conditions demonstrated by affected individuals. Sometimes referral to a specialist 
dermatologist is warranted and subsequent treatment regimens may not be evident
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in GP records. Therefore the pattern of consultation with a GP for these complaints 
does not provide a reliable indication of seriousness.
Acne and hirsutism are common conditions amongst women with polycystic ovary 
syndrome (PCOS) (also known as Stein-Leventhal syndrome). PCOS is associated 
with obesity, dyslipidaemia and insulin resistance independent of obesity1*4 and 
women with PCOS thus have an intrinsically adverse cardiovascular risk profile.
This is supported by evidence of a higher prevalence of cerebrovascular and 
cardiovascular morbidity5 and a positive family history of thrombotic disease in 
women with PCOS.4 CPA/EE is contra-indicated during pregnancy and in women 
predisposed to hepatic or thromboembolic episodes. 6
Company data indicate that since its introduction in 1987, sales of CPA/EE have 
increased steadily, particularly after the “pill scare” of 1995/ There was a marked 
rise in the number of spontaneous reports of VTE associated with CPA/EE after 
1995 (before 1995 there were about 2 reports per year compared with about 20 
reports per year between 1995 and 1998).
Two of the studies that prompted the Committee on Safety of Medicines’ 1995 
warning regarding VTE risk in women using ‘third generation’ oral contraceptives8 
also reported a significantly raised risk of VTE associated with CPA/EE. In one the 
adjusted odds ratio for VTE associated with so-called ‘other’ COCs (CPA/EE and 
chlormadinone acetate) was 15.70 (CI9 5  3.90,63.15) compared with no OC use. 9 
The subsequent study10 reported an odds ratio of 14.9 (CI9 5  3.7,59.4) for use of 
CPA/EE 35pg and 3.8 (Cl951.4,10.7) for use of CPA/EE 50pg, compared with no OC 
use. The fact that the lower oestrogen dose formulation had a greater OR than the 
higher dose formulation is contrary to current understanding of the causal 
mechanism of VTE and suggests there may have been uncontrolled confounding or 
bias.
We have reported an elevated risk of VTE associated with CPA/EE previously.11*13 
The earliest study used data from the General Practice Research Database (GPRD) 
and Mediplus database for women aged 15-49 who had been prescribed oral 
contraceptives (including CPA/EE) and found crude incidence rates for VTE in
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women prescribed CPA/EE of 2.2 cases/10,000 exposed woman years (EWY) in the 
GPRD study and 4.9 cases/10,000 EWY in the Mediplus study.11 In the case- 
control analyses where use of levonorgestrel products was the reference, neither 
the GPRD nor the Mediplus database yielded significantly increased risks for VTE 
using year-of-birth matched controls. Analysis using controls matched within 5-year 
age bands, however, indicated a statistically significant increased risk for VTE 
associated with CPA/EE use (ORadj 2.3 [CI951.1,4.8]). These results and age- 
banding effects were confirmed subsequently.12 Our most recent paper described a 
study nested in a GPRD population of women with acne, hirsutism or PCOS.13 The 
results of case-control analysis indicated an increased risk for VTE associated with 
CPA/EE use compared with use of conventional COCs (ORadj2.88[CI95 1.40,5.92]).
In 2001 Vasilakis-Scaramozza & Jick published a research letter in the Lancet in 
which they reported an increased risk of VTE associated with CPA/EE in women 
aged between 16 and 39 years registered with general practices contributing to the 
GPRD.14 Compared with women prescribed COC products containing 
levonorgestrel, they reported an adjusted risk of VTE raised almost four-fold in 
women prescribed CPA/EE (O R adj3.9 [CI951.1,13.4]). The way in which the base 
population was defined was unusual. Cases and controls were selected from a 
study population of all women aged 16-39 ever prescribed CPA/EE and a sample of 
women prescribed a product containing levonorgestrel between 1/1/92 and 
31/12/1999. All cases and controls were current users of CPA/EE or levonorgestrel 
on the index date -  those women not exposed or using another product would have 
been excluded. As a result the sample of levonorgestrel users cannot be random 
because by design there would have been an artificially high proportion of CPA/EE 
users amongst women treated with levonorgestrel. This may have introduced 
significant bias.
Because CPA/EE is indicated for the treatment of acne or hirsutism and thereby 
provides a treatment option for women with PCOS, the increased ORs found in 
previous studies may have been the result of confounding by indication. We have 
described utilisation patterns of CPA/EE in women aged between 15 and 39 using 
data from the GPRD.7 Our data indicated that nearly a quarter of women prescribed 
CPA/EE had no recorded indication for CPA/EE (an acne diagnosis, prescription of
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an acne therapy or PCOS-like symptoms) prior to or on the date of their first 
CPA/EE prescription. Whilst mindful of completeness of recording on the GPRD, it 
does seem that in the UK there is some prescribing of CPA/EE outside its licence. 
We believe, therefore, that CPA/EE users represent a heterogeneous group of 
women a significant proportion of whom have adverse cardiovascular risk profiles.
This study used data from the GPRD to re-evaluate the risk of VTE associated with 
exposure to CPA/EE. First we present previously unpublished adjusted risk 
estimates for VTE in women exposed to CPA/EE compared with the risk in women 
using conventional COCs derived from analyses in all women aged between 15 and 
39. Because the cardiovascular risk profile of most women prescribed CPA/EE 
probably differs from the general female population, we then derived those risk 
estimates for women of the same age but restricted to those who had diagnoses of 
acne, hirsutism or PCOS. This part of the analysis uses methodology that evolved 
from that previously reported13 and employs stricter criteria for case definition in 
terms of acne status.
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M ethods
The GPRD contains the anonymised patient records from general practices in the 
UK of some 4% of the UK general population at any one time. The validity and utility 
of this database for studies of drug safety have been published elsewhere.15'18
The GPRD contains registration data linked to three types of coded entry. The three 
coded fields are: (a) medical records (information on diagnoses and symptoms 
recorded using Oxford Medical Indexing System [OXMIS] or Read codes); (b) 
therapy records (information on drugs prescribed with reference to Prescription 
Pricing Authority [PPA] codes, dosage and quantity); (c) so-called ‘prevention’ 
records (information on height, weight, smoking habit, alcohol consumption, blood 
pressure etc).
Stu d y  populations
The initial study population comprised women aged between 15 and 39 registered 
with a general practitioner (GP) who provided data to the GPRD at any time 
between 1st January 1992 and 31st December 1998. Women were selected from 
only those practices contributing data considered by the GPRD management team 
to be of research quality (‘up-to-standard’) at the time of a patient’s qualification for 
entry into the study. Data were used from a total of 618 such practices. For each 
woman, a pre-requisite of 6 months’ up-to-standard data were required for entry into 
the study. Study subjects could leave or join the study cohort at any time during the 
study period. Within the initial study population women with diagnoses of acne, 
hirsutism or PCOS were identified and included in the nested study population.
Identification  of w om en  w ith  a cn e , hirsutism  or PCOS
Appropriate OXMI S/Read codes were used to select women with hirsutism or acne 
diagnoses after 1st January 1992. Because of the chronic nature of acne, an ‘acne 
period’ was defined for each woman with an acne diagnosis. The acne period 
commenced two years prior to the first diagnosis of acne and ended one year after 
the last diagnosis and was censored according to registration dates. All women with 
a clear diagnosis of polycystic ovaries or Stein-Leventhal syndrome were included in 
the PCOS cohort (codes for PCOS perse are not used on the GPRD). Also
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included were those women with three or more PCOS markers (acne, 
hirsutism/alopecia, anovulation/infertility, amenorrhoea/oligomenorrhoea, obesity, 
endocrinological measures).
C ase  identification
We identified all women with an OXMIS/Read code for pulmonary embolism (PE) or 
deep vein thrombosis (DVT) between 1st January 1992 and 31st December 1998 
whilst aged 15-39. For women with more than one VTE event, the first event within 
the study window was used. The ‘event date’ was taken as the date upon which the 
first symptoms were recorded. These symptoms included haemoptysis, shortness 
of breath, chest pain and swelling or redness of a limb. Only fatal events and those 
with evidence of anticoagulant therapy, oral anticoagulants or heparin for 
pregnancy-related events were included. A validation study on the GPRD has 
indicated that long-term anticoagulation therapy or mortality criteria ensure that at 
least 85% of VTE cases are supported by other evidence.18 Amongst potential VTE 
cases, those with acne, hirsutism or PCOS were identified.
The complete patient records for each potential case were scrutinised to confirm the 
diagnosis and establish an event date whilst remaining blind to exposure status.
C alculation  of w o m an -tim e  denom inators  
‘Observed woman years’
The number of ‘observed woman years’ (OWY) was calculated from the number of 
days each woman was registered with the practice and at risk of VTE in the study 
window during each calendar year, stratified by 5-year age group. In the initial study 
cohort, OWY were stratified by acne and PCOS status. For women with acne, the 
OWY with acne were derived from each contributing woman’s ‘acne period’ as 
described above. For women with PCOS, OWY were calculated from the total 
registered time as for all other women. In the nested population total OWY for 
women with hirsutism or PCOS were similarly derived from the total registered time. 
Amongst women with acne in the nested study population however, OWY were 
derived from the acne period censored in line with the GPRD registration restrictions 
imposed on cases with acne (see below).
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‘Exposed woman years’ to CPA/EE or conventional COCs
A file was compiled from the GPRD therapy records representing the OC and 
CPA/EE prescriptions for each woman registered on the GPRD. In this file, OC or 
CPA/EE use was mapped to each day in the study period. The mapped utilisation 
was then adjusted to take account of overlapping prescriptions. In women where 
there were overlapping prescriptions for different products, the exposure to the first 
product was truncated to the day of the switch and a new period of exposure to the 
switched product assumed from the subsequent day. Non-overlapping scripts were 
represented in the file as discontinuous periods of exposure whether or not there 
was a change in product. It was thereby possible to identify which product (if any) 
any woman was using on any particular day.11
All potential study subjects had to have at least 6 months’ up-to-standard data 
before qualifying for the study population and the calculations of OWY and EWY 
were thus adjusted accordingly.
Case-control study
In the initial study, four controls were randomly selected from the study population 
for each case of VTE identified, matched by general practice and year of birth. For 
the nested study, we selected up to seven controls for each case, matched in the 
same way. Potentially, cases could be selected as controls for other cases until 
their event date. Controls had to be registered on the database on the event date of 
the matched case.
All GPRD records for each case and control were reviewed and coded with 
reference to a list of potentially relevant medical histories. The number of 
consultations with the GP in the 6 months prior to the event/index date was used as 
a proxy marker for general health status. Because GPRD observations are limited 
by censoring issues, the potential effect on risk of duration of exposure to OCs or 
CPA/EE was not addressed in this study.
In the initial case-control study cases and controls with acne or PCOS were 
identified and the analysis conducted accordingly (women were considered to have 
acne if the event/index date fell within the defined ‘acne period’). Cases and
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controls contributing to the nested case-control study were required to fulfil more 
stringent inclusion criteria. For a case with acne to qualify for inclusion in the nested 
case-control study, the event date had to fall within the ‘acne period’ and there had 
to be at least one year’s registration data prior to the index date and two years’ data 
after the index date to confirm acne status. The same constraint was applied to 
controls with acne. All cases and controls with hirsutism or PCOS were included in 
the analysis.
Analyses
The rate of VTE was calculated and compared between those women exposed to 
CPA/EE and those exposed to conventional COCs. Incidence rate ratios (IRRs) 
with 95% confidence intervals were calculated using Stata version 7.0 (Stata,
College Station, Texas, USA). Backwards and forwards stepwise conditional logistic 
regression was used to identify variables for inclusion in the full multiple logistic 
regression model using p<0.05 as the level for inclusion/exclusion. Risk estimates 
for VTE were calculated and adjusted for confounders and nuisance variables.
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R e s u l t s
A g e - s p e c if ic  in c id e n c e  r a t e  r a t io s
We identified 1,128 women from the initial study cohort (all women aged 15-39) who 
had had a VTE during the study period. Amongst these 59 had diagnoses of acne, 
hirsutism or PCOS and were included in the nested study cohort. Twenty-five of the 
1,128 cases and 12 of the 59 cases with acne, hirsutism or PCOS had been 
exposed to CPA/EE on the event date (6.86 cases and 11.03 cases per 10,000 
EWY to CPA/EE respectively). Of the 25 CPA/EE-exposed cases in the initial study 
cohort, 12 (48%) had acne and 4 (16%) had PCOS.
Table 7.1 shows the crude IRRs for CPA/EE exposure versus exposure to 
conventional COCs in all women and in women with acne, hirsutism or PCOS. The 
following IRRs were derived from analyses in all women. The IRR for VTE in 
women exposed to CPA/EE compared with conventional COCs was significantly 
raised to 1.92 (CI951.22,2.88). PCOS appeared to be associated with an increased 
risk of VTE - the IRR for VTE in women with PCOS compared with non-PCOS 
women was significantly raised (1.84 [CI951.10,2.89]). Amongst women exposed to 
CPA/EE, the rate of VTE was higher amongst women with PCOS compared with 
those without PCOS although the IRR did not reach statistical significance (IRR 2.71 
[CI95 0.68,8.04]). Exposure to CPA/EE was associated with a higher risk of VTE in 
women with PCOS (IRR 4.34 [CI951.05,13.62]) than in those without PCOS (IRR 
2.50 [Cl951.54,3.83]) although the IRRs were not statistically different from each 
other. There was no difference in the baseline rate of VTE in women with acne 
compared with that in women without acne. (PCOS and acne are not mutually 
exclusive conditions.) The IRR for VTE in women with acne using CPA/EE versus 
CPA/EE users without acne was not significant (1.19 [Cl95 0.50,2.84]). Use of 
CPA/EE was associated with an increased risk of VTE in women with acne (IRR 
3.70 CI951.78,7.08) and in women without acne (IRR 2.52 [CI951.34,4.33]) -  these 
risk estimates are not statistically significantly different from each other. Preliminary 
age-stratified analyses indicated an increased risk of VTE with increasing age 
although the risk estimates were sensitive to age-banding decisions as the case 
number was small.
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Amongst women with acne, hirsutism or PCOS the crude IRR for CPA/EE exposure 
versus exposure to conventional COCs was significantly raised (2.51 [ C I 9 5  
1.07,5.75]) and preliminary age-stratified analysis suggested that the risk of VTE 
increased with age (data not shown).
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Table 7.1 Incidence rate ratios for VTE (1992-1998)
VTE (n) OWY/EWY* Rate+ Rate ratios (CI95)
All women aged 15-39
Baseline rate 1128 4477021 2.52
Women exposed to CPA/EE
Women exposed to conventional COCs (ref)
25
349
36432
974805
6.86
3.58
1.92 (1.22,2.88)
Women with PCOS 
Women without PCOS (ref)
19
1109
41281
4435741
4.60
2.50
1.84 (1.10,2.89)
Women with PCOS exposed to CPA/EE 
Women without PCOS exposed to CPA/EE (ref)
4
21
2390
34042
16.73
6.17
2.71 (0.68,8.04)
Women with PCOS exposed to CPA/EE 
Women with PCOS not exposed to CPA/EE (ref)
4
15
2390
38891
16.73
3.86
4.34 (1.05,13.62)
Women without PCOS exposed to CPA/EE 
Women without PCOS not exposed to CPA/EE (ref)
21
1088
34042
4401699
6.17
2.47
2.50 (1.54,3.83)
Women with acne 
Women without acne (ref)
59
1069
245763
4231259
2.40
2.53
0.95 (0.72,1.24)
Women with acne exposed to CPA/EE 
Women without acne exposed to CPA/EE (ref)
12
13
15879
20554
7.56
6.32
1.19(0.50,2.84)
Women with acne exposed to CPA/EE 
Women with acne not exposed to CPA/EE (ref)
12
47
15879
229884
7.56
2.04
3.70 (1.78,7.08)
Women without acne exposed to CPA/EE 
Women without acne not exposed to CPA/EE (ref)
13
1056
20554
4210705
6.32
2.51
2.52 (1.34,4.33)
Women aged 15-39 with acne, hirsutism or PCOS
Baseline rate 59 135795 4.34
Women exposed to CPA/EE
Women exposed to conventional COCs (ref)
12
15
10881
34203
11.03
4.39
2.51 (1.07,5.75)
* Observed women years/exposed women years as appropriate;t Rate per 10,000 OWY/EWY
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C a s e - c o n t r o l  s t u d ie s
Table 7.2 presents the characteristics of cases and controls and crude odds ratios 
(ORs) for VTE in all women and women with acne, hirsutism or PCOS. Amongst all 
women, seven cases were orphaned -  none of these had been exposed to CPA/EE 
on the index date. For the remaining 1,121 cases the majority (97%) had four 
controls. Ten cases from the nested population were orphaned, including four 
CPA/EE-exposed cases. Of the remaining 49 cases in the nested study, 82% had 
at least two controls.
In all women we found an increased unadjusted risk for VTE associated most 
strongly with prior VTE events, high consultation rates with the GP, pregnancy 
(especially the intra/postnatal period) and recent surgery or trauma. Other 
significant risk factors for VTE in all women included PCOS, a low BMI (<20), a high 
BMI (30+), total abstinence from alcohol, 10 or more units of alcohol per week, 
smoking, varicose veins, cancer (diagnosis before the event/index date or within 
three months after the event/index date), a history of hypertension, a high number of 
recent GP consultations, chronic illness and prior use of oral steroids. In women 
with acne, hirsutism or PCOS only one control had had a prior event, the association 
between VTE and intra/postnatal period of pregnancy persisted, there was no 
significant difference in smoking status between cases and controls and cases and 
controls were more homogeneous with regard to BMI. Also amongst women with 
acne, hirsutism or PCOS, the significant association remained between VTE and 
total abstinence from alcohol, a high number of recent GP consultations and chronic 
illness. With reference to use of conventional COCs, the crude OR for VTE 
associated with exposure to CPA/EE was 1.39 (Clgg 0.82,2.37) in all women and 
1.31 (Clgs 0.35,4.92) in women with acne, hirsutism or PCOS.
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Table 
7.2 
Characteristics 
of cases 
and 
controls
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Table 
7.2 
Characteristics 
of cases 
and 
controls 
(continued)
ancer diagnose 
before 
or up 
to 
three 
months 
after the 
event/index 
date;2 W
om
en 
without evidence 
of current or recent pregnancy, current use 
of oral 
contraception 
(or CPA/EE) and 
not m
enopausal;3 Including 
term
inated 
pregnancies; « Progesterone-only 
pill;5 W
ithin 
the 
six-week 
period 
prior to 
event/index 
date 
Asthm
a, diabetes, thyroid 
disease, renal disease, Crohn's 
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Based upon the results of stepwise conditional logistic regression varicose veins, 
smoking, PCOS status and acne were dropped from the analysis within the cohort of 
all women aged 15-39. The results of the conditional logistic regression analysis are 
given in Table 7.3. In these women the strongest predictors of VTE were recent 
surgery or trauma (OR 26.87 [C W  3.97,51.70]) and a prior VTE event (OR 21.47 
[C W  0.80,42.67]). Our analysis confirmed that pregnancy was strongly and 
significantly associated with an increased VTE risk in all women, especially in 
women who had delivered within the 6 weeks prior to the index date or whose 
pregnancy had been terminated (OR 5.81 [Cl95 3.88,8.71]) (reference group=COC 
users). Compared with the same reference group, the adjusted OR associated with 
CPA/EE use in all women was OR 1.45 (Cl950.80,2.64). Increasing BMI was 
associated with an increased risk of VTE although women with a BMI under 20 
appeared to be at greatest risk.
The variable for reproductive status was forced into the stepwise regression analysis 
in the cohort of women with acne, hirsutism or PCOS. Only the number of recent 
GP consultations and alcohol consumption were found to contribute significantly to 
the outcome. The final model yielded an adjusted OR for VTE risk associated with 
exposure to CPA/EE of 1.71 (CI9 5  0.31,9.49) with users of conventional COCs as the 
reference group (Table 7.3).
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Table 7.3 Conditional logistic regression analyses
All women Women with acne, hirsutism or PCOS
(5545 observations) (186 observations)
Variable OR (95% CIs) OR (95% CIs)
VTE prior to 1992 
Reproductive status
21.47(10.80,42.67) -
Antenatal period 1.03 (0.75,1.42) 1.01 (0.20,5.06)
Intra/postnatal period1 5.81 (3.88,8.71) 2.81 (0.17,45.34)
Use of conventional COCs reference reference
Use of POPs 0.42 (0.22,0.81) 1.30 (0.01,175.41)
Use of CPA/EE 1.45 (0.80,2.64) 1.71 (0.31,9.49)
Menopause 0.66 (0.34,1.29) 0.11 (0.00,2.69)
None2
Body mass index
0.38 (0.31,0.46) 0.49 (0.14,1.74)
<20 2.05(1.47,2.86) -
20-24 reference -
25-29 1.04 (0.82,1.31) -
30-34 1.43(1.06,1.94) -
35+ 1.89(1.29,2.77) -
Unknown 1.18 (0.91,1.51) 
Number of consultations with the GP in prior 6 months
None 0.16(0.12,0.22) 0.49 (0.13,1.82)
1-2 0.42 (0.34,0.51) 0.21 (0.05,0.94)
3-9 reference reference
10+ 2.03 (1.58,2.61) 4.18(1.04,16.81)
Chronic illness 2.19(1.77,2.71) -
Surgery/trauma 
Alcohol consumption
26.87 (13.97,51.70)
None - 5.44(1.51,19.64)
1-9 units per week - reference
10-21 units per week - 0.35 (0.03,4.18)
22+ units per week - 8.57 (0.32,228.23)
Unknown - 3.50 (0.91,13.44)
1 Including terminated pregnancies
2 Women without evidence of current or recent pregnancy, current use of oral contraception 
(or CPA/EE) and not menopausal
Reference categories = no disease/no exposure unless otherwise indicated.
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D iscussion
Results from analysis of the initial study cohort of all women aged 15-39 indicated a 
significantly higher crude rate of VTE in women exposed to CPA/EE compared with 
women exposed to conventional COCs (IR R1.92 [CI9 5 1.22,2.88]) and a significantly 
higher rate of VTE in women with PCOS compared with women without PCOS (IRR 
1.84 [CI9 5 1.10,2.89]). We observed a number of other risk factors for VTE including 
a history of VTE, recent pregnancy, increasing BMI, chronic illness, surgery or 
trauma, smoking, varicose veins and a high number of recent consultations with the 
G P. The association between VTE and a BMI < 20 is probably confounded by ill 
health. PCOS was associated with a crude OR for VTE of 1.74 (Cl951.01,2.98) 
based on 19 cases but the risk of VTE for women with acne was not significantly 
different from that in women without acne (OR 1.14 [Cl95 0.85,1.54]). The adjusted 
OR associated with exposure to CPA/EE was not significantly different from that 
associated with conventional COCs (1.45 [CI9 5  0.80,2.64]).
Thus, analysis of the original study cohort demonstrated that women with PCOS 
were at almost twice the risk of VTE compared with women without PCOS, 
irrespective of OC use. For those women using CPA/EE to treat to PCOS therefore, 
we would expect to observe an increased risk of VTE when comparing the risk for 
CPA/EE users with the VTE risk in users of conventional COCs because of the 
indication for which CPA/EE is licensed (PCOS was evident in 4 (16%) of the 
CPA/EE-exposed cases and 4 (9%) of the CPA/EE-exposed controls). In an effort 
to estimate the risk of VTE associated with CPA/EE more efficiently, we repeated 
our analyses in women with acne, hirsutism or PCOS - a group of women that 
essentially has an increased risk of VTE that might be amplified by exposure to 
CPA/EE. Building upon the methodology described in previous work13 we refined 
the case definition to optimise the likelihood of current acne amongst cases and 
controls included because they had acne diagnoses. In that nested population, the 
crude rate of VTE in women exposed to CPA/EE was 11.03 cases/10,000 EWY, 
which was significantly higher than that amongst women exposed to conventional 
COCs (IRR 2.51 [CI9 5 1.07,5.75).
Twelve cases in the nested population were exposed to CPA/EE at the time of the 
VTE and two of these had acne but no other apparent indication for the use of
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CPA/EE. In women whose only complaint is acne it would be reasonable to 
consider risk estimates for VTE associated with exposure to CPA/EE against the 
risk of adverse events associated with other acne therapies. The adverse reactions 
associated with topical acne treatments include local inflammation and occasionally 
photosensitivity. The tetracyclines have been associated with vestibular 
disturbances, hyperpigmentation and photosensitivity and, more seriously, lupus-like 
reactions and hepatitis. The treatment options for women whose acne proves non- 
responsive to topical or oral antibiotic treatment include CPA/EE and oral retinoids 
although in the UK the use of isotretinoin requires specialist dermatological 
supervision.19 Isotretinoin is teratogenic and in women of childbearing age 
concomitant use of a combined oestrogen-progesterone oral contraceptive is 
recommended.20 The potential side effects of isotretinoin use include 
hypervitaminosis A-like symptoms, benign intracranial hypertension, alopecia, liver 
disease, elevated serum cholesterol levels, photosensitivity and pancreatitis. More 
recently spontaneous reports linking the use of isotretinoin with severe depression 
and suicide attempts have been cited21 although there is currently no 
epidemiological evidence to support a causal association.22
We could not demonstrate that the adjusted risk of VTE associated with the use of 
CPA/EE was significantly greater than the risk associated with the use of 
conventional COCs. The oestrogen component of the CPA/EE formulation in current 
use and used by women in our study barely exceeds that of the majority of 
conventional COCs. A review of the prescribing information for all women exposed 
to conventional COCs on the index date revealed that all formulations contained 
either 30pg or 35pg of ethinyloestradiol. CPA itself has not been associated with 
VTE and to our knowledge there is no biological plausibility for any such 
relationship.
The number of cases was small in this study, particularly in the nested analysis. 
Certainly the identification of potential study subjects is limited by the completeness 
of recording on the GPRD and it is likely that disease misclassification exists in 
terms of acne, hirsutism or PCOS. Earlier we alluded to the difficulty in ascribing 
disease severity using GPRD records, particularly in women with acne diagnoses - 
the pattern of consultation with a GP for acne cannot be used to define acne
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severity nor can we expect to identify all women with acne. The process by which 
PCOS women were identified was carefully considered but could similarly render the 
PCOS population misrepresentative. GPRD prescribing data is almost complete,17 
which reduces the likelihood of misclassification in terms of exposure status, 
although compliance with prescribed medications cannot be firmly established.
The cases and controls remaining in the nested study described here were those 
that originated from earlier work but fulfilled more rigorous inclusion criteria.
Certainly if the study were to be repeated using those inclusion criteria from the 
outset, although the case number would be unaltered, the inclusion of more 
matched controls would increase the statistical confidence surrounding the resultant 
point estimate.
In conclusion, although we could not demonstrate that the risk of VTE in women 
prescribed CPA/EE was significantly greater than that risk in women using 
conventional COCs, it is possible that the morbidity associated with more severe 
symptoms in women prescribed CPA/EE may include an elevated VTE risk. We 
cannot determine disease severity using routinely collected data such as that 
available on the GPRD and further work is planned to explore the underlying risk 
profiles of CPA/EE users.
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8.1
Discussion & Conclusions
Intro ductio n
As described on pages 1.3-1.12, acne is a condition that presents with considerable 
variation in severity. In its mildest form, acne may persist for only a relatively short 
period of time and cause little distress. For those individuals more severely 
affected, acne might persist for years with scarring and psychological sequelae that 
could have a considerable impact on the quality of life. For the mildest symptoms 
products available OTC may prove adequate and pose relatively minor risks 
(bleaching or staining of clothes, mild and transient skin irritation). Isotretinoin is 
indicated for the most severe forms of acne but it is a toxic teratogen and is 
available in the UK only under specialist dermatologist care. Whilst acknowledging 
that individuals may manage acne without recourse to GP care and that an 
individual's behaviour does not always correspond with acne severity, it is likely that 
acne diagnosed and treated in UK general practice ranges between mild and 
moderately severe, sometimes warranting treatment with oral antibiotics {eg 
minocycline) or CPA/EE. Prescribing general physicians need to be aware of the 
side effect profiles of anti-acne drugs to make the best risk-benefit assessment for 
their patients.
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G eneral  F indings
This thesis presents six peer-reviewed papers together contributing to an 
understanding of drug utilisation and adverse events associated with drug use, 
essentially in acne. Chapter Two is a critical review of published case reports, case 
series and spontaneous reports (SRs) focusing on the evidence for liver disease 
associated with exposure to minocycline prescribed for acne. We describe two 
distinct types of reaction closely associated with the duration of exposure to 
minocycline. An often severe hypersensitivity-type reaction (HSR) occurred within 
about five weeks of exposure to minocycline and there was an indication that some 
ethnic groups might be more susceptible. An autoimmune hepatitis was typically 
associated with a much longer duration of exposure. Our analysis of the WHO data 
on spontaneous reports confirmed the division of reactions into these two distinct 
types. The review of case reports, case series and SRs indicated that there did 
appear to be an association between hepatic disorders and the use of minocycline 
for acne but that an assessment of the level of risk associated with minocycline 
exposure could be evaluated only with further observational study.
Chapter Three describes such an observational investigation. A cohort analysis and 
case-control study were designed to establish risk estimates for liver disease in 
people prescribed minocycline and to compare those risk estimates with the risk in 
people using tetracycline or oxytetracycline (hereafter referred to as 
(oxy)tetracycline). We concluded that there did appear to be a weak association 
between liver disease and the use of minocycline for acne but that the risk of liver 
disease with minocycline was not greater than the risk with (oxy)tetracycline. The 
attributable risk of liver disease associated with minocycline was 5.7 cases/100,000 
exposed person months (EPM) compared with 2.4 cases/100,000 EPM in those 
using (oxy)tetracycline.
After completing the work on minocycline and liver disease, the next research 
exercise was to address issues surrounding CPA/EE and the associated risk of VTE 
or liver disease. Whilst the anti-androgen CPA alone may be used to treat prostate 
cancer and some other male disorders, in combination with ethinyloestradiol it is 
used by women and is specifically licensed for the treatment of hirsutism and acne 
that has proved refractory to treatment of conventional antibiotics. CPA/EE is also a
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treatment option for women with PCOS. According to its licensed indications and 
the prevalence of those conditions for which CPA/EE is indicated, it could be 
concluded that CPA/EE is a drug used primarily to treat acne. GPRD data 
suggested that some CPA/EE was being prescribed off-label for contraceptive 
purposes, however, without evidence of the conditions for which it is indicated. 
Importantly after the pill scare of 1995 there was a marked increase in CPA/EE’s 
share of the UK OC market. The data presented in Chapter Four arose from our 
exploration of OC prescribing patterns amongst women with and without acne or 
PCOS. We demonstrated that whilst a large proportion of CPA/EE was prescribed 
to women with acne and/or PCOS, that proportion decreased after the pill scare. 
This has important implications in CPA/EE risk assessment studies.
The risk of VTE in women with acne, hirsutism or PCOS probably differs from that in 
the general population. This may also be true for liver disease. To explore the risks 
associated with CPA/EE the analyses must adequately control for confounding by 
acne, hirsutism or PCOS. This might be achieved by careful adjustment of analyses 
amongst all women or possibly more efficiently by nesting analyses amongst women 
with acne, hirsutism or PCOS.
Chapter Five describes the findings of our study on VTE risk and CPA/EE amongst 
women with acne, hirsutism or PCOS. We found an increased risk of VTE 
associated with CPA/EE use compared with the use of conventional COCs although 
we concluded that residual confounding by indication could not be excluded. The 
study described in Chapter Six found no evidence to support an association 
between the use of CPA/EE and liver disease in women with acne, hirsutism or 
PCOS although this could have been due to a lack of statistical power.
The last paper in this thesis (Chapter Seven) explores the methodological issues in 
the studies establishing VTE risk and the use of CPA/EE. The results of the study in 
all women are presented for comparison alongside a re-analysis of the data from the 
nested population. We concluded that the adjusted risk of VTE amongst women 
prescribed CPA/EE was not significantly different from the risk posed by 
conventional COCs. How important confounding is in the association between VTE
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and CPA/EE remains unclear especially as the nested analysis did not appear to 
resolve the issue.
Our database studies described a population of people with acne diagnosed by GPs 
that probably ranged in severity between mild and moderately severe. Because 
some patients with acne will manage their condition without resorting to a GP 
consultation, some patients with acne may be missed from our study populations. It 
is probably reasonable to assume, however, that those included in our study 
populations because they had a diagnosis of acne did have a significant complaint. 
Patients with the most severe types of acne potentially complicate our analyses and 
interpretation of the findings because a GP may diagnose acne in the primary care 
setting but refer the patient to a specialist dermatologist for treatment. This is 
particularly relevant for patients treated with oral isotretinoin.
It is likely that minocycline and CPA/EE are prescribed to patients with acne that 
ranges in severity between mild and moderately severe. The risks associated with 
minocycline include those typical of tetracyclines {eg gastrointestinal upsets) and 
others more specific to minocycline use (ie HSRs and AIM). Clinicians should be 
aware of the possibility of adverse effects from long-term use of minocycline and 
that some patients may be predisposed to adverse events. CPA/EE not only treats 
acne and hirsutism but also provides effective contraceptive cover. The risks 
associated with CPA/EE use include those typically associated with conventional 
COCs although the risk of VTE is likely to be closely correlated with underlying 
morbidity in CPA/EE users.
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M etho do lo g ic a l  issues
Studies in this thesis typically follow a classical pattern of pharmacoepidemiological 
investigation whereby analysis of spontaneous reports (SRs) and published 
literature is followed by risk assessment studies.
Case reports, case series and SRs provide an opportunity for physicians to 
disseminate their experience of unusual or previously unknown clinical events and 
side effects associated with drug use. They are of limited value, however, in 
establishing causality and in risk assessment for a number of reasons. No 
comparison group exists and it is possible that the patient reported is in some way 
different from the majority of patients who have the disease or who are treated with 
the drug in question. Also rates of under-reporting and reporting bias are 
unquantifiable. Reasons for under-reporting may arise through the characteristics of 
ADRs {eg an ADR may not be recognised because the event resembles a common 
condition that could have occurred spontaneously or the ADR is one that has 
become less unusual) or through the habits of reporting physicians - doctors may be 
unaware of their obligations and responsibilities or simply may not have the time to 
send in a report. Another source of reporting bias arises through a heightened 
awareness amongst doctors about special interest drugs (some countries use SR 
data to generate advisory information about particular drugs and disseminate that 
information via bulletins and medical journals).
Our appraisal of the published literature on case reports and case series where liver 
disease was associated with minocycline exposure was thus limited by the 
information provided within those reports. Full appraisal of case reports is assisted 
by information about (a) the temporal relationship between exposure and event, (b) 
the presence or absence of other factors that might also cause the event, (c) the 
result of withdrawing or re-introducing the drug (rechallenge), (e) the dose 
administered and (f) other information supporting an association {eg previous 
cases). For some of the cases we describe in the literature review the information 
provided was scant, for others it appeared to be more complete. Our initial opinion 
about the likelihood of associations was, in some cases, reassessed in the light of 
further information sourced elsewhere. This was especially important with the 
deaths that had been attributed to a hepatic event caused by minocycline use.
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The risk assessment studies performed using the GPRD presented a number of 
methodological issues and these are addressed in the following paragraphs.
Id e n t if y in g  t h e  c a s e s
Included in our case population for the minocycline study and the CPA/EE study on 
liver disease were patients with diagnostic codes relating to altered liver function. 
Sometimes altered liver function is transient and of little clinical significance but it 
can also be associated with more serious disease. Because of the limitations of 
GPRD coding practices, all patients with altered liver function were eligible for the 
study populations (assuming no exclusion criteria were met). It is likely that some 
patients with transient episodes of altered liver function were missed perhaps 
because the episode passed unnoticed or it was considered insignificant. In both 
the minocycline and CPA/EE studies the majority of liver cases were included 
because there was a diagnosis of altered liver function. The inclusion of potentially 
mild and/or transient episodes of liver dysfunction could have diluted the effects of 
exposure and this issue is addressed in the papers. Amongst CPA/EE users we 
were also exploring the risk of VTE. The identification of women with VTE required 
a diagnostic code for VTE, pulmonary embolism or deep vein thrombosis plus 
evidence of anticoagulant therapy. It is possible that events could have been 
missed if diagnoses made in hospital or prescriptions for anticoagulants issued by 
hospital pharmacies were not entered into the GPs records. Since 1997 the 
completeness of recording hospital outcomes in patient’s GPRD records has not 
been validated (personal communication: Louise Wood, MHRA). GPs were not 
asked to validate VTE cases in these studies and this will be a consideration in 
future work.
E s t a b l is h in g  e x p o s u r e  s t a t u s
The majority of prescriptions issued by GPs are computer generated and will be 
recorded on the GPRD. Prescriptions issued in hospital or by family planning clinics 
may be missed, however, and because compliance with prescribed medication 
cannot be determined, there is likely to be some misclassification in terms of 
exposure status. This is an acknowledged limitation of the GPRD. It is possible that 
GPs will monitor patients prescribed some drugs more closely perhaps because
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they associate certain exposures with particular risks. Patients using minocycline, 
for example, may be more likely to have mild symptoms investigated. Whether 
misclassification in terms of exposure status is differential or non-differential is an 
important consideration in understanding the potential dilution or amplification of 
effects.
R e s id u a l  c o n f o u n d in g
Whilst people prescribed minocycline or CPA/EE are likely to have acne, they may 
also have varying degrees of underlying morbidity. This is especially true for 
CPA/EE users who may have other symptoms suggestive of PCOS. It is possible 
that our analyses could have inadequately controlled for confounding by indication 
because there was insufficient or inaccurate information about our study subjects. 
This could have arisen either because signs and symptoms were not brought to the 
attention of the GP, because they were not considered clinically significant and thus 
not recorded, or because of the limitations imposed by vague or inaccurate GPRD 
code dictionaries. Omission of important information might otherwise arise through 
a feature of database studies that poses significant limitations to observational 
studies. These ‘censoring’ issues are described next.
C e n s o r in g  is s u e s
If a patient registers with a practice that is contributing to the GPRD and that 
practice is currently contributing data that satisfies quality checks (ie is ‘up-to- 
standard’), clinical and prescribing information about that patient will be available on 
the GPRD from the date of registration (or first consultation/first prescription if the 
events are not contemporaneous). Some historical information may be entered into 
the patient’s records but any reference to such material in epidemiological studies 
carries its own limitations. Thus that patient’s medical history and use of prescribed 
drugs remains largely unknown prior to the date they registered with the general 
practice. Similarly little will be known about a practice’s existing patients prior to the 
date upon which that practice begins to contribute data to the GPRD. The 
truncation of data imposed either by the date of a patient’s registration with a 
general practice, the date upon which a practice starts to contribute to the database
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or the date upon which the data is up-to-standard is generally referred to as ‘left- 
censoring’ (Figure 8.1).
In the same way that a ‘left-censor’ date is established for each patient, there is a 
date upon which data cease to be contributed to the database -  the date of ‘right 
censor’. This may be the date when a patient has left the practice (perhaps died or 
moved away), when the practice stops contributing to the GPRD or when data are 
no longer up-to-standard. In other instances the date of right censor will be the last 
date of data collection for the GPRD.
Figure 8.1 Schematic to illustrate GPRD censoring issues
Left censor date Right censor date
©.
I
Each heavy line in the above diagram represents a theoretical period of registration for 
one patient on the GPRD. The dotted lines show how medical and prescribing 
experience outside the censor dates remains unknown.
.©
O
Censoring might affect reliable detection of cases, determination of exposure status 
and identification of confounding variables. In the studies on liver disease, for 
example, where patients with prior liver disease were excluded, diagnoses made 
before the left-censor date may have been missed. Similarly relevant events might 
occur after the right-censor date. There are ways to address these censoring issues 
including defining a ‘run-in period’ from the date of left censor to establish with
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greater certainty whether events or exposures of interest are incident or first-ever, or 
by ensuring that patients who qualify for study have a certain minimum period of 
registration after the left censor date.
GPRD p o w e r
The GPRD is a large source of longitudinal data from general practice in the UK.
For most studies reported in this thesis, over 8 million person years were 
represented. Despite the quantity of GPRD data, however, sometimes GPRD 
studies may be under-powered (eg our analysis of liver disease amongst women 
with acne, hirsutism or PCOS [Chapter Six]). An up-dated version of the GPRD will 
soon be available with considerably more data and we hope this will facilitate more 
robust analyses.
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TO WHOM DO THESE FINDINGS APPLY?
The majority of patients prescribed minocycline have acne and acne is most 
prevalent between the ages of 15 and 39. Thus the study addressing the risk of 
liver disease amongst people prescribed minocycline was nested appropriately and 
the findings are relevant to the majority of patients who use minocycline. CPA/EE 
users are probably a more heterogenous group because there is likely to be some 
prescribing off-label. It appears from GPRD data that women are sometimes 
prescribed CPA/EE for contraception purposes alone and that this was particularly 
so after the 1995 pill scare (Chapter Four). Whilst there might be some under­
recording of acne or other indications for CPA/EE amongst such women, the risks 
associated with CPA/EE used for contraception only may warrant further 
investigation. The risk estimates amongst all women aged 15-39 did not indicate an 
increased risk for VTE with CPA/EE use after adjusting for diagnosed acne, 
hirsutism of PCOS and this finding was supported by results from the study nested 
amongst women with indications for CPA/EE use.
Whether non-viral liver disease is more common amongst individuals with acne is a 
question that has arisen through this work (Chapter Three) and provides an 
opportunity for further research. Given the complex morbidity associated with acne 
in some women, the baseline risk of VTE amongst such women is probably higher 
than amongst women without acne or other symptoms suggestive of PCOS. We 
have tried to address this issue by careful adjustment (Chapters Five & Seven) 
although it is possible that residual confounding by disease severity or missed 
diagnoses is important.
Therefore in principle we can say that the findings presented in this thesis apply to 
individuals in the general population with acne. Further work is planned to describe 
women prescribed CPA/EE and disease severity in particular by way of a 
prospective field study (see Recommendations for Further Work).
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How DO OUR RESULTS AND INTERPRETATIONS DIFFER FROM THOSE OF 
OTHERS?
L iv e r  d is e a s e  a n d  m in o c y c l in e
Our preliminary review of the literature and spontaneous reports on minocycline and 
liver disease supported the recognised division of ADRs into early onset 
hypersensitivity-type reactions (HSRs) and an autoimmune-type hepatitis after a 
longer course of exposure (Chapter Two). Since completing our review, more case 
reports, case series and reviews have been published that detail such reactions in 
patients prescribed minocycline (Appendices II & III). Critical appraisal of these 
papers has not been carried out. To our knowledge, ours is the only published 
study to date on the incidence of liver disease amongst patients prescribed 
minocycline (Chapter Three).
CPA/EE AND VTE
The association between CPA/EE and VTE has been described in some papers 
focussing on the risk of VTE with use of conventional COCs45'47 and another 
addressing the risk of fatal pulmonary embolism with COCs.48 The WHO study45 
and Parkin study48 in particular were limited by small numbers of exposed 
individuals whilst the Lidegaard study47 quoted a risk estimate for CPA/EE that was 
very similar to the risk amongst uses of levonorgestrel products. Earlier findings by 
Farmer et a t6 have been described in Chapter Seven.
The only published paper that, like ours, specifically addresses the risk of VTE in 
women prescribed CPA/EE is from Vasilakis-Scaramozza and Jick.49 Whilst we 
described a non-significant adjusted risk estimate for VTE amongst CPA/EE users 
of 1.71 with reference to use of conventional COCs (Chapter Seven), Vasilakis- 
Scaramozza & Jick reported a significantly elevated adjusted risk estimate of 3.9 
relative to use of products containing levonorgestrel. Like ours the Vasilakis- 
Scaramozza and Jick study was conducted using the GPRD and so the 
contradictory findings deserve special attention.
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The Vasilakis-Scaramozza & Jick study population included all women aged 16-39 
who had ever received at least one prescription for CPA/EE. Also included in the 
study population was a random sample of women who had been prescribed a 
product containing levonorgestrel between 1/1/1992 and 31/12/1999. Women 
prescribed CPA/EE before 1992 would have been included in the study population. 
Past use of CPA/EE amongst levonorgestrel users or past use of levonorgestrel 
amongst CPA/EE users was not described although the selection criteria meant that 
amongst the women prescribed levonorgestrel all those ever prescribed CPA/EE 
would be included. Because of the conditions for which CPA/EE is indicated, it is 
likely that women with acne, hirsutism or PCOS would be over-represented in the 
sample of women prescribed levonorgestrel products.
As in our study, case status was confirmed by a diagnostic code for VTE and a 
prescription for anticoagulation therapy. (Vasilakis-Scaramozza & Jick defined a 
subset of cases with positive Doppler imaging or VQ scan although subset analysis 
was consistent with analysis using all anticoagulant-treated cases.) Cases and 
controls had to be current users of either a levonorgestrel product or CPA/EE on the 
index date. Any cases/controls found to be using an OC product other than CPA/EE 
or levonorgestrel on the index date would have been excluded post hoc as they did 
not meet the inclusion criteria. This would have particular implications for women 
with acne who were more likely to be using products containing desogestrel or 
gestodene prior to the 1995 pill scare (Chapter Four). The exclusion of cases 
and/or controls based on exposure status may lead to selection bias. It is difficult to 
determine the direction of such bias, if present, in this particular situation.
Vasilakis-Scaramozza & Jick described a study population where 31% of cases and 
28% of controls had acne. These proportions seem rather high but this can be 
explained by the fact they sampled from all CPA/EE users and a fraction of 
levonorgestrel users. Some of this latter group may have been PC4 (‘morning-after 
pill') users although most of them will probably have been COC users -  this cannot be 
determined from the paper. The resulting study population will have been a mixture of 
women with acne (the CPA/EE users) and women with a below average likelihood of 
androgenic skin conditions, because they were getting levonorgestrel (instead of 
CPA/EE, desogestrel, gestodene, or norgestimate). It is difficult to tell whether
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adjusting for acne in their study will have adequately controlled for all confounding by 
this condition, especially considering the effects of restricting a GPRD study population 
according to the amount of registered time. The paper does not explain how women 
with PCOS were identified.
We found a risk estimate for VTE associated with CPA/EE amongst all women of
1.45 (0.80,2.64) (Chapter Seven) with reference to use of conventional COCs. 
Unlike Vasilakis-Scaramozza & Jick’s study, ours was not restricted to current 
levonorgestrel or CPA/EE users and we adjusted for, rather than excluded, women 
with conditions predisposing to thrombosis.
It is difficult to make direct comparisons between our paper and the Vasilakis- 
Scaramozza & Jick paper because of differences in study design and methodology. 
Our main concern is the reliability of Vasilakis-Scaramozza & Jick’s risk estimate 
given the way in which the study population was defined. It is difficult to estimate 
what impact the biases introduced by the Vasilakis-Scaramozza & Jick study design 
and case selection would have on the resultant risk estimates.
CPA/EE AND LIVER DISEASE
The Multicentre International Liver Tumour Study (MILTS)50 compared the risk 
associated with ever having used combined oral contraceptives (specifically 
cyproterone acetate (CPA) formulations) amongst 317 women with primary 
hepatocellular carcinoma (HOC) aged under 65 years and age-matched controls. 
The investigators reported that they found no evidence for an increased risk of HCC 
associated with CPA. We could not find any other observational studies specifically 
investigating the risk of liver disease in women prescribed CPA/EE.
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R e c o m m e n d a t io n s  f o r  f u r t h e r  w o r k
We have compared risk estimates for liver disease in patients prescribed 
minocycline with that in patients prescribed (oxy)tetracycline and compared the risk 
°f VTE and liver disease in CPA/EE users with the risk in women prescribed 
conventional COCs. Most minocycline and CPA/EE users have acne although 
some CPA/EE users derive from a population with diverse and sometimes complex 
morbidity. The methodologies described in the papers (specifically Chapters Five & 
Seven) were carefully considered but leave unresolved issues such as residual 
confounding by indication.
F u r t h e r  GPRD w o r k
We will soon have access to a new version of the GPRD that holds considerably 
more data than previous versions. It is likely that the issue of under-powered 
studies would be resolved although the problem of residual confounding by 
indication will remain - narrower confidence intervals around point estimates could 
further complicate the interpretation of analyses.
Use of therapeutic products should be considered in the light of their full spectrum of 
benefits and risks. The studies presented in this thesis focus on liver disease and 
VTE. It is proposed that further study should be conducted to describe the full risk 
profile of CPA/EE as a treatment for acne, hirsutism and PCOS compared with 
alternative treatments, including minocycline, in a potentially much larger population 
of women with acne, hirsutism of PCOS. Cases would be defined by identifying all 
adverse medical events that occur during treatment - specifically liver disease and 
VTE as well as photosensitivity, systemic lupus erythematosus, alopecia, 
pancreatitis, depression and hypervitaminosis A-like symptoms. Similarly exposed 
age- and practice-matched controls would be selected for case-control analysis.
F ie l d  s t u d y
An important consideration during our work on CPA/EE was the issue of residual 
confounding by indication because of the limited insight into disease severity 
provided by GPRD medical records. It is proposed that a field study would help to
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elucidate the characteristics of women prescribed CPA/EE in general practice and 
would allow disease severity to be established. A questionnaire could be sent to 
each women prescribed CPA/EE to enquire about demographics and other 
treatments used for acne, hirsutism or PCOS (as appropriate) including prescribed 
medications, OTC medication and visits to a beautician. To establish the severity 
and extent of any acne or hirsutism women would be asked to describe their 
symptoms with reference to pictures of different types of acne and by indicating 
which parts of the body were affected by acne or hirsutism diagrammatically. Other 
questions would be designed to identify the presence or absence of other PCOS 
symptoms. A further questionnaire could be developed for GPs to assess their 
considerations when choosing between different types of treatment or OCs for 
women with acne, hirsutism or PCOS.
E u r o d a t a b a s e s
The UK GPRD is used widely and its utility has been demonstrated through a 
number of projects. It is the largest database of its kind in Europe but it is not 
unique. Similar schemes operate in The Netherlands, Germany, Denmark, Scotland 
and France. All are smaller than the GPRD, some have less detail whilst others 
include details of hospital admission as well as primary care. At present there is no 
co-ordinated agency that holds information on the content, rules of access, size or 
ownership of these databases. Theoretically, if suitable databases could be 
identified, they could provide a rich source of information to investigate further 
issues surrounding the use of CPA/EE and associated risks.
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C o n c l u s io n s
Acne is a common condition amongst young men and women. It varies in severity 
and might have a considerable impact on an individual’s quality of life. Many topical 
and oral drugs are available to treat acne and the choice of treatment will depend 
inter alia upon severity, past experience and perceived risk. The baseline risk of 
adverse events in people with acne may be different from the general population 
because of known or unknown co-morbidities. Women with acne may have 
hirsutism or other symptoms of PCOS. An adverse cardiovascular risk profile has 
been associated with PCOS and it is possible that features of the syndrome render 
affected individuals at higher risk of other adverse events. These observations 
complicate analyses of risk associated with the use of drugs for acne, hirsutism or 
PCOS.
Physicians should be aware of the real, albeit small, risk of hypersensitivity-type 
reactions associated with minocycline during the early weeks of exposure, the 
potential severity of HSRs and of the possibility that some ethnic groups are more at 
risk than others. Patients who use minocycline for over a year might develop lupus­
like symptoms and evidence of an autoimmune hepatitis. Usually autoimmune 
hepatitis is less severe and resolves without sequelae on discontinuation of therapy. 
In women the use of CPA/EE does not appear to be associated with an increased 
risk of liver disease and the association with VTE is attenuated when the analysis is 
adjusted for confounding by acne, hirsutism and PCOS. CPA/EE does not appear 
to afford an increased risk of VTE.
We hope to conduct a field study to describe women prescribed CPA/EE with more 
clarity than can be achieved using routinely collected data. This together with more 
work exploring a broader range of adverse events amongst OC users, CPA/EE 
users and women prescribed other acne therapies, will assist in the interpretation of 
the risk associated with CPA/EE and help to put the findings into context.
Our findings thus far suggest that CPA/EE and minocycline are safe treatments for 
acne provided that prescribing clinicians are aware of the risks posed by underlying 
co-morbidity in some individuals.
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